

# EAU Guidelines on Urolithiasis

C. Türk (Chair), T. Knoll (Vice-chair), A. Petrik, K. Sarica,  
A. Skolarikos, M. Straub, C. Seitz  
Guidelines Associates: S. Dabestani, T. Drake, N. Grivas,  
Y. Ruhayel, A.K. Tepeler

# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	6
1.1	Aims and scope	6
1.2	Panel composition	6
1.3	Available publications	6
1.4	Publication history and summary of changes	6
1.4.1	Publication history	6
1.4.2	Summary of changes	6
2.	METHODS	7
2.1	Data identification	7
2.2	Review	7
2.3	Future goals	7
3.	GUIDELINES	7
3.1	Prevalence, aetiology, risk of recurrence	7
3.1.1	Introduction	7
3.1.2	Stone composition	8
3.1.3	Risk groups for stone formation	9
3.2	Classification of stones	9
3.2.1	Stone size	10
3.2.2	Stone location	10
3.2.3	X-ray characteristics	10
3.3	Diagnostic evaluation	10
3.3.1	Diagnostic imaging	10
3.3.1.1	Evaluation of patients with acute flank pain/suspected ureteral stones	10
3.3.1.2	Radiological evaluation of patients with renal stones	11
3.3.2	Diagnostics - metabolism-related	11
3.3.2.1	Basic laboratory analysis - non-emergency urolithiasis patients	12
3.3.2.2	Analysis of stone composition	12
3.3.3	Diagnosis in special groups and conditions	12
3.3.3.1	Diagnostic imaging during pregnancy	12
3.3.3.2	Children	12
3.3.3.2.1	Diagnostic imaging	13
3.3.3.2.2	Ultrasound	13
3.3.3.2.3	Plain films (KUB radiography)	13
3.3.3.2.4	Intravenous urography (IVU)	13
3.3.3.2.5	Helical computed tomography (CT)	13
3.3.3.2.6	Magnetic resonance urography (MRU)	13
3.4	Disease management	13
3.4.1	Management of patients with renal or ureteral stones	13
3.4.1.1	Renal colic	13
3.4.1.2	Management of sepsis and/or anuria in obstructed kidney	14
3.4.1.3	General recommendations and precautions for stone removal	15
3.4.1.3.1	Antibiotic therapy	15
3.4.1.3.2	Antithrombotic therapy and stone treatment	15
3.4.1.3.3	Obesity	17
3.4.1.3.4	Stone composition	17
3.4.1.3.5	Steinstrasse	17
3.4.2	Specific stone management in renal stones	17
3.4.2.1	Types of treatments	18
3.4.2.1.1	Conservative treatment (Observation)	18
3.4.2.1.2	Pharmacological treatment	18
3.4.2.1.2.1	Percutaneous irrigation chemolysis	18
3.4.2.1.2.2	Oral chemolysis	18
3.4.2.1.3	Extracorporeal shock wave lithotripsy (SWL)	18
3.4.2.1.3.1	Contraindications of extracorporeal shock wave lithotripsy	18
3.4.2.1.3.2	Best clinical practice	19

	3.4.2.1.3.3	Complications of extracorporeal shock wave lithotripsy	20
	3.4.2.1.4	Endourology techniques for renal stone removal	20
	3.4.2.1.4.1	Percutaneous nephrolithotomy (PNL)	20
		3.4.2.1.4.1.1 Contraindications	20
		3.4.2.1.4.1.2 Best clinical practice	21
		3.4.2.1.4.1.3 Complications	22
	3.4.2.1.4.2	Ureterorenoscopy for renal stones (RIRS)	22
	3.4.2.1.4.3	Open and laparoscopic surgery for removal of renal stones	22
	3.4.2.2	Indication for active stone removal of renal stones	23
	3.4.2.3	Selection of procedure for active removal of renal stones	23
	3.4.2.3.1	Stones in renal pelvis or upper/middle calices	23
	3.4.2.3.2	Stones in the lower renal pole	23
	3.4.2.3.3	Recommendations for the selection of procedures for active removal of renal stones	24
3.4.3		Specific stone management of Ureteral stones	25
	3.4.3.1	Types of treatment	25
	3.4.3.1.1	Conservative treatment / observation	25
	3.4.3.1.2	Pharmacological treatment, Medical expulsive therapy (MET)	25
		3.4.3.1.2.1 Medical expulsive therapy after extracorporeal shock wave lithotripsy (SWL)	26
		3.4.3.1.2.2 Medical expulsive therapy after ureteroscopy	26
		3.4.3.1.2.3 Medical expulsive therapy and ureteral stents (see 3.4.3.1.4.1.2 )	26
		3.4.3.1.2.4 Duration of medical expulsive therapy treatment	26
	3.4.3.1.3	SWL	26
	3.4.3.1.4	Endourology techniques	27
		3.4.3.1.4.1 Ureteroscopy (URS)	27
		3.4.3.1.4.1.1 Contraindications	27
		3.4.3.1.4.1.2 Best clinical practice in ureterorenoscopy (URS)	27
		3.4.3.1.4.1.3 Complications	28
		3.4.3.1.4.2 Percutaneous antegrade ureteroscopy	28
	3.4.3.1.5	Laparoscopic ureteral stone removal	28
	3.4.3.2	Indications for active removal of ureteral stones	29
		3.4.3.2.5.1 Bleeding disorder	29
	3.4.3.3	Selection of procedure for active removal of ureteral stones	29
3.4.4		Management of patients with residual stones	30
	3.4.4.1	Therapy	30
3.4.5		Management of specific patient groups	30
	3.4.5.1	Management of urinary stones and related problems during pregnancy	30
	3.4.5.2	Management of stones in patients with urinary diversion	31
		3.4.5.2.1 Aetiology	31
		3.4.5.2.2 Management	31
		3.4.5.2.3 Prevention	31
	3.4.5.3	Management of stones in patients with neurogenic bladder	31
		3.4.5.3.1 Aetiology, clinical presentation and diagnosis	31
		3.4.5.3.2 Management	32
	3.4.5.4	Management of stones in transplanted kidneys	32
		3.4.5.4.1 Aetiology	32
		3.4.5.4.2 Management	32
		3.4.5.4.3 Special problems in stone removal	33
3.4.6		Management of urolithiasis in children	33
	3.4.6.1	Stone removal	33
		3.4.6.1.1 Medical expulsive therapy (MET) in children	33

	3.4.6.1.2	Extracorporeal shock wave lithotripsy	34
	3.4.6.1.3	Endourological procedures	34
	3.4.6.1.3.1	Percutaneous nephrolithotripsy (PNL)	34
	3.4.6.1.3.2	Ureteroscopy	34
	3.4.6.1.3.3	Open or laparoscopic surgery	35
	3.4.6.1.3.4	Special considerations on recurrence prevention	35
4.		FOLLOW UP: METABOLIC EVALUATION AND RECURRENCE PREVENTION	35
	4.1	General metabolic considerations for patient work-up	35
	4.1.1	Evaluation of patient risk	35
	4.1.2	Urine sampling	36
	4.1.3	Timing of specific metabolic work-up	37
	4.1.4	Reference ranges of laboratory values	37
	4.1.5	Risk indices and additional diagnostic tools	37
	4.2	General considerations for recurrence prevention	39
	4.2.1	Fluid intake	39
	4.2.2	Diet	39
	4.2.3	Lifestyle	40
	4.2.4	Recommendations for recurrence prevention	40
	4.3	Stone-specific metabolic evaluation and pharmacological recurrence prevention	40
	4.3.1	Introduction	40
	4.4	Calcium oxalate stones	41
	4.4.1	Diagnosis	41
	4.4.2	Interpretation of results and aetiology	41
	4.4.3	Specific treatment	42
	4.4.4	Recommendations for pharmacological treatment of patients with specific abnormalities in urine composition	42
	4.5	Calcium phosphate stones	43
	4.5.1	Diagnosis	43
	4.5.2	Interpretation of results and aetiology	43
	4.5.3	Pharmacological therapy	44
	4.5.4	Recommendations for the treatment of calcium phosphate stones	44
	4.6	Disorders and diseases related to calcium stones	44
	4.6.1	Hyperparathyroidism	44
	4.6.2	Granulomatous diseases	44
	4.6.3	Primary hyperoxaluria	44
	4.6.4	Enteric hyperoxaluria	44
	4.6.5	Renal tubular acidosis	45
	4.6.6	Nephrocalcinosis	46
	4.6.6.1	Diagnosis	46
	4.7	Uric acid and ammonium urate stones	47
	4.7.1	Diagnosis	47
	4.7.2	Interpretation of results	47
	4.7.3	Specific treatment	47
	4.8	Struvite and infection stones	48
	4.8.1	Diagnosis	48
	4.8.2	Specific treatment	49
	4.8.3	Recommendations for therapeutic measures of infection stones	49
	4.9	Cystine stones	50
	4.9.1	Diagnosis	50
	4.9.2	Specific treatment	51
	4.9.2.1	Pharmacological treatment of cystine stones	51
	4.9.3	Recommendations for the treatment of cystine stones	52
	4.10	2,8-Dihydroxyadenine stones and xanthine stones	52
	4.10.1	2,8-Dihydroxyadenine stones	52
	4.10.2	Xanthine stones	53
	4.10.3	Fluid intake and diet	53
	4.11	Drug stones	53
	4.12	Matrix Stones	53

4.13	Unknown stone composition	53
5.	REFERENCES	54
6.	CONFLICT OF INTEREST	81

# 1. INTRODUCTION

## 1.1 Aims and scope

The European Association of Urology (EAU) Urolithiasis Guidelines Panel have prepared these guidelines to help urologists assess evidence-based management of stones/calculi and incorporate recommendations into clinical practice. The document covers most aspects of the disease, which is still a cause of significant morbidity despite technological and scientific advances. The Panel is aware of the geographical variations in healthcare provision.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account.

## 1.2 Panel composition

The EAU Urolithiasis Guidelines Panel consists of an international group of clinicians with particular expertise in this area. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <http://uroweb.org/guideline/urolithiasis/>.

## 1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and in a number of versions for mobile devices. These are abridged versions which may require consultation together with the full text versions. Also a number of translated versions and scientific publications are available [1-6]. All documents can be accessed through the EAU website: <http://uroweb.org/guideline/urolithiasis/>.

## 1.4 Publication history and summary of changes

### 1.4.1 Publication history

The EAU Urolithiasis Guidelines were first published in 2000. This 2016 document presents a limited update of the 2015 publication of the EAU Urolithiasis Guidelines.

### 1.4.2 Summary of changes

Key changes for the 2016 publication:

The literature for the entire document has been assessed and updated, whenever relevant (see Methods section below).

- Limited changes were made to the Section 3.4.1.1 - Renal colic
- The findings of the systematic review performed by the Panel (What are the benefit and harms of URS compared with SWL in the treatment of upper ureteral stones in children and adults? [305]) have been included in Section 3.4.3.3 - Selection of procedure for active removal of ureteral stones.
- Section 3.4.1.3.2 - Antithrombotic therapy and stone treatment - has been expanded with new data. New table 3.4.1 - Risk stratification for bleeding and table 3.4.2 - Suggested therapies for antithrombotic therapy in stone removal have been added.
- Figure 3.4.1 - Treatment algorithm for renal calculi has been amended; priority of treatment modalities has changed to shockwave lithotripsy and ureterorenoscopy as first choice of treatment modalities for small upper urinary stones.
- Recent data has been included in Section 3.4.3.1.2 - Pharmacological treatment, Medical expulsive therapy (MET), which resulted in a lower recommendation (2015 recommendation was GR A).

Recommendation for MET	LE	GR
Offer $\alpha$ -blockers as MET as one of the treatment options.	1a	C

## 2. METHODS

### 2.1 Data identification

For the 2016 Urolithiasis Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive scoping exercise covering all areas of the guideline was performed. The search was limited to studies representing high levels of evidence only (i.e. systematic reviews with meta-analysis, randomised controlled trials (RCTs), and prospective non-randomised comparative studies only) published in the English language. The search was restricted to articles published during the period from August 11<sup>th</sup> 2014 to September 4<sup>th</sup>, 2015. Databases covered by the search included Medline, EMBASE and the Cochrane Libraries. A total of 487 unique records were identified, and screened for relevance. The search strategy is published online: <http://uroweb.org/guideline/urolithiasis/?type=appendices-publications>.

Two sections of the text have been updated based on two systematic reviews (SRs). These SRs were performed using standard Cochrane SR methodology; <http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html>.

Systematic review topics:

- What are the comparative benefits and harms of the different percutaneous nephrolithotomy (PCNL) tract sizes? [7].
- What are the benefits and harms of ureteroscopy (URS) compared with shock wave lithotripsy (SWL) in the treatment of upper ureteral stones in children and adults? [305].

Recommendations in this text are assessed according to their level of evidence (LE) and Guidelines are given a grade of recommendation (GR), according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [8]. Additional methodology information can be found in the general Methodology section of this print, and online at the EAU website: <http://uroweb.org/guidelines/>. A list of Associations endorsing the EAU Guidelines can also be viewed on line at the above address.

### 2.2 Review

The 2015 Urolithiasis Guidelines were subjected to peer review prior to publication.

### 2.3 Future goals

Further results on ongoing and new systematic reviews will be included in the 2017 update of the Urolithiasis Guidelines.

## 3. GUIDELINES

### 3.1 Prevalence, aetiology, risk of recurrence

#### 3.1.1 Introduction

Stone incidence depends on geographical, climatic, ethnic, dietary and genetic factors. The recurrence risk is basically determined by the disease or disorder causing the stone formation. Accordingly, the prevalence rates for urinary stones vary from 1% to 20% [9]. In countries with a high standard of life such as Sweden, Canada or the US, renal stone prevalence is notably high (> 10%). For some areas an increase of more than 37% over the last 20 years is reported [10] (Table 3.1.1).

**Table 3.1.1: Prevalence and incidence of urolithiasis from two European countries [11, 12]**

	Germany 2000 (%)	Spain 2007 (%)
<i>Prevalence</i>	4.7	5.06
Females	4.0	NA
Males	5.5	NA
<i>Incidence</i>	1.47	0.73
Females	0.63	NA
Males	0.84	NA

Stones can be classified into those caused by: infection, or non-infectious causes (infection and non-infection stones); genetic defects [13]; or adverse drug effects (drug stones) (Table 3.1.2).

**Table 3.1.2: Stones classified by aetiology\***

<b>Non-infection stones</b>
• Calcium oxalate
• Calcium phosphate
• Uric acid
<b>Infection stones</b>
• Magnesium ammonium phosphate
• Carbonate apatite
• Ammonium urate
<b>Genetic causes</b>
• Cystine
• Xanthine
• 2,8-dihydroxyadenine
<b>Drug stones</b>

\*See Section 4.4.2

### 3.1.2 Stone composition

Stone composition is the basis for further diagnostic and management decisions. Stones are often formed from a mixture of substances. Table 3.1.3 lists the clinically most relevant substances and their mineral components.

**Table 3.1.3: Stone composition**

Chemical name	Mineral name	Chemical formula
Calcium oxalate monohydrate	Whewellite	$\text{CaC}_2\text{O}_4 \cdot \text{H}_2\text{O}$
Calcium oxalate dihydrate	Wheddelite	$\text{CaC}_2\text{O}_4 \cdot 2\text{H}_2\text{O}$
Basic calcium phosphate	Apatite	$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$
Calcium hydroxyl phosphate	Carbonite apatite	$\text{Ca}_5(\text{PO}_3)_3(\text{OH})$
b-tricalcium phosphate	Whitlockite	$\text{Ca}_3(\text{PO}_4)_2$
Carbonate apatite phosphate	Dahllite	$\text{Ca}_5(\text{PO}_4)_3\text{OH}$
Calcium hydrogen phosphate	Brushite	$\text{PO}_4 \cdot 2\text{H}_2\text{O}$
Calcium carbonate	Aragonite	$\text{CaCO}_3$
Octacalcium phosphate		$\text{Ca}_8\text{H}_2(\text{PO}_4)_6 \cdot 5\text{H}_2\text{O}$
Uric acid	Uricite	$\text{C}_5\text{H}_4\text{N}_4\text{O}_3$
Uric acid dihydrate	Uricite	$\text{C}_5\text{H}_4\text{O}_3 \cdot 2\text{H}_2\text{O}$
Ammonium urate		$\text{NH}_4\text{C}_5\text{H}_3\text{N}_4\text{O}_3$
Sodium acid urate monohydrate		$\text{NaC}_5\text{H}_3\text{N}_4\text{O}_3 \cdot \text{H}_2\text{O}$
Magnesium ammonium phosphate	Struvite	$\text{MgNH}_4\text{PO}_4 \cdot 6\text{H}_2\text{O}$
Magnesium acid phosphate trihydrate	Newberyite	$\text{MgHPO}_4 \cdot 3\text{H}_2\text{O}$
Magnesium ammonium phosphate monohydrate	Dittmarite	$\text{MgNH}_4(\text{PO}_4) \cdot 1\text{H}_2\text{O}$
Cystine		$[\text{SCH}_2\text{CH}(\text{NH}_2)\text{COOH}]_2$
Gypsum	Calcium sulphate dihydrate Zinc phosphate tetrahydrate	$\text{CaSO}_4 \cdot 2\text{H}_2\text{O}$ $\text{Zn}_3(\text{PO}_4)_2 \cdot 4\text{H}_2\text{O}$
Xanthine		
2,8-Dihydroxyadenine		
Proteins		
Cholesterol		
Calcite		
Potassium urate		
Trimagnesium phosphate		



Melamine		
Matrix		
Drug stones	<ul style="list-style-type: none"> <li>• Active compounds crystallising in urine</li> </ul>	
	<ul style="list-style-type: none"> <li>• Substances impairing urine composition (Section 4.11)</li> </ul>	
Foreign body calculi		

### 3.1.3 Risk groups for stone formation

The risk status of stone formers is of particular interest because it defines the probability of recurrence or regrowth, and is imperative for pharmacological treatment.

About 50% of recurrent stone formers have just one lifetime recurrence [11, 14]. Highly recurrent disease is observed in slightly more than 10% of patients. Stone type and disease severity determine low- or high-risk of recurrence (Table 3.1.4) [15, 16].

**Table 3.1.4: High-risk stone formers [15-25]**

<b>General factors</b>
Early onset of urolithiasis (especially children and teenagers)
Familial stone formation
Brushite-containing stones (CaHPO <sub>4</sub> ·2H <sub>2</sub> O)
Uric acid and urate-containing stones
Infection stones
Solitary kidney (the kidney itself does not particularly increase the risk of stone formation, but prevention of stone recurrence is of more importance)
<b>Diseases associated with stone formation</b>
Hyperparathyroidism
Metabolic syndrome
Nephrocalcinosis
Polycystic kidney disease (PKD)
Gastrointestinal diseases (i.e., jejunio-ileal bypass, intestinal resection, Crohn's disease, malabsorptive conditions, enteric hyperoxaluria after urinary diversion) and bariatric surgery [21]
Sarcoidosis
Spinal cord injury, neurogenic bladder
<b>Genetically determined stone formation</b>
Cystinuria (type A, B and AB)
Primary hyperoxaluria (PH)
Renal tubular acidosis (RTA) type I
2,8-Dihydroxyadeninuria
Xanthinuria
Lesch-Nyhan syndrome
Cystic fibrosis
<b>Drugs associated with stone formation</b>
<b>Anatomical abnormalities associated with stone formation</b>
Medullary sponge kidney (tubular ectasia)
Ureteropelvic junction (UPJ) obstruction
Calyceal diverticulum, calyceal cyst
Ureteral stricture
Vesico-uretero-renal reflux
Horseshoe kidney
Ureterocele

## 3.2 Classification of stones

Urinary stones can be classified according to size, location, X-ray characteristics, aetiology of formation, composition, and risk of recurrence [11, 26-28].

### 3.2.1 Stone size

Stone size is usually given in one or two dimensions, and stratified into those measuring up to 5, 5-10, 10-20, and > 20 mm in largest diameter.

### 3.2.2 Stone location

Stones can be classified according to anatomical position: upper, middle or lower calyx; renal pelvis; upper, middle or distal ureter; and urinary bladder. Treatment of bladder stones is not discussed here.

### 3.2.3 X-ray characteristics

Stones can be classified according to plain X-ray appearance [kidney-ureter-bladder (KUB) radiography] (Table 3.2.1), which varies according to mineral composition [28]. Non-contrast-enhanced computed tomography (NCCT) can be used to classify stones according to density, inner structure and composition, which can affect treatment decisions (Section 3.4.1.4.4) [27, 28].

**Table 3.2.1: X-ray characteristics**

Radiopaque	Poor radiopacity	Radiolucent
Calcium oxalate dihydrate	Magnesium ammonium phosphate	Uric acid
Calcium oxalate monohydrate	Apatite	Ammonium urate
Calcium phosphates	Cystine	Xanthine
		2,8-Dihydroxyadenine
		Drug-stones (Section 4.11)

Stratification of stones according to aetiology, composition and risk of recurrence is addressed in Section 3.1.

## 3.3 Diagnostic evaluation

### 3.3.1 Diagnostic imaging

The clinical situation will inform on the most appropriate imaging modality, which will differ for a suspected ureteral stone or a suspected renal stone.

Standard evaluation includes a detailed medical history and physical examination. Patients with ureteral stones usually present with loin pain, vomiting, and sometimes fever, but may also be asymptomatic [29].

Ultrasound (US) should be used as the primary diagnostic imaging tool, although pain relief, or any other emergency measures should not be delayed by imaging assessments. Ultrasound is safe (no risk of radiation), reproducible and inexpensive. It can identify stones located in the calices, pelvis, and pyeloureteric and vesicoureteric junctions (US with filled bladder), as well as in patients with upper urinary tract dilatation. US has a sensitivity of 45% and specificity of 94% for ureteric stones and a sensitivity of 45% and specificity of 88% for renal stones [30] [31].

The sensitivity and specificity of KUB radiography is 44-77% and 80-87%, respectively [32]. KUB radiography should not be performed if NCCT is considered [33], however, it is helpful in differentiating between radiolucent and radiopaque stones and for comparison during follow-up.

Recommendation	LE	GR
With fever or solitary kidney, and when diagnosis is doubtful, immediate imaging is indicated.	4	A*

\*Upgraded following panel consensus.

#### 3.3.1.1 Evaluation of patients with acute flank pain/suspected ureteral stones

Non-contrast-enhanced computed tomography has become the standard for diagnosing acute flank pain, and has replaced intravenous urography (IVU). Non-contrast-enhanced computed tomography can determine stone diameter and density. When stones are absent, the cause of abdominal pain should be identified. In evaluating patients with suspected acute urolithiasis, NCCT seems to be significantly more accurate than IVP [34].

Recommendation	LE	GR
Following initial US assessment, use NCCT to confirm stone diagnosis in patients with acute flank pain, because it is superior to IVU.	1a	A

IVU = intravenous urography; NCCT = non-contrast enhanced computed tomography; US = ultrasound.

Non-contrast-enhanced computed tomography can detect uric acid and xanthine stones, which are radiolucent

on plain films, but not indinavir stones [35]. Non-contrast-enhanced computed tomography can determine stone density, inner structure of the stone and skin-to-stone distance and surrounding anatomy; all of which affect selection of treatment modality [28, 36-38]. The advantage of non-contrast imaging must be balanced against loss of information on renal function and urinary collecting system anatomy, as well as higher radiation dose (Table 3.1).

Radiation risk can be reduced by low-dose CT [39]. In patients with body mass index (BMI) < 30, low-dose CT has been shown to have a sensitivity of 86% for detecting ureteric stones < 3 mm and 100% for calculi > 3 mm [40]. A meta-analysis of prospective studies [41] has shown that low-dose CT diagnosed urolithiasis with a pooled sensitivity of 96.6% (95% CI: 95.0-97.8) and specificity of 94.9% (95% CI: 92.0-97.0).

**Table 3.3.1: Radiation exposure of imaging modalities [42-45]**

Method	Radiation exposure (mSv)
KUB radiography	0.5-1
IVU	1.3-3.5
Regular-dose NCCT	4.5-5
Low-dose NCCT	0.97-1.9
Enhanced CT	25-35

### 3.3.1.2 Radiological evaluation of patients with renal stones

Recommendations	LE	GR
Perform a contrast study if stone removal is planned and the anatomy of the renal collecting system needs to be assessed.	3	A*
Use enhanced CT in complex cases because it enables 3D reconstruction of the collecting system, as well as measurement of stone density and skin-to-stone distance. IVU may also be used.	4	C

\*Upgraded based on panel consensus.

CT = computed tomography; IVU = intravenous urography.

### 3.3.2 Diagnostics - metabolism-related

Each emergency patient with urolithiasis needs a succinct biochemical work-up of urine and blood besides imaging. At that point, no distinction is made between high- and low-risk patients for stone formation.

**Table 3.3.2: Recommendations: basic laboratory analysis - emergency urolithiasis patients [16, 17, 46, 47]**

Recommendations	GR
<b>Urine</b>	
Dipstick test of spot urine sample	A*
<ul style="list-style-type: none"> <li>• red cells</li> <li>• white cells</li> <li>• nitrite</li> <li>• approximate urine pH</li> </ul> Urine microscopy and/or culture	A
<b>Blood</b>	
Serum blood sample	A*
<ul style="list-style-type: none"> <li>• creatinine</li> <li>• uric acid</li> <li>• (ionised) calcium</li> <li>• sodium</li> <li>• potassium</li> </ul> Blood cell count <ul style="list-style-type: none"> <li>• CRP</li> </ul>	
Perform a coagulation test (PTT and INR) if intervention is likely or planned.	A*

\*Upgraded based on panel consensus.

CRP = C-reactive protein; INR = international normalised ratio; PTT = partial thromboplastin time.

### 3.3.2.1 Basic laboratory analysis - non-emergency urolithiasis patients

Biochemical work-up is similar for all stone patients. However, if no intervention is planned, examination of sodium, potassium, C-reactive protein, and blood coagulation time can be omitted.

Only patients at high-risk for stone recurrence should undergo a more specific analytical programme [16]. Stone-specific metabolic evaluation is described in Chapter 4.

The easiest means to achieve correct diagnosis is by analysis of a passed stone using a validated method as listed below (see 3.2.2). Once mineral composition is known, a potential metabolic disorders can be identified.

### 3.3.2.2 Analysis of stone composition

Stone analysis should be performed in all first-time stone formers.

In clinical practice, repeat stone analysis is needed in the case of:

- recurrence under pharmacological prevention;
- early recurrence after interventional therapy with complete stone clearance;
- late recurrence after a prolonged stone-free period [48].

Patients should be instructed to filter their urine to retrieve a concrement for analysis. Stone passage and restoration of normal renal function should be confirmed.

The preferred analytical procedures are infrared spectroscopy (IRS) or X-ray diffraction (XRD) [49-51]. Equivalent results can be obtained by polarisation microscopy, but only in centres with expertise. Chemical analysis (wet chemistry) is generally deemed to be obsolete [49].

Recommendations	LE	GR
Perform stone analysis in first-time formers using a valid procedure (XRD or IRS).	2	A
Repeat stone analysis in patients: <ul style="list-style-type: none"><li>• presenting with recurrent stones despite drug therapy;</li><li>• with early recurrence after complete stone clearance;</li><li>• with late recurrence after a long stone-free period because stone composition may change [47].</li></ul>	2	B

IRS = infrared spectroscopy; XRD = X-ray diffraction.

### 3.3.3 Diagnosis in special groups and conditions

#### 3.3.3.1 Diagnostic imaging during pregnancy

In pregnant women diagnostic imaging (exposure to ionising radiation) might be associated with teratogenic risks and development of (childhood) malignancies. The risk for the child crucially depends on gestational age and amount of radiation delivered. X-ray imaging during the first trimester should be reserved for patients in which alternative imaging methods have failed [52, 53].

Ultrasound (when necessary using change in renal resistive index and transvaginal/transabdominal US with a full bladder) has become the primary radiological diagnostic tool when evaluating pregnant patients suspected of renal colic. However, normal physiological changes in pregnancy can mimic ureteral obstruction [54].

Magnetic resonance imaging (MRI) can be used, as a second-line procedure, to define the level of urinary tract obstruction, and to visualise stones as a filling defect [55, 56].

Low dose CT protocols reduce the radiation exposure and are currently recommended to be used judiciously in pregnant women as a last-line option [57, 58].

Recommendations	LE	GR
Use ultrasound as the preferred method of imaging in pregnant women.	1a	A*
In pregnant women, use MRI as a second-line imaging modality.	3	C
In pregnant women, use low-dose CT as a last-line option.	3	C

\*Upgraded following panel consensus.

CT = computed tomography; MRI = magnetic resonance imaging.

#### 3.3.3.2 Children

Paediatric patients with urinary stones have a high risk of recurrence; therefore, standard diagnostic procedures for high-risk patients apply (Section 3.1.3 and Chapter 4).

Summary of evidence	LE
In paediatric patients, the most common non-metabolic disorders facilitating stone formation are vesicoureteral reflux, ureteropelvic junction obstruction, neurogenic bladder, and other voiding difficulties [59].	4

Recommendations	GR
In all paediatric patients, complete a metabolic evaluation based on stone analysis.	A
Collect stone material for analysis to classify the stone type.	A*

\*Upgraded following panel consensus.

### 3.3.3.2.1 Diagnostic imaging

When selecting diagnostic procedures to identify urolithiasis in paediatric patients, it should be remembered that these patients might be uncooperative, require anaesthesia, or be sensitive to ionising radiation [60-62]. Again, the principle of ALARA (As Low As Reasonably Achievable) should be observed.

### 3.3.3.2.2 Ultrasound

Ultrasound is the primary imaging technique [60] in paediatrics. Its advantages are absence of radiation and no need for anaesthesia. Imaging should include both the fluid-filled bladder with adjoining portion of the ureters, as well as the upper ureter [63-67].

Colour Doppler US shows differences in the ureteric jet [64] and resistive index of the arciform arteries of both kidneys, which are indicative of the grade of obstruction [65].

Nevertheless, US fails to identify stones in > 40% of paediatric patients [66-69] (LE: 4), and provides limited information on renal function.

### 3.3.3.2.3 Plain films (KUB radiography)

KUB radiography can help to identify stones and their radiopacity, and facilitate follow-up.

### 3.3.3.2.4 Intravenous urography (IVU)

The radiation dose for IVU is comparable to that for voiding cystourethrography (0.33 mSV) [70]. However, the need for contrast medium injection is a major drawback.

### 3.3.3.2.5 Helical computed tomography (CT)

Recent low-dose CT protocols have been shown to significantly reduce radiation exposure [45] [71].

In children, only 5% of stones escape detection by NCCT [57, 64, 71]. Sedation or anaesthesia is rarely needed with modern high-speed CT apparatus.

### 3.3.3.2.6 Magnetic resonance urography (MRU)

Magnetic resonance urography cannot be used to detect urinary stones. However, it might provide detailed anatomical information about the urinary collecting system, the location of an obstruction or stenosis in the ureter, and renal parenchymal morphology [72].

Recommendations	GR
In children, use ultrasound as first-line imaging modality when a stone is suspected; it should include the kidney, fluid-filled bladder and the ureter next to the kidney and the (filled) bladder.	B
If US does not provide the required information, perform a KUB radiography (or low-dose NCCT).	B

US = ultrasound; KUB = kidney, ureter, bladder; NCCT = non-contrast enhanced computed tomography.

## 3.4 Disease management

### 3.4.1 Management of patients with renal or ureteral stones

Treatment decisions for upper urinary tract calculi are based on several general aspects such as stone composition, stone size, and symptoms.

#### 3.4.1.1 Renal colic

##### Pain relief

Pain relief is the first therapeutic step in patients with an acute stone episode [73, 74].

Non-steroidal anti-inflammatory drugs (NSAIDs) including metamizole (synonym: dipyrone), a pyrazolone NSAID, are effective in patients with acute stone colic [75, 76], and have better analgesic efficacy than opioids. Patients receiving NSAIDs are less likely to require further analgesia in the short term.

It should be taken into consideration that the use of diclofenac and ibuprofen increased major coronary events. Diclofenac is contraindicated in patients with congestive heart failure (New York Heart Association class II-IV), ischaemic heart disease, peripheral arterial- and cerebrovascular disease. Patients with significant risk factors for cardiovascular events should be treated with diclofenac only after careful consideration. As risks increase with dose and duration, the lowest effective dose should be used for the shortest duration [77, 78].

Opioids, particularly pethidine, are associated with a high rate of vomiting compared to NSAIDs, and carry a greater likelihood of further analgesia being needed [79, 80] (see below). If an opioid is used, it is recommended that it is not pethidine.

#### *Prevention of recurrent renal colic*

Facilitation of passage of ureteral stones is discussed in Section 3.4.3.1.2.

For patients with ureteral stones that are expected to pass spontaneously, NSAID tablets or suppositories (e.g., diclofenac sodium, 100-150 mg/day, 3-10 days) may help reduce inflammation and the risk of recurrent pain [80-82]. Although diclofenac can affect renal function in patients with already reduced function, it has no functional effect in patients with normal kidney function [83] (LE: 1b).

In a double-blind, placebo-controlled trial, recurrent pain episodes of stone colic were significantly fewer in patients treated with NSAIDs (as compared to no NSAIDs) during the first 7 days of treatment [82]. Daily  $\alpha$ -blockers might reduce recurrent colic (Section 3.4.3.1.2).

If analgesia cannot be achieved medically, drainage, using stenting or percutaneous nephrostomy or stone removal, should be performed.

<b>Recommendations</b>	<b>GR</b>
Provide immediate pain relief in acute stone episodes.	A
Whenever possible, offer an NSAID as the first drug of choice. e.g. metamizol (dipyrone); alternatively, depending on cardio-vascular risk factors diclofenac*, indomethacin or ibuprofen**.	A
Offer hydromorphone, pentazocine or tramadol as a second choice.	C
Use $\alpha$ -blockers to reduce recurrent colic in informed patients.	C

\*Affects glomerular filtration rate (GFR) in patients with reduced renal function (LE: 2a).

\*\*Recommended to counteract recurrent pain after ureteral colic.

NSAID = nonsteroidal anti-inflammatory drug.

<b>Summary of evidence</b>	<b>LE</b>
For symptomatic ureteral stones, urgent stone removal as first-line treatment is a feasible option in selected cases (see text).	1b

#### *3.4.1.2 Management of sepsis and/or anuria in obstructed kidney*

The obstructed kidney with all signs of urinary tract infection (UTI) and/or anuria is a urological emergency. Urgent decompression is often necessary to prevent further complications in infected hydronephrosis secondary to stone-induced, unilateral or bilateral renal obstruction.

#### *Decompression*

Currently, there are two options for urgent decompression of obstructed collecting systems:

- placement of an indwelling ureteral stent;
- percutaneous placement of a nephrostomy tube.

There is little evidence to support the superiority of percutaneous nephrostomy over retrograde stenting for primary treatment of infected hydronephrosis. There is no good-quality evidence to suggest that ureteric stenting has more complications than percutaneous nephrostomy [84, 85].

Only one RCT [86] assessed decompression of acute infected hydronephrosis. The complications of percutaneous nephrostomy insertion have been reported consistently, but those of ureteric stent insertion are less well described [84]. Definitive stone removal should be delayed until the infection is cleared following a complete course of antimicrobial therapy.

In children, ureteric stents might have some advantage compared to PCN in case of acute anuria [87].

<b>Summary of evidence</b>	<b>LE</b>
For decompression of the renal collecting system, ureteral stents and percutaneous nephrostomy catheters are equally effective.	1b

<b>Recommendations</b>	<b>LE</b>	<b>GR</b>
Urgently decompress the collecting system in case of sepsis with obstructing stones, using percutaneous drainage or ureteral stenting.	1b	A
Delay definitive treatment of the stone until sepsis is resolved.	1b	A

#### *Further measures*

Following urgent decompression of the obstructed and infected urinary collecting system, both urine- and blood samples should be sent for culture-antibiogram sensitivity testing, and antibiotics should be initiated immediately thereafter or continued if initiated prior to testing. The regimen should be re-evaluated in the light of the culture-antibiogram test. Intensive care might become necessary.

<b>Recommendations</b>	<b>GR</b>
Collect (again) urine for antibiogram test following decompression.	A*
Start antibiotics immediately (+ intensive care if necessary).	
Re-evaluate antibiotic regimen following antibiogram findings.	

*\*Upgraded based on panel consensus.*

### 3.4.1.3 General recommendations and precautions for stone removal

#### 3.4.1.3.1 Antibiotic therapy

Urinary tract infections should always be treated if stone removal is planned. In patients with clinically significant infection and obstruction, drainage should be performed for several days, via a stent or percutaneous nephrostomy, before starting stone removal.

<b>Recommendation</b>	<b>GR</b>
Obtain a urine culture or perform urinary microscopy before any treatment is planned.	A*

*\*Upgraded following panel consensus.*

#### *Perioperative antibiotic prophylaxis*

For risk of infection following ureteroscopy and percutaneous stone removal, no clear-cut evidence exists [88, 89]. In a review of a large database of patients undergoing percutaneous nephrolithotomy, it was found that in patients with negative baseline urine culture, antibiotic prophylaxis significantly reduced the rate of post-operative fever and other complications [90]. Single dose administration was found to be sufficient [91].

<b>Recommendations</b>	<b>LE</b>	<b>GR</b>
Exclude or treat UTIs prior to stone removal.	1b	A
Offer perioperative antibiotic prophylaxis to all patients undergoing endourological treatment.	1b	A*

*UTI = urinary tract infection*

#### 3.4.1.3.2 Antithrombotic therapy and stone treatment

Patients with a bleeding diathesis, or receiving antithrombotic therapy, should be referred to an internist for appropriate therapeutic measures before deciding on and during stone removal [92-96]. In patients with an uncorrected bleeding diathesis, the following are at elevated risk of haemorrhage or perinephric haematoma (PNH) (high-risk procedures):

- shockwave lithotripsy (SWL) (hazard ratio of PNH up to 4.2 during anticoagulant/antiplatelet medication [97] [LE: 2]);
- percutaneous nephrolithotripsy;
- percutaneous nephrostomy;
- laparoscopic surgery;
- open surgery [92, 98, 99].

Shockwave lithotripsy is feasible and safe after correction of the underlying coagulopathy [100-104]. In the case of an uncorrected bleeding disorder or continued antithrombotic therapy, ureterorenoscopy (URS), in contrast to SWL and PNL, might offer an alternative approach since it is associated with less morbidity [105-

109]. Only data on flexible ureteroscopy is available which support the superiority of URS in the treatment of proximal ureteric stones [106, 110].

**Table 3.4.1: Risk stratification for bleeding** [94-96, 111]

<b>Low-risk bleeding procedures</b>	Cystoscopy Flexible cystoscopy Ureteral catheterization Extraction of ureteric stent Ureteroscopy
<b>High-risk bleeding procedures</b>	SWL Percutaneous nephrostomy Percutaneous nephrolithotripsy

**Table 3.4.2: Suggested strategy for antithrombotic therapy in stone removal** [94-96]  
(In collaboration with cardiologist only)

	Bleeding risk	Risk of thromboembolism		
		Low risk	Intermediate risk	High risk
Warfarin Dabigatran Rivaroxaban Apixaban	Low-risk procedure	May be continued INR low therapeutic range 2.5.	Bridging therapy	Bridging therapy
	High-risk procedure	May be temporarily discontinued at appropriate interval. Bridging therapy is strongly recommended	Bridging therapy	Bridging therapy
Aspirin	Low-risk procedure	Continue	Continue	Elective surgery: postpone. Non-deferrable surgery: continue
	High-risk procedure	Discontinue	Elective surgery: postpone. Non-deferrable surgery: continue, if possible.	Elective surgery: postpone. Non-deferrable surgery: continue.
Thienopyridine agents (P2Y12 receptor inhibitors)	Low-risk procedure	Discontinue 5 days before intervention. Resume within 24-72 hours with a loading dose.	Continue	Elective surgery: postpone. Non-deferrable surgery: continue.
	High-risk procedure	Discontinue 5 days before intervention and resume within 24-72 hours with a loading dose.	Elective surgery: postpone. Non-deferrable surgery: discontinue 5 days before procedure and resume within 24-72 hours with a loading dose. Bridging therapy - GPIIb/IIIa inhibitors if aspirin is discontinued.	Elective surgery: postpone. Non-deferrable surgery: discontinue 5 days before procedure and resume within 24-72 hours, with a loading dose. Bridging therapy - GPIIb/IIIa inhibitors.



Recommendations	LE	GR
Offer active surveillance to patients at high-risk for thrombotic complications in the presence of an asymptomatic caliceal stone.		C
Decide on temporary discontinuation, or bridging of antithrombotic therapy in high-risk patients, in consultation with the internist.	3	B
Prefer retrograde (flexible) ureterorenoscopy if stone removal is essential and antithrombotic therapy cannot be discontinued, since it is associated with less morbidity.	2a	A*

\*Upgraded based on panel consensus.

#### 3.4.1.3.3 Obesity

Obesity can cause a higher risk due to anaesthesiological measurements, and a lower success rate after SWL and PNL.

#### 3.4.1.3.4 Stone composition

Stones composed of brushite, calcium oxalate monohydrate, or cystine are particularly hard as well as stones with high density in NCCT [36]. Percutaneous nephrolithotomy or ureterorenoscopy (RIRS) and URS are alternatives for removal of large SWL-resistant stones.

Recommendations	LE	GR
Consider the stone composition before deciding on the method of removal (based on patient history, former stone analysis of the patient or HU in unenhanced CT. Stones with density > 1,000 HU on NCCT are less likely to be disintegrated by SWL.		
Attempt to dissolve radiolucent stones (See Section 3.4.2.1.2.2).	2a	B

CT = computed tomography; HU = Hounsfield unit; NCCT = non-contrast enhanced computed tomography; SWL = shockwave lithotripsy.

#### 3.4.1.3.5 Steinstrasse

Steinstrasse is an accumulation of stone fragments or stone gravel in the ureter, which does not pass within a reasonable period of time, and interferes with the passage of urine [112]. Steinstrasse occurs in 4-7% cases of SWL [113], and the major factor in steinstrasse formation is stone size [114].

Insertion of a ureteral stent before SWL prevents formation of steinstrasse in stones > 15 mm in diameter [115]. A major problem of steinstrasse is ureter obstruction, which can be silent in 23% of cases [116, 117].

When steinstrasse is asymptomatic, conservative treatment is an initial option. Medical expulsion therapy significantly increases stone expulsion and reduces the need for endoscopic intervention [118, 119].

Summary of evidence	LE
Medical expulsion therapy increases the stone expulsion rate of steinstrasse [118].	1b
When spontaneous passage is unlikely, further treatment of steinstrasse is indicated.	4
Shockwave lithotripsy is indicated in asymptomatic and symptomatic cases, with no evidence of UTI, when large stone fragments are present [120].	4
Ureteroscopy is effective for the treatment of steinstrasse [121].	3
Placement of a percutaneous nephrostomy tube or ureteral stent is indicated for symptomatic ureteric obstruction with/without UTI.	4

Recommendations	LE	GR
Treat steinstrasse associated with urinary tract infection/fever preferably with percutaneous nephrostomy.	4	C
Treat steinstrasse when large stone fragments are present with shockwave lithotripsy or ureterorenoscopy.	4	C

#### 3.4.2 Specific stone management in renal stones

The natural history of small, non-obstructing asymptomatic calculi is not well defined, and the risk of progression is unclear. There is still no consensus on the follow-up duration, timing and type of intervention. Treatment options are observation, chemolysis or active stone removal.

### 3.4.2.1 Types of treatments

#### 3.4.2.1.1 Conservative treatment (Observation)

Observation of renal stones, especially in calices, depends on their natural history (Section 3.4.2.2).

Summary of evidence	LE
It is still debatable whether renal stones should be treated, or whether annual follow-up is sufficient for asymptomatic caliceal stones that have remained stable for 6 months.	

Recommendations	GR
Follow-up periodically in cases where renal stones are not treated (initially after 6 months and yearly follow-up of symptoms and stone status [US, KUB or CT]).	A*

*\*Upgraded based on panel consensus.*

CT = computed tomography; KUB = kidney, bladder, ureter (plain film); US = ultrasound.

#### 3.4.2.1.2 Pharmacological treatment

##### 3.4.2.1.2.1 Percutaneous irrigation chemolysis

Today, percutaneous chemolysis is rarely used. Percutaneous irrigation chemolysis may be an option for infection- and uric acid stones [122, 123]. For dissolution of struvite stones, Suby's G solution (10% hemiacidrin; pH 3.5-4) can be used [124].

##### 3.4.2.1.2.2 Oral chemolysis

Stones composed of uric acid, but not sodium or ammonium urate, can be dissolved by oral chemolysis. Prior stone analysis may provide information on stone composition. Urinary pH measurement and X-ray characteristics may provide information on the type of stone.

Oral chemolitholysis is based on alkalinisation of urine by application of alkaline citrate or sodium bicarbonate [123, 125]. The pH should be adjusted to 7.0-7.2. Chemolysis is more effective at a higher pH, which might lead to calcium phosphate stone formation.

Monitoring of radiolucent stones during therapy is the domain of US, however, repeat NCCT might be necessary.

In the case of uric acid obstruction of the collecting system, oral chemolysis in combination with urinary drainage is indicated [126]. A combination of alkalinisation with tamsulosin seems to achieve the highest stone-free rates (SFRs) for distal ureteral stones [126].

Recommendations	GR
Inform the patient how to modify the dosage of alkalinising medication according to urine pH, which is a direct consequence of such medication.	A
Inform the patient how to monitor urine pH by dipstick three times a day (at regular intervals). Morning urine must be included.	A
Carefully monitor radiolucent stones during/after therapy.	A*
Inform the patient of the significance of compliance.	A

*\*Upgraded based on panel consensus.*

#### 3.4.2.1.3 Extracorporeal shock wave lithotripsy (SWL)

Success depends on the efficacy of the lithotripter and the following factors:

- size, location (ureteral, pelvic or calyceal), and composition (hardness) of the stones (Section 3.4.3.2);
- patient's habitus (Section 3.4.2.2);
- performance of SWL (best practice, see below).

Each of these factors has an important influence on retreatment rate and final outcome of SWL.

##### 3.4.2.1.3.1 Contraindications of extracorporeal SWL

There are several contraindications to the use of extracorporeal SWL, including:

- pregnancy, due to the potential effects on the foetus [127];
- bleeding diatheses, which should be compensated for at least 24 h before and 48 h after treatment [128];
- uncontrolled UTIs;
- severe skeletal malformations and severe obesity, which prevent targeting of the stone;
- arterial aneurysm in the vicinity of the stone [129];
- anatomical obstruction distal to the stone.

### 3.4.2.1.3.2 Best clinical practice

#### *Stenting*

Routine use of internal stents before SWL does not improve SFR [130] (LE: 1b). A JJ stent reduces the risk of renal colic and obstruction, but does not reduce formation of steinstrasse or infective complications [131].

#### *Pacemaker*

Patients with a pacemaker can be treated with SWL, provided that appropriate technical precautions are taken; patients with implanted cardioverter defibrillators must be managed with special care (firing mode temporarily reprogrammed during SWL treatment). However, this might not be necessary with new-generation lithotripters [132].

#### *Shock wave rate*

Lowering shock wave frequency from 120 to 60-90 shock waves/min improves SFR [83, 133-137]. Tissue damage increases with shock wave frequency [138-142].

<b>Recommendation</b>	<b>LE</b>	<b>GR</b>
Use a shock wave frequency of 1.0-1.5 Hz.	1a	A

#### *Number of shock waves, energy setting and repeat treatment sessions*

The number of shock waves that can be delivered at each session depends on the type of lithotripter and shock wave power. There is no consensus on the maximum number of shock waves.

Starting SWL on a lower energy setting with stepwise power (and SWL sequence) ramping can achieve vasoconstriction during treatment [140], which prevents renal injury [143, 144]. Animal studies [145] and a prospective randomised study [146] have shown better SFRs (96% vs. 72%) using stepwise power ramping, but no difference has been found for fragmentation or evidence of complications after SWL, irrespective of whether ramping was used [147].

There are no conclusive data on the intervals required between repeated SWL sessions. However, clinical experience indicates that repeat sessions are feasible (within 1 day for ureteral stones).

<b>Summary of evidence</b>	<b>LE</b>
Clinical experience has shown that repeat sessions are feasible (within 1 day for ureteral stones).	4

#### *Improvement of acoustic coupling*

Proper acoustic coupling between the cushion of the treatment head and the patient's skin is important.

Defects (air pockets) in the coupling gel reflect 99% of shock waves [148]. Ultrasound gel is probably the most widely used agent available for use as a lithotripsy coupling agent [149].

<b>Recommendation</b>	<b>LE</b>	<b>GR</b>
Ensure correct use of the coupling agent because this is crucial for effective shock wave transportation.	2a	B

#### *Procedural control*

Results of treatment are operator dependent, and better results are obtained by experienced clinicians. During the procedure, careful imaging control of localisation contributes to outcome quality [150].

<b>Recommendation</b>	<b>LE</b>	<b>GR</b>
Maintain careful fluoroscopic and/or ultrasonographic monitoring during the procedure.		A*

\*Upgraded based on panel consensus.

#### *Pain control*

Careful control of pain during treatment is necessary to limit pain-induced movements and excessive respiratory excursions [151-153].

<b>Recommendation</b>	<b>LE</b>	<b>GR</b>
Use proper analgesia because it improves treatment results by limiting induced movements and excessive respiratory excursions.	4	C

### Antibiotic prophylaxis

No standard antibiotic prophylaxis before SWL is recommended. However, prophylaxis is recommended in the case of internal stent placement ahead of anticipated treatments and in the presence of increased bacterial burden (e.g., indwelling catheter, nephrostomy tube, or infectious stones) [154-156].

Recommendation	LE	GR
In the case of infected stones or bacteriuria, prescribe antibiotics prior to SWL.	4	C

### Medical therapy after extracorporeal shock wave lithotripsy

Medical expulsion therapy after SWL for ureteral or renal stones can expedite expulsion and increase SFRs, as well as reduce additional analgesic requirements [157-166] (Section 3.4.2.1.2.1.2).

#### 3.4.2.1.3.3 Complications of extracorporeal shock wave lithotripsy

Compared to PNL and URS, there are fewer overall complications with SWL [167, 168] (Table 3.4.1).

**Table 3.4.1: SWL-related complications** [113, 116, 169-181]

Complications			%	Ref.
Related to stone fragments	Steinstrasse		4 - 7	[113, 116, 169]
	Regrowth of residual fragments		21 - 59	[170, 171]
	Renal colic		2 - 4	[172]
Infectious	Bacteriuria in non-infection stones		7.7 - 23	[170, 173]
	Sepsis		1 - 2.7	[170, 173]
Tissue effect	Renal	Haematoma, symptomatic	< 1	[174]
		Haematoma, asymptomatic	4 - 19	[174]
	Cardiovascular	Dysrhythmia	11 - 59	[170, 175]
		Morbid cardiac events	Case reports	[170, 175]
	Gastrointestinal	Bowel perforation	Case reports	[176-178]
		Liver, spleen haematoma	Case reports	[178-181]

The relationship between SWL and hypertension or diabetes is unclear. Published data are contradictory, however, no evidence exists supporting the hypothesis that SWL may cause long-term adverse effects [6, 182-186].

#### 3.4.2.1.4 Endourology techniques for renal stone removal

##### 3.4.2.1.4.1 Percutaneous nephrolithotomy (PNL)

Percutaneous nephrolithotripsy remains the standard procedure for large renal calculi. Different rigid and flexible endoscopes are available and the selection is mainly based on the surgeon's own preference. Standard access tracts are 24-30 F. Smaller access sheaths, < 18 French, were initially introduced for paediatric use, but are now increasingly popular in adults.

The efficacy of miniaturised systems seems to be high, but longer operation times apply and benefit compared to standard PNL for selected patients has yet to be demonstrated [187]. There is some evidence that smaller tracts cause less bleeding complications, but further studies need to evaluate this issue. Smaller instruments bear the risk of increasing intrarenal pelvic pressure [7] [188-192].

##### 3.4.2.1.4.1.1 Contraindications

Patients receiving anticoagulant therapy must be monitored carefully pre- and post-operatively. Anticoagulant therapy must be discontinued before PNL [105].

Other important contraindications include:

- untreated UTI;
- tumour in the presumptive access tract area;
- potential malignant kidney tumour;
- pregnancy (Section 3.4.3.1).

#### 3.4.2.1.4.1.2 Best clinical practice

##### *Intracorporeal lithotripsy*

Several methods for intracorporeal lithotripsy are available (the devices are discussed in Section 3.4.1.2.1.1.5). During PNL, ultrasonic and pneumatic systems are most commonly used for rigid nephroscopy. When using miniaturised instruments, laser lithotripsy is associated with lower stone migration than with pneumatic lithotripsy [193]. Flexible endoscopes require laser lithotripsy to maintain tip deflection and the Ho:YAG laser has become the standard, as for ureteroscopy [194]. Electrohydraulic lithotripsy (EHL) is highly effective, but is no longer considered as a first-line technique, due to possible collateral damage [195].

Recommendations	GR
Use ultrasonic, ballistic and Ho:YAG devices for intracorporeal lithotripsy during PNL.	A*
When using flexible instruments, use the Ho:YAG laser since it is currently the most effective device.	

*\*Upgraded based on panel consensus.*

*Ho:YAG = holmium:yttrium-aluminium-garnet; PNL = percutaneous nephrolithotomy.*

##### *Preoperative imaging*

Preprocedural evaluations are summarised in Section 3.3.1. In particular, PNL, US or CT of the kidney and the surrounding structures can provide information regarding interpositioned organs within the planned percutaneous path (e.g., spleen, liver, large bowel, pleura, and lung) [196].

Recommendation	GR
Perform preprocedural imaging, including contrast medium where possible or retrograde study when starting the procedure, to assess stone comprehensiveness and anatomy of the collecting system to ensure safe access to the renal stone.	A*

*\*Upgraded based on panel consensus.*

Antibiotic therapy - see General recommendations and precautions for stone removal (See Section 3.4.1.4.1).

##### *Positioning of the patient*

Both prone and supine positions are equally safe.

Although the supine position confers some advantages, it depends on appropriate equipment being available to position the patient correctly, for example, X-ray devices and an operating table. Most studies cannot demonstrate an advantage of supine PNL in terms of OR time. In some series, stone-free rate is lower than for the prone position despite a longer OR time. Prone position offers more options for puncture and is therefore preferred for upper pole or multiple access [197-199]. The Urolithiasis Guidelines Panel will be setting up a systematic review to assess this topic.

##### *Puncture*

Colon interposition in the access tract of PNL can lead to colon injuries. Pre-operative CT or intraoperative US allows identification of the tissue between the skin and kidney and lowers the incidence of bowel injury [200, 201].

##### *Dilatation*

Dilatation of the percutaneous access tract can be achieved using a metallic telescope, single (serial) dilators, or a balloon dilatator. Although there are papers demonstrating that single step dilation is equally effective as other methods, the difference in outcomes is most likely related to surgeon experience rather than to the technology used [200].

##### *Nephrostomy and stents*

The decision on whether or not to place a nephrostomy tube at the end of the PNL procedure depends on several factors, including:

- presence of residual stones;
- likelihood of a second-look procedure;
- significant intraoperative blood loss;
- urine extravasation;
- ureteral obstruction;
- potential persistent bacteriuria due to infected stones;

- solitary kidney;
- bleeding diathesis;
- planned percutaneous chemolitholysis.

Small bore nephrostomies seem to have advantages in terms of post-operative pain [202, 203].

Tubeless PNL is performed without a nephrostomy tube. When neither a nephrostomy tube nor a ureteral stent is introduced, the procedure is known as totally tubeless PNL. In uncomplicated cases, the latter procedure results in a shorter hospital stay, with no disadvantages reported [204-206].

Recommendation	LE	GR
In uncomplicated cases, perform a tubeless (without nephrostomy tube) or totally tubeless (without nephrostomy tube and ureteral stent) PNL procedures as it is a safe alternative.	1b	A

PNL = percutaneous nephrolithotomy.

#### 3.4.2.1.4.1.3 Complications

The most common post-operative complications associated with PNL are fever and bleeding, urinary leakage, and problems due to residual stones (Table 3.4.2).

Table 3.4.2: Complications following PNL [207]

Complications	Trans-fusion	Embolisation	Urinoma	Fever	Sepsis	Thoracic complication	Organ injury	Death	LE
(Range)	(0-20%)	(0-1.5%)	(0-1%)	(0-32.1%)	(0.3-1.1%)	(0-11.6%)	(0-1.7%)	(0-0.3%)	1a
N = 11,929	7%	0.4%	0.2%	10.8%	0.5%	1.5%	0.4%	0.05%	

Peri-operative fever can occur, even with a sterile pre-operative urinary culture and peri-operative antibiotic prophylaxis, because the renal stones themselves may be a source of infection. Intra-operative renal stone culture may therefore help to select post-operative antibiotics [208, 209]. Intraoperative irrigation pressure < 30 mm Hg and unobstructed post-operative urinary drainage may be important factors in preventing post-operative sepsis. Bleeding after PNL may be treated by brief clamping of the nephrostomy tube. Superselective embolic occlusion of the arterial branch may become necessary in the case of severe bleeding.

#### 3.4.2.1.4.2 Ureterorenoscopy for renal stones (RIRS)

Technical improvements including endoscope miniaturisation, improved deflection mechanism, enhanced optical quality and tools, and introduction of disposables have led to an increased use of URS for both, renal and ureteral stones. Major technological progress has been achieved for RIRS [210-212]. Digital scopes demonstrate shorter operation times due to the improvement in image quality [211-213]. For best clinical practice see Section 3.4.3.1.4.1.2 - Ureteral stones-URS.

Stones that cannot be extracted directly must be disintegrated. If it is difficult to access stones that need disintegration within the lower renal pole, it may help to displace them into a more accessible calyx [214].

Recommendation	GR
Use flexible URS in case PNL or SWL are not an option (even for stones larger than 2 cm). However, in that case there is a higher risk that a follow-up procedure and placement of a ureteral stent may be needed. In complex stone cases, use open or laparoscopic approaches as possible alternatives.	B

PNL = percutaneous nephrolithotomy; SWL = shockwave lithotripsy; URS = ureterorenoscopy.

#### 3.4.2.1.4.3 Open and laparoscopic surgery for removal of renal stones

Advances in SWL and endourological surgery (URS and PNL) have significantly decreased the indications for open or laparoscopic stone surgery [215-221]. There is a consensus that most complex stones, including partial and complete staghorn stones, should be approached primarily with PNL. Additionally, a combined approach with PNL and RIRS may also be an appropriate alternative. However, if a reasonable number of percutaneous approaches are not likely to be successful, or if multiple, endourological approaches have been performed unsuccessfully; open or laparoscopic surgery may be a valid treatment option [222-229].

Recommendations	LE	GR
Offer laparoscopic or open surgical stone removal in rare cases in which SWL, (flexible) URS and PNL fail, or are unlikely to be successful.	3	C
When expertise is available, perform surgery laparoscopically before proceeding to open surgery, especially when the stone mass is centrally located.	3	C

PNL = percutaneous nephrolithotomy; SWL = shockwave lithotripsy; URS = ureterorenoscopy.

#### 3.4.2.2 Indication for active stone removal of renal stones [230]

- Stone growth;
- Stones in high-risk patients for stone formation;
- Obstruction caused by stones;
- Infection;
- Symptomatic stones (e.g., pain or haematuria);
- Stones > 15 mm;
- Stones < 15 mm if observation is not the option of choice.
- Patient preference;
- Comorbidity;
- Social situation of the patient (e.g., profession or travelling);
- Choice of treatment.

The risk of a symptomatic episode or need for intervention of patients with asymptomatic renal stones seems to be ~10-25% per year, with a cumulative 5-year event probability of 48.5% [231-234]. A prospective RCT with > 2 years clinical follow-up reported no significant difference between SWL and observation when they compared asymptomatic caliceal stones < 15 mm in terms of SFR, symptoms, requirement for additional treatment, quality of life (QoL), renal function, or hospital admission [235]. Although some have recommended prophylaxis for these stones to prevent renal colic, haematuria, infection, or stone growth, conflicting data have been reported [231, 233, 236]. In a follow-up period of almost 5 years after SWL, two series have demonstrated that up to 25% of patients with small residual fragments needed treatment [171, 237].

Summary of evidence	LE
Although the question of whether caliceal stones should be treated is still unanswered, stone growth, de novo obstruction, associated infection, and acute and/or chronic pain are indications for treatment [230, 238, 239].	3

Recommendations	GR
Assess comorbidity and patient preference when making treatment decisions.	C

#### 3.4.2.3 Selection of procedure for active removal of renal stones

For general recommendations and precautions see Section 3.4.1.3.

##### 3.4.2.3.1 Stones in renal pelvis or upper/middle calices

Shockwave lithotripsy, PNL and RIRS are available treatment modalities for renal calculi. While PNL efficacy is hardly affected by stone size, the SFRs after SWL or URS are inversely proportional to stone size [240-243]. Shockwave lithotripsy achieves good SFRs for stones up to 20 mm, except for those at the lower pole [242, 244]. Endourology is considered an alternative because of the reduced need of repeated procedures and consequently a shorter time until stone-free status is achieved. Stones > 20 mm should be treated primarily by PNL, because SWL often requires multiple treatments, and has the risk of ureteral obstruction (colic or steinstrasse) with the need for adjunctive procedures (Figure 3.4.1) [167]. Retrograde renal surgery cannot be recommended as first-line treatment for stones > 20 mm in uncomplicated cases as SFR is decreasing, and staged procedures have become necessary [245-247]. However, it may be a first-line option in patients where PNL is not an option or contraindicated.

##### 3.4.2.3.2 Stones in the lower renal pole

The stone clearance rate after SWL seems to be lower for stones in the inferior calyx than for other intrarenal locations. Although the disintegration efficacy of SWL is not limited compared to other locations, the fragments often remain in the calyx and cause recurrent stone formation. The reported SFR of SWL for lower pole calculi is 25-95%. The preferential use of endoscopic procedures is supported by some current reports, even for stones smaller than 1 cm [167, 240-244, 247-254].

The following can impair successful stone treatment by SWL:

- steep infundibular-pelvic angle;
- long calyx;
- narrow infundibulum (Table 3.4.4) [140, 250].

Further anatomical parameters cannot yet be established. The value of supportive measures such as inversion, vibration or hydration remains under discussion.

**Table 3.4.4: Unfavourable factors for SWL success for lower caliceal stones** [140, 250, 251, 255]

<b>Factors that make SWL less likely</b>
Shockwave-resistant stones (calcium oxalate monohydrate, brushite, or cystine).
Steep infundibular-pelvic angle.
Long lower pole calyx (> 10 mm).
Narrow infundibulum (< 5 mm).

If there are negative predictors for SWL, PNL and RIRS might be a reasonable alternative, even for smaller calculi [248]. Retrograde renal surgery seems to have comparable efficacy to SWL [167, 244]. Recent clinical experience has suggested a higher stone free rate of RIRS compared to SWL, but at the expense of greater invasiveness. Depending on operator skills, stones up to 3 cm can be treated by RIRS [250, 256-258]. However, staged procedures are frequently required.

In complex stone cases, open or laparoscopic approaches are possible alternatives (see appropriate chapters).


#### 3.4.2.3.3 Recommendations for the selection of procedures for active removal of renal stones

<b>Recommendations</b>	<b>GR</b>
Offer SWL and endourology (PNL, RIRS) as treatment options for stones < 2 cm within the renal pelvis and upper or middle calices.	B
Perform PNL as first-line treatment of larger stones > 2 cm.	B
In case PNL is not an option, treat larger stones (> 2 cm) with flexible URS or SWL. However, in that case there is a higher risk that a follow-up procedure and placement of a ureteral stent may be needed.	B
For the lower pole, perform PNL or RIRS, even for stones > 1 cm, as the efficacy of SWL is limited (depending on favourable and unfavourable factors for SWL).	B

*PNL = percutaneous nephrolithotomy; RIRS = retrograde renal surgery; SWL = shock wave lithotripsy; URS = ureterorenoscopy.*



**Figure 3.4.1: Treatment algorithm for renal calculi**



\*The term ‘Endourology’ encompasses all PNL and URS interventions.

PNL = percutaneous nephrolithotomy; RIRS = retrograde renal surgery; SFR = stone-free rate; SWL = shockwave lithotripsy; URS = ureterorenoscopy;

**3.4.3 Specific stone management of Ureteral stones**

**3.4.3.1 Types of treatment**

**3.4.3.1.1 Conservative treatment / observation**

There are only limited data regarding spontaneous stone passage according to stone size [259]. It is estimated that 95% of stones up to 4 mm pass within 40 days [6].

Observation is feasible in informed patients who develop no complications (infection, refractory pain, deterioration of renal function).

Recommendations	LE	GR
In patients with newly diagnosed small* ureteral stones, if active removal is not indicated (Section 3.4.2.2), observation with periodic evaluation is an optional initial treatment.	1a	A
Appropriate medical therapy should be offered to these patients to facilitate stone passage during observation.		

\*See stratification data [6].

Based on the analysis of available evidence, an exact cut-off size for stones that are likely to pass spontaneously cannot be provided; ≤ 10 mm may be considered a best estimate [6]. Therefore, the Panel decided not to include stone size in this recommendation and would rather limit “small”, suggesting ≤ 6 mm.

The Panel is aware of the fact that spontaneous stone expulsion decreases with increasing stone size and that there are differences between individual patients.

**3.4.3.1.2 Pharmacological treatment, Medical expulsive therapy (MET)**

Medical expulsive therapy should only be used in informed patients. Treatment should be discontinued if complications develop (infection, refractory pain, deterioration of renal function). When using α-blockers for

MET possible side-effects include retrograde ejaculation and hypotension [82].

Meta-analyses have shown that patients with ureteral stones treated with  $\alpha$ -blockers or nifedipine are more likely to pass stones with fewer colic episodes than those not receiving such therapy [82, 261].

Meta-analyses based on small, single centre trials should be interpreted on principle with caution even if the pooled effect is statistically significant. With these limitations in mind, MET has been recommended by the EAU Urolithiasis Guidelines Panel. Further large, multicentric RCTs are needed to confirm the present evidence. The recently published data from Pickard *et al.* is based on a methodologically high quality trial with robust concealment of allocated treatment, demonstrating that tamsulosin and nifedipine are not effective in the routine expectant management of ureteral stones causing a ureteric colic [262]. Although not primarily investigated, this study seriously questions the effectiveness of MET using  $\alpha$ - or calcium channel blockers; not only for ureteral stones and generated fragments but also for their capability of limiting pain.

Summary of evidence	LE
There is evidence in a large number of small single centre trials that MET accelerates spontaneous passage of ureteral stones and fragments generated with SWL, and limits pain [82, 119, 166, 261, 263-267].	1a
There is new evidence from a large multicentric high quality trial that tamsulosin and nifedipine have no expulsive effect, nor limit pain in patients with ureteral stones.	1b

Based on studies with a limited number of patients [268, 269] (LE: 1b), no recommendation for the use of corticosteroids in combination with  $\alpha$ -blockers in MET can be made.

Summary of evidence	LE
There is no evidence to support the use of corticosteroids as monotherapy for MET. Insufficient data exist to support the use of corticosteroids in combination with $\alpha$ -blockers as an accelerating adjunct [268-270].	1b
Patients who elect for an attempt at spontaneous passage or MET should have well-controlled pain, no clinical evidence of sepsis, and adequate renal functional reserve.	

Recommendations for MET	LE	GR
Offer $\alpha$ -blockers as MET as one of the treatment options.	1a	C
Counsel patients regarding the lack of efficacy in a recent large multicentric trial, attendant risks of MET, including associated drug side effects as well as inform the patient that $\alpha$ -blockers are administered off-label <sup>†**</sup> .	1b	A*
Follow up patients in short intervals to monitor stone position and assessed for hydronephrosis.	4	A*

<sup>†</sup> It is not known if tamsulosin harms the human foetus or if it is found in breast milk.

\*Upgraded based on panel consensus.

\*\*MET in children cannot be recommended due to the limited data in this specific population.

MET = medical expulsion therapy.

#### 3.4.3.1.2.1 Medical expulsive therapy after extracorporeal shock wave lithotripsy (SWL)

An RCT and a meta-analysis have shown that MET after SWL for ureteral or renal stones can expedite expulsion and increase SFRs and reduce analgesic requirements [163, 166, 262] (LE: 1a).

#### 3.4.3.1.2.2 Medical expulsive therapy after ureteroscopy

Medical expulsion therapy following Ho:YAG laser lithotripsy increases SFRs and reduces colic episodes [271] (LE: 1b).

#### 3.4.3.1.2.3 Medical expulsive therapy and ureteral stents (see 3.4.3.1.4.1.2 )

#### 3.4.3.1.2.4 Duration of medical expulsive therapy treatment

Most studies have had a duration of one month. No data are currently available to support other time-intervals.

#### 3.4.3.1.3 SWL

For best clinical practice, see Section 3.4.2.1.4.1.2 (Renal stones).

### Stenting

The 2007 AUA/EAU Guidelines on the management of ureteral calculi state that routine stenting is not recommended as part of SWL [6]. When the stent is inserted, patients often suffer from frequency, dysuria, urgency, and suprapubic pain [272].

Recommendation	LE	GR
Do not routinely use a stent as part of SWL treatment of ureteral stones.	1b	A

SWL = *shock wave lithotripsy*.

#### 3.4.3.1.4 Endourology techniques

##### 3.4.3.1.4.1 Ureteroscopy (URS)

The current standard for rigid ureterorenoscopes are tip diameters of < 8 F. Rigid URS can be used for the whole ureter [6]. However, technical improvements, enhanced quality and tools as well as the availability of digital scopes also favour the use of flexible ureteroscopes in the ureter [210].

##### 3.4.3.1.4.1.1 Contraindications

Apart from general problems, for example, with general anaesthesia or untreated UTIs, URS can be performed in all patients without any specific contraindications.

##### 3.4.3.1.4.1.2 Best clinical practice in ureterorenoscopy (URS)

###### *Access to the upper urinary tract*

Most interventions are performed under general anaesthesia, although local or spinal anaesthesia is possible. Intravenous sedation is suitable for female patients with distal ureteral stones [273].

Antegrade URS is an option for large, impacted proximal ureteral calculi [274] (Section 3.4.3.1.4.2).

###### *Safety aspects*

Fluoroscopic equipment must be available in the operating room. We recommend placement of a safety wire, even though some groups have demonstrated that URS can be performed without it [275, 276].

Balloon and plastic dilators should be available if necessary.

Prior rigid ureteroscopy can be helpful for optical dilatation followed by flexible URS if necessary. If ureteral access is not possible, insertion of a JJ stent followed by URS after 7-14 days offers an alternative procedure.

Recommendation	GR
Place a safety wire.	C

###### *Ureteral access sheaths*

Hydrophilic-coated ureteral access sheaths, which are available in different calibres (inner diameter from 9 F upwards), can be inserted via a guide wire, with the tip placed in the proximal ureter.

Ureteral access sheaths allow easy multiple access to the upper urinary tract and therefore significantly facilitate URS. The use of ureteral access sheaths improves vision by establishing a continuous outflow, decreasing intrarenal pressure, and potentially reduces operating time [277, 278].

The insertion of ureteral access sheaths may lead to ureteral damage, whereas the risk was lowest in pre-stented systems [279]. No data on long-term consequences are available [279, 280]. Use of ureteral access sheaths depends on the surgeon's preference.

###### *Stone extraction*

The aim of URS is complete stone removal. "Dust and go" strategies should be limited to the treatment of large (renal) stones.

Stones can be extracted by endoscopic forceps or baskets. Only baskets made of nitinol can be used for flexible URS [281].

Recommendation	LE	GR
Do not perform stone extraction using a basket without endoscopic visualisation of the stone (blind basketing).	4	A*

\*Upgraded based on panel consensus.

### Intracorporeal lithotripsy

The most effective lithotripsy system is the Ho:YAG laser, which has become the gold standard for ureteroscopy and flexible nephroscopy (Section 3.4.2.1.4.1.2), because it is effective for all stone types [282, 283]. Pneumatic and US systems can be used with high disintegration efficacy in rigid URS [284, 285].

However, stone migration into the kidney is a common problem, which can be prevented by placement of special antimigration tools proximal of the stone [286].

Recommendation	LE	GR
Use Ho:YAG laser lithotripsy for (flexible) URS.	3	B

Ho:YAG = holmium:yttrium-aluminium-garnet; URS = ureterorenoscopy.

### Stenting before and after URS

Routine stenting is not necessary before URS. However, pre-stenting facilitates ureteroscopic management of stones, improves the SFR, and reduces complications [287].

Randomised prospective trials have found that routine stenting after uncomplicated URS (complete stone removal) is not necessary; stenting might be associated with higher post-operative morbidity [288-290]. A ureteric catheter with a shorter indwelling time (1 day) may also be used, with similar results [291].

Stents should be inserted in patients who are at increased risk of complications (e.g., ureteral trauma, residual fragments, bleeding, perforation, UTIs, or pregnancy), and in all doubtful cases, to avoid stressful emergencies. The ideal duration of stenting is not known. Most urologists favour 1-2 weeks after URS.

Alpha-blockers reduce the morbidity of ureteral stents and increase tolerability [292, 293]. A recently published meta-analysis provides evidence for improvement of ureteral stent tolerability with tamsulosin [294].

Summary of evidence	LE
In uncomplicated URS, a stent need not be inserted.	1a
An $\alpha$ -blocker can reduce stent-related symptoms.	1b

URS = ureterorenoscopy.

### 3.4.3.1.4.1.3 Complications

The overall complication rate after URS is 9-25% [6, 295, 296]. Most are minor and do not require intervention.

Ureteral avulsion and strictures are rare (< 1%). Previous perforations are the most important risk factor for complications.

### 3.4.3.1.4.2 Percutaneous antegrade ureteroscopy

Percutaneous antegrade removal of ureteral stones is a consideration in selected cases, i.e. large, impacted proximal ureteral calculi with dilated renal collecting system [297], or when the ureter is not amenable to retrograde manipulation [274, 298-301].

Recommendation	GR
Use percutaneous antegrade removal of ureteral stones as an alternative when SWL is not indicated or has failed, and when the upper urinary tract is not amenable to retrograde URS.	A

SWL = shock wave lithotripsy; URS = ureterorenoscopy.

### 3.4.3.1.5 Laparoscopic ureteral stone removal

Few studies have reported laparoscopic stone removal (Section 3.4.2.1.4.3). These procedures are usually reserved for special cases; therefore, the reported data could not be used to compare procedures with each other or with SWL or URS. These more invasive procedures have yielded high SFRs [224].

Recommendation	LE	GR
For ureterolithotomy, perform laparoscopy for large impacted stones when endoscopic lithotripsy or SWL has failed.	2	B

SWL = shock wave lithotripsy.

3.4.3.2 Indications for active removal of ureteral stones [6, 259, 302]

Indications for active removal of ureteral stones are:

- Stones with low likelihood of spontaneous passage;
- Persistent pain despite adequate analgesic medication;
- Persistent obstruction;
- Renal insufficiency (renal failure, bilateral obstruction, or single kidney).

For general recommendations and precautions see Section 3.4.1.3.

Obesity can cause a lower success rate after SWL and PNL and may influence the choice of treatment.

Summary of evidence	LE
In the case of a severe obesity, URS is a more promising therapeutic option than SWL.	2b

SWL = shockwave lithotripsy; URS = ureterorenoscopy.

3.4.3.2.5.1 Bleeding disorder


URS can be performed in patients with bleeding disorders, with a moderate increase in complications (see also Section 3.4.1.3) [105, 108].

3.4.3.3 Selection of procedure for active removal of ureteral stones

Overall SFRs after URS or ESWL for ureteral stones are comparable. However, larger stones achieve earlier stone-free status with URS. Although URS is effective for ureteric calculi, it has greater potential for complications. However, in the current endourological era, the complication rate and morbidity of ureteroscopy have been significantly reduced [303, 304].

These findings are confirmed by the preliminary results of a recent systematic review performed by the Urolithiasis Guidelines Panel [305]. Compared to SWL, ureteroscopic management of proximal ureteral calculi is associated with significantly higher SFRs, lower re-treatment rates and less need for secondary and adjunctive procedures. However, ureteroscopic management is associated with higher complication rates and a longer hospital stay. Further well-designed RCTs with sufficient power are needed to better address the efficacy, complications and other treatment-related parameters of both modalities.

Figure 3.4.2: Recommended treatment options (if indicated for active stone removal) (GR: A\*)



\*Upgraded following panel consensus.

SWL = shockwave lithotripsy; URS = ureterorenoscopy.

Recommendation	GR
Inform patients that URS has a better chance of achieving stone-free status with a single procedure.	A*
Inform patients that URS has higher complication rate when compared to SWL.	A*

\*Upgraded following panel consensus.

SWL = shockwave lithotripsy; URS = ureteronoscopy.

#### 3.4.4 Management of patients with residual stones

The clinical problem of residual renal stones is related to the risk of developing:

- new stones from such nidi (heterogeneous nucleation);
- persistent UTI;
- dislocation of fragments with/without obstruction and symptoms [171, 306, 307].

Recommendations	LE	GR
Identify biochemical risk factors and appropriate stone prevention in patients with residual fragments or stones [171, 307, 308].	1b	A
Follow-up patients with residual fragments or stones regularly to monitor disease course.	4	C

Recurrence risk in patients with residual fragments after treatment of infection stones is higher than for other stones [308]. For all stone compositions, 21-59% of patients with residual stones required treatment within 5 years. Fragments > 5 mm are more likely than smaller ones to require intervention [171, 306, 309].

##### 3.4.4.1 Therapy

The indications for active removal of residual stones and selection of the procedure are based on the same criteria as for primary stone treatment (Section 3.4.2.4) and includes repeat SWL [310].

If intervention is not required, medical therapy according to stone analysis, patient risk group, and metabolic evaluation might help to prevent regrowth of residual fragments [311-313].

Summary of evidence	LE
For well-disintegrated stone material in the lower calix, an inversion therapy with simultaneous mechanical percussion manoeuvre under enforced diuresis may facilitate stone clearance [314].	1b

Recommendations	LE	GR
After SWL and URS, and in the presence of residual fragments, offer MET using an $\alpha$ -blocker to improve fragment clearance.	1a	A

MET = medical expulsive therapy; SWL = shockwave lithotripsy; URS = ureteronoscopy.

**Table 3.4.5: Recommendations for the treatment of residual fragments**

Residual fragments, stones (largest diameter)	Symptomatic residuals	Asymptomatic residuals	LE	GR
< 4-5 mm	Stone removal	Reasonable follow-up (dependent on risk factors)	4	C
> 5 mm	Stone removal	4	C	

#### 3.4.5 Management of specific patient groups

##### 3.4.5.1 Management of urinary stones and related problems during pregnancy

Clinical management of a pregnant urolithiasis patient is complex and demands close collaboration between patient, radiologist, obstetrician and urologist. For diagnostic imaging see Section 3.3.1.

If spontaneous passage does not occur, or if complications develop (e.g., induction of premature labour), placement of a ureteral stent or a percutaneous nephrostomy tube is necessary [315-317]. Unfortunately, these temporising therapies are often associated with poor tolerance, and they require multiple exchanges during pregnancy, due to the potential for rapid encrustation. Uteroscopy has become a reasonable alternative in these situations [318-320]. Although feasible, retrograde endoscopic and percutaneous removal of renal stones during pregnancy remain an individual decision and should be performed only in experienced centres [321].

Pregnancy remains an absolute contraindication for SWL.

Summary of evidence	LE
If intervention becomes necessary, placement of a ureteral stent or a percutaneous nephrostomy tube are readily available primary options.	3
Ureteroscopy is a reasonable alternative to avoid long-term stenting/drainage.	1a
Regular follow-up until final stone removal is necessary due to the higher encrustation tendency of stents during pregnancy.	

Recommendation	GR
Treat all non-complicated cases of urolithiasis in pregnancy conservatively (except those that have clinical indications for intervention).	A

### 3.4.5.2 Management of stones in patients with urinary diversion

#### 3.4.5.2.1 Aetiology

Patients with urinary diversion are at high risk for stone formation in the renal collecting system and ureter or in the conduit or continent reservoir [322-324]. Metabolic factors (hypercalciuria, hyperoxaluria and hypocitraturia), infection with urease-producing bacteria, foreign bodies, mucus secretion, and urinary stasis are responsible for stone formation [325] (Section 3.1.3). One study has shown that the risk for recurrent upper-tract stones in patients with urinary diversion subjected to PNL was 63% at 5 years [326].

#### 3.4.5.2.2 Management

Smaller upper-tract stones can be treated effectively with SWL [299, 327]. In the majority, endourological techniques are necessary to achieve stone-free status [298]. In individuals with long, tortuous conduits or with invisible ureter orifices a retrograde endoscopic approach might be difficult or impossible.

Summary of evidence	LE
The choice of access depends on the feasibility of orifice identification in the conduit or bowel reservoir. Whenever a retrograde approach is impossible, percutaneous access with antegrade URS is the alternative.	4

Recommendation	GR
Perform PNL to remove large renal stones in patients with urinary diversion, as well as for ureteral stones that cannot be accessed via a retrograde approach or that are not amenable to SWL.	A*

*PNL = percutaneous nephrolithotomy; SWL = shockwave lithotripsy; URS = ureterorenoscopy.*

For stones in the conduit, a trans-stomal approach can be used to remove all stone material (along with the foreign body) using standard techniques, including intracorporeal lithotripsy and flexible endoscopes. Transstomal manipulations in continent urinary diversion must be performed carefully to avoid disturbance of the continence mechanism [328].

Before considering any percutaneous approach in these cases, CT should be undertaken to assess the presence of an overlying bowel, which could make this approach unsafe [329], and if present, an open surgical approach should be considered.

#### 3.4.5.2.3 Prevention

Recurrence risk is high in these patients [326]. Metabolic evaluation and close follow-up of the patients are necessary to obtain the risk parameters for effective long-term prevention. Preventive measures include medical management of metabolic abnormalities, appropriate therapy of urinary infections, and hyperdiuresis or regular irrigation of continent reservoirs [330].

### 3.4.5.3 Management of stones in patients with neurogenic bladder

#### 3.4.5.3.1 Aetiology, clinical presentation and diagnosis

Patients with neurogenic bladder develop urinary calculi because of additional risk factors such as bacteriuria, pelvicaliectasis, vesicoureteral reflux, renal scarring, lower urinary tract reconstruction, and thoracic spinal defect [331]. The main issues are urinary stasis and infection (Section 3.1.3). Indwelling catheters and surgical interposition of bowel segments for treatment of bladder dysfunction both facilitate UTI. Although calculi can form at any level of the urinary tract, they occur more frequently in the bladder; especially if bladder augmentation has been performed [332, 333].

Diagnosis of stones may be difficult and delayed in the absence of clinical symptoms due to sensory

impairment and vesicourethral dysfunction. Difficulties in self-catheterisation should lead to suspicion of bladder calculi. Imaging studies are needed (US, CT) to confirm clinical diagnosis prior to surgical intervention.

#### 3.4.5.3.2 Management

Management of calculi in patients with neurogenic bladder is similar to that described in Section 3.3.3. In MMC (myelomeningocele) patients, latex allergy is common, therefore, appropriate measures need to be taken regardless of the treatment [334]. Any surgery in these patients must be performed under general anaesthesia because of the impossibility of using spinal anaesthesia. Bone deformities often complicate positioning on the operating table [335]. The risk of stone formation after augmentation cystoplasty in immobile patients with sensory impairment can be significantly reduced by irrigation protocols [330].

For efficient long-term stone prevention in patients with neurogenic bladder, correction of the metabolic disorder, appropriate infection control, and restoration of normal storing/voiding function of the bladder are needed.

Summary of evidence	LE
Patients undergoing urinary diversion and/or suffering from neurogenic bladder dysfunction are at risk for recurrent stone formation.	3

Recommendation	GR
Take appropriate measures regardless of the treatment provided since in myelomeningocele patients latex allergy is common.	B

#### 3.4.5.4 Management of stones in transplanted kidneys

##### 3.4.5.4.1 Aetiology

Transplant patients depend on their solitary kidney for renal function. Impairment causing urinary stasis/obstruction therefore requires immediate intervention or drainage of the transplanted kidney. Risk factors in these patients are multifold:

- Immunosuppression increases the infection risk, resulting in recurrent UTIs.
- Hyperfiltration, excessively alkaline urine, renal tubular acidosis, and increased serum calcium caused by persistent tertiary hyperparathyroidism [336] are biochemical risk factors.

Stones in kidney allografts have an incidence of 0.2-1.7% [337-339].

Recommendation	LE	GR
Perform US or NCCT to rule out calculi in patients with transplanted kidneys, unexplained fever, or unexplained failure to thrive (particularly in children) [340].	4	B

NCCT = non-contrast enhanced computed tomography; US = ultrasound.

##### 3.4.5.4.2 Management

Treatment decisions for selecting the appropriate technique for stone removal from a transplanted kidney are difficult. Although management principles are similar to those applied in other single renal units [341-344], additional factors such as transplant function, coagulative status, and anatomical obstacles due to the iliacal position of the organ, directly influence the surgical strategy.

For large or ureteral stones, careful percutaneous access and subsequent antegrade endoscopy are more favourable. The introduction of small flexible ureteroscopes and the holmium laser has made ureteroscopy a valid treatment option for transplant calculi. However, one must be aware of potential injury to adjacent organs [345-347]. Retrograde access to transplanted kidneys is difficult due to the anterior location of the ureteral anastomosis, and ureteral tortuosity [348-350].

Summary of evidence	LE
Conservative treatment for small asymptomatic stones is only possible under close surveillance and in absolutely compliant patients.	
SWL for small calyceal stones is an option with minimal complication risk, but localisation of the stone can be challenging and SFRs are poor [351, 352].	4



Recommendations	GR
Offer patients with transplanted kidneys, any of the contemporary treatment modalities, including shockwave therapy, (flexible) ureteroscopy, and percutaneous nephrolithotomy as management options.	B
Complete metabolic evaluation after stone removal.	A*

\*Upgraded following panel consensus.

#### 3.4.5.4.3 Special problems in stone removal

**Table 3.4.6: Special problems in stone removal**

Caliceal diverticulum stones	<ul style="list-style-type: none"> <li>• SWL, PNL (if possible) or RIRS.</li> <li>• Can also be removed using laparoscopic retroperitoneal surgery [353-357].</li> <li>• Patients may become asymptomatic due to stone disintegration (SWL), whilst well-disintegrated stone material remains in the original position due to narrow caliceal neck.</li> </ul>
Horseshoe kidneys	<ul style="list-style-type: none"> <li>• Can be treated in line with the options described above [358].</li> <li>• Passage of fragments after SWL might be poor.</li> <li>• Acceptable stone free rates can be achieved with flexible ureteroscopy [359].</li> </ul>
Stones in pelvic kidneys	<ul style="list-style-type: none"> <li>• SWL, RIRS, PNL or laparoscopic surgery.</li> <li>• For obese patients, the options are RIRS, PNL or open surgery.</li> </ul>
Stones formed in a continent reservoir	<ul style="list-style-type: none"> <li>• See Section 3.4.4.</li> <li>• Each stone must be considered and treated individually.</li> </ul>
Patients with obstruction of the ureteropelvic junction	<ul style="list-style-type: none"> <li>• When outflow abnormality requires correction, stones can be removed by PNL together with percutaneous endopyelotomy or open/laparoscopic reconstructive surgery.</li> <li>• URS together with endopyelotomy with Ho:YAG.</li> <li>• Incision with an Acucise balloon catheter might be considered, provided the stones can be prevented from falling into the pelvi-ureteral incision [360-363].</li> </ul>

Ho:YAG = holmium:yttrium-aluminium-garnet; SWL = shockwave lithotripsy; PNL = percutaneous nephrolithotomy; URS = ureterorenoscopy; RIRS = retrograde renal surgery.

#### 3.4.6 Management of urolithiasis in children

Rates of urolithiasis have increased in developed countries, and there has been a shift in the age group experiencing a first stone episode [11, 364, 365]. More than 1% of all urinary stones are seen in patients aged < 18 years. As a result of malnutrition and racial factors, paediatric urolithiasis remains an endemic disease in some areas (e.g., Turkey and the Far East); elsewhere, the rates are similar to those observed in developed countries [366-369].

For diagnostic procedures see Section 3.3.3.2., for acute decompression see Section 3.4.1.2.

##### 3.4.6.1 Stone removal

Several factors must be considered when selecting treatment procedures for children. Compared to adults, children pass fragments more rapidly after SWL [49]. For endourological procedures, the smaller organs in children must be considered when selecting instruments for PNL or URS. Anticipation of the expected stone composition should be taken into account when selecting the appropriate procedure for stone removal (cystine stones are more resistant to SWL).

Summary of evidence	LE
Spontaneous passage of a stone is more likely in children than in adults [59].	4

##### 3.4.6.1.1 Medical expulsive therapy (MET) in children

Medical expulsive therapy has already been discussed in Section 3.4.3.1.2 but not addressing children. Although the use of  $\alpha$ -blockers is very common in adults, there are few data to demonstrate their safety and efficacy in children; however tamsulosin seems to support stone passage [62, 370-372].

#### 3.4.6.1.2 Extracorporeal shock wave lithotripsy

Extracorporeal shock wave lithotripsy remains the least-invasive procedure for stone management in children [373-378].

SFRs of 67-93% in short-term and 57-92% in long-term follow-up studies have been reported. In children, compared with adults, SWL can achieve more effective disintegration of large stones, together with swifter and uncomplicated discharge of large fragments [375, 379]. As in adults the slow delivery rate of shock waves may improve the stone clearance rates [379]. Stones located in calices, as well as abnormal kidneys, and large stones, are more difficult to disintegrate and clear. The likelihood of urinary obstruction is higher in such cases, and children should be followed closely for the prolonged risk of urinary tract obstruction. The retreatment rate is 13.9-53.9%, and the need for ancillary procedures and/or additional interventions is 7-33% [375, 377].

The need for general anaesthesia during SWL depends on patient age and the lithotripter used. General or dissociative anaesthesia is administered in most children aged < 10 years, to avoid patient and stone motion and the need for repositioning [375, 377]. With modern lithotripters, intravenous sedation or patient-controlled analgesia have been used in selected cooperative older children [380] (LE: 2b). There are concerns regarding the safety and potential biological effects of SWL on immature kidneys and surrounding organs in children. However, during short- and long-term follow-up, no irreversible functional or morphological side effects of high-energy shock waves have been demonstrated. In addition, when the potential deterioration of renal function is taken into account (although transient), restricting the number of shock waves and the energy used during each treatment session helps protect the kidneys [381-384].

If the stone burden requires an ureteral stent, alternative procedures should be considered. Ureteral stents are seldom needed following SWL of upper tract stones, ureteral pre-stenting decreases the SFR after initial treatment [373-375].

Summary of evidence	LE
In children, the indications for SWL are similar to those in adults; however, they pass fragments more easily.	3
Children with renal stones of a diameter up to 20 mm (~300 mm <sup>2</sup> ) are ideal candidates for SWL.	1b

SWL = *shockwave lithotripsy*.

#### 3.4.6.1.3 Endourological procedures

Improvement in intracorporeal lithotripsy devices and development of smaller instruments facilitate PNL and URS in children.

##### 3.4.6.1.3.1 Percutaneous nephrolithotripsy (PNL)

Pre-operative evaluation and indications for PNL in children are similar to those in adults. Provided appropriate size instruments and US guidance are used, age is not a limiting factor, and PNL can be performed safely by experienced operators, with less radiation exposure, even for large and complex stones [385-389]. Stone-free rates are between 68% and 100% after a single session, and increase with adjunctive measures, such as second-look PNL, SWL and URS [385].

As for adults, tubeless PNL is safe in children, in well-selected cases [390, 391].

Summary of evidence	LE
For paediatric patients, the indications for PNL are similar to those in adults.	1a

Recommendation	GR
In children, perform PNL for the treatment of renal pelvic or caliceal stones with a diameter > 20 mm (~300 mm <sup>2</sup> ).	C

PNL = *percutaneous nephrolithotomy*.

##### 3.4.6.1.3.2 Ureteroscopy

Although SWL is still the first-line treatment for most ureteral stones, it is unlikely to be successful for stones > 10 mm in diameter, or for impacted, calcium oxalate monohydrate or cystine stones, or stones in children with unfavourable anatomy and in whom localisation is difficult [392, 393].

If SWL is not promising, ureteroscopy can be used. With the clinical introduction of smaller-calibre

instruments, this modality has become the treatment of choice for medium and larger distal ureteric stones in children [392-396].

Different lithotripsy techniques, including ultrasonic, pneumatic and laser lithotripsy, are all safe and effective (Section 3.4.3.1.4.1.2) [397, 398].

Recommendation	LE	GR
For intracorporeal lithotripsy, use the same devices as in adults (Ho:YAG laser, pneumatic- and US lithotripters).	3	C

*Ho:YAG = holmium:yttrium-aluminium-garnet; US = ultrasound.*

Flexible ureteroscopy has become an efficacious treatment for paediatric upper urinary tract stones. It might be particularly effective for treatment of proximal ureteral calculi and for stones < 1.5 cm in the lower pole calices [398-401].

#### 3.4.6.1.3.3 Open or laparoscopic surgery

Most stones in children can be managed by SWL and endoscopic techniques. Therefore, the rate of open procedure has dropped significantly [402-404]. Indications for surgery include: failure of primary therapy for stone removal; very young children with complex stones; congenital obstruction that requires simultaneous surgical correction; severe orthopaedic deformities that limit positioning for endoscopic procedures; and abnormal kidney position [373, 374, 386]. Open surgery can be replaced by laparoscopic procedures in experienced hands [403, 404].

#### 3.4.6.1.3.4 Special considerations on recurrence prevention

All paediatric stone formers need metabolic evaluation and recurrence prevention with respect to the detected stone type. In radiolucent stones oral chemolysis may be considered as an alternative to SWL [405]. In the case of obstructive pathology in association with the established metabolic abnormalities, treatment should not be delayed. Children are in the high-risk group for stone recurrence [62, 406] (Chapter 4).

## 4. FOLLOW UP: METABOLIC EVALUATION AND RECURRENCE PREVENTION

### 4.1 General metabolic considerations for patient work-up


#### 4.1.1 Evaluation of patient risk

After stone passage, every patient should be assigned to a low- or high-risk group for stone formation (Figure 4.1).

For correct classification, two items are mandatory:

- reliable stone analysis by infrared spectroscopy or X-ray diffraction;
- basic analysis (Section 3.3.2).

**Figure 4.1 Assignment of patients to low- or high-risk groups for stone formation**



Only high-risk stone formers require specific metabolic evaluation. Stone type is the deciding factor for further diagnostic tests. The different stone types include:

- calcium oxalate;
- calcium phosphate;
- uric acid;
- ammonium urate;
- struvite (and infection stones);
- cystine;
- xanthine;
- 2,8-Dihydroxyadenine;
- drug stones;
- stones of unknown composition.

#### 4.1.2 **Urine sampling**

Specific metabolic evaluation requires collection of two consecutive 24-h urine samples [407, 408]. The collecting bottles should be prepared with 5% thymol in isopropanol or stored at  $\leq 8^{\circ}\text{C}$  during collection to prevent the risk of spontaneous crystallisation in the urine [409, 410]. Pre-analytical errors can be minimised by carrying out urinalysis immediately after collection. Alternatively boric acid (10 g powder per urine container) can also be used. The collecting method should be chosen in close cooperation with the particular laboratory. Urine pH should be assessed during collection of freshly voided urine four times daily [17, 409] using sensitive pH-dipsticks or a pH-meter.

Spot urine samples are an alternative method of sampling, particularly when 24-h urine collection is difficult, for example, in non-toilet trained children [411]. Spot urine studies normally link the excretion rates to creatinine [411], but these are of limited use because the results may vary with collection time and patients' sex, body weight and age.

#### 4.1.3 **Timing of specific metabolic work-up**

For the initial specific metabolic work-up, the patient should stay on a self-determined diet under normal daily conditions and should ideally be stone free for at least 20 days [412].

Follow-up studies are necessary in patients taking medication for recurrence prevention [413]. The first follow-up 24-h urine measurement is suggested 8-12 weeks after starting pharmacological prevention of stone recurrence. This enables drug dosage to be adjusted if urinary risk factors have not normalised, with further 24-h urine measurements if necessary. Once urinary parameters have been normalised, it is sufficient to perform 24-h urine evaluation every 12 months. The panel realise that on this issue there is only very limited published evidence. The Urolithiasis Guidelines Panel aim to set up a systematic review on the ideal timing of the 24-hour urine collection.

#### 4.1.4 **Reference ranges of laboratory values**

Tables 4.1 - 4.4 provide the internationally accepted reference ranges for the different laboratory values in serum and urine.

**Table 4.1: Normal laboratory values for blood parameters in adults [414]**

Blood parameter	Reference range	
Creatinine	20-100 µmol/L	
Sodium	135-145 mmol/L	
Potassium	3.5-5.5 mmol/L	
Calcium	2.0-2.5 mmol/L (total calcium)	
	1.12-1.32 mmol/L (ionised calcium)	
Uric acid	119-380 µmol/L	
Chloride	98-112 mmol/L	
Phosphate	0.81-1.29 mmol/L	
Blood gas analysis	pH	7.35-7.45
	pO <sub>2</sub>	80-90 mmHg
	pCO <sub>2</sub>	35-45 mmHg
	HCO <sub>3</sub>	22-26 mmol/L
	BE	± 2 mmol/L

*BE = base excess (loss of buffer base to neutralise acid); HCO = bicarbonate; PCO = partial pressure of carbon dioxide; PO = partial pressure of oxygen.*

#### 4.1.5 **Risk indices and additional diagnostic tools**

Several risk indices have been developed to describe the crystallisation risk for calcium oxalate or calcium phosphate in urine [415-418]. However, clinical validation of these risk indices for recurrence prediction or therapy improvement is ongoing.

**Table 4.2: Normal laboratory values for urinary parameters in adults**

Urinary Parameters	Reference ranges and limits for medical attention
pH	Constantly > 5.8 (suspicious of RTA)
	Constantly > 7.0 (suspicious of infection)
	Constantly ≤ 5.8 (suspicious of acidic arrest)
Specific weight	> 1.010
Creatinine	7-13 mmol/day females
	13-18 mmol/day males
Calcium	> 5.0 mmol/day (see Fig. 4.2)
	≥ 8.0 mmol/day (see Fig. 4.2)
Oxalate	> 0.5 mmol/day (suspicious of enteric hyperoxaluria)
	≥ 1.0 mmol/day (suspicious of primary hyperoxaluria)
Uric acid	> 4.0 mmol/day (women), 5 mmol/day (men)
Citrate	< 2.5 mmol/day
Magnesium	< 3.0 mmol/day
Inorganic phosphate	> 35 mmol/day
Ammonium	> 50 mmol/day
Cystine	> 0.8 mmol/day

RTA = renal tubular acidosis.

**Table 4.3: Normal values for spot urine samples: creatinine ratios (solute/creatinine) in adults [419]**

Parameter/Patient age	Ratio of solute to creatinine	units
<b>Calcium</b>	<b>mol/mol</b>	<b>mg/mg</b>
< 12 months	< 2.0	0.81
1-3 years	< 1.5	0.53
1-5 years	< 1.1	0.39
5-7 years	< 0.8	0.28
> 7 years	< 0.6	0.21
<b>Oxalate</b>	<b>mol/mol</b>	<b>mg/g</b>
0-6 months	< 325-360	288-260
7-24 months	< 132-174	110-139
2-5 years	< 98-101	80
5-14 years	< 70-82	60-65
> 16 years	< 40	32
<b>Citrate</b>	<b>mol/mol</b>	<b>g/g</b>
0-5 years	> 0.25	0.42
> 5 years	> 0.15	0.25
<b>Magnesium</b>	<b>mol/mol</b>	<b>g/g</b>
	> 0.63	> 0.13
<b>Uric acid</b>	< 0.56 mg/dl (33 imol/L) per GFR (ratio x plasma creatinine)	
> 2 years		

**Table 4.4: Solute excretion in 24-h urine samples in children [419]\*\***

Calcium/24 h	Citrate/24 h		Cystine/24 h		Oxalate/24 h		Urate/24 h	
	Boys	Girls	< 10 y	> 10 y	All age groups	< 1 y	1-5 y	> 5 y
< 0.1 mmol/kg/24 h	> 1.9 mmol/1.73 m <sup>2</sup> /24 h	> 1.6 mmol/1.73 m <sup>2</sup> /24 h	< 55 μmol/1.73 m <sup>2</sup> /24 h	< 200 μmol/1.73 m <sup>2</sup> /24 h	< 0.5 mmol/1.73 m <sup>2</sup> /24 h	< 70 μmol/kg/24 h	< 65 μmol/kg/24 h	< 55 μmol/kg/24 h
< 4 mg/kg/24 h	> 365 mg/1.73 m <sup>2</sup> /24 h	> 310 mg/1.73 m <sup>2</sup> /24 h	< 13 mg/1.73 m <sup>2</sup> /24 h	< 48 mg/1.73 m <sup>2</sup> /24 h	< 45 mg/1.73 m <sup>2</sup> /24 h	< 13 mg/kg/24 h	< 11 mg/kg/24 h	< 9.3 mg/kg/24 h

\*\*24 h urine parameters are diet and gender dependent and may vary geographically.

## 4.2 General considerations for recurrence prevention

All stone formers, independent of their individual risk, should follow the preventive measures in Table 4.5. The main focus of these is normalisation of dietary habits and lifestyle risks. Stone formers at high risk need specific prophylaxis for recurrence, which is usually pharmacological treatment and based on stone analysis.

**Table 4.5: General preventive measures**

Fluid intake (drinking advice)	Fluid amount: 2.5-3.0 L/day Circadian drinking Neutral pH beverages Diuresis: 2.0-2.5 L/day Specific weight of urine: < 1010
Nutritional advice for a balanced diet	Balanced diet* Rich in vegetables and fibre Normal calcium content: 1-1.2 g/day Limited NaCl content: 4-5 g/day Limited animal protein content: 0.8-1.0 g/kg/day
Lifestyle advice to normalise general risk factors	BMI: retain a normal BMI level Adequate physical activity Balancing of excessive fluid loss

*Caution: The protein need is age dependent, therefore protein restriction in childhood should be handled carefully.*

*\* Avoid excessive consumption of vitamin supplements.*

### 4.2.1 Fluid intake

An inverse relationship between high fluid intake and stone formation has been repeatedly demonstrated [420-422]. The effect of fruit juices is mainly determined by the presence of citrate or bicarbonate [423]. If hydrogen ions are present, the net result is neutralisation. However, if potassium is present, both pH and citrate are increased [424, 425]. One large fair-quality RCT randomly assigned men with more than one past renal stone of any type and soft drink consumption greater than 160 mL/day to reduced soft drink intake or no treatment. Although the intervention significantly reduced the risk for symptomatic recurrent stones (RR: 0.83 [CI: 0.71-0.98]), the level of evidence for this outcome was low because results were from only one trial [422, 426].

### 4.2.2 Diet

A common sense approach to diet should be taken, that is, a mixed balanced diet with contributions from all food groups, without any excesses [422, 427, 428].

*Fruits, vegetables and fibres:* fruit and vegetable intake should be encouraged because of the beneficial effects of fibre, although the role of the latter in preventing stone recurrences is debatable [429-432]. The alkaline content of a vegetarian diet also increases urinary pH.

*Oxalate:* excessive intake of oxalate-rich products should be limited or avoided to prevent high oxalate load [423], particularly in patients who have high oxalate excretion.

*Vitamin C:* although vitamin C is a precursor of oxalate, its role as a risk factor in calcium oxalate stone formation remains controversial [433]. However, it seems wise to advise calcium oxalate stone formers to avoid excessive intake.

*Animal protein:* should not be taken in excess [434, 435] and limited to 0.8-1.0 g/kg body weight. Excessive consumption of animal protein has several effects that favour stone formation, including hypocitraturia, low urine pH, hyperoxaluria and hyperuricosuria.

*Calcium intake:* should not be restricted unless there are strong reasons due to the inverse relationship between dietary calcium and stone formation [430, 436]. The daily requirement for calcium is 1,000 to 1,200 mg [17]. Calcium supplements are not recommended except in enteric hyperoxaluria, when additional calcium should be taken with meals to bind intestinal oxalate [422, 435, 437].

*Sodium:* the daily sodium (NaCl) intake should not exceed 3-5 g [17]. High intake adversely affects urine composition:

- calcium excretion is increased by reduced tubular reabsorption;
- urinary citrate is reduced due to loss of bicarbonate;
- increased risk of sodium urate crystal formation.

Calcium stone formation can be reduced by restricting sodium and animal protein [434, 435]. A positive correlation between sodium consumption and risk of first-time stone formation has been confirmed only in women [436, 438]. There have been no prospective clinical trials on the role of sodium restriction as an independent variable in reducing the risk of stone formation.

*Urate*: intake of purine-rich food should be restricted in patients with hyperuricosuric calcium oxalate [439, 440] and uric acid stones. Intake should not exceed 500 mg/day [17].

#### 4.2.3 Lifestyle

Lifestyle factors may influence the risk of stone formation, for example, obesity [441] and arterial hypertension [442, 443].

#### 4.2.4 Recommendations for recurrence prevention

Recommendations	LE	GR
Advise patients that a generous fluid intake is to be maintained, allowing for a 24-h urine volume $\geq$ 2.5 L.	1b	A
In patients with a small urine volume, advise patients to increase fluid intake.	1b	A

### 4.3 Stone-specific metabolic evaluation and pharmacological recurrence prevention

#### 4.3.1 Introduction

Pharmacological treatment is necessary in patients at high-risk for recurrent stone formation. The ideal drug should halt stone formation, have no side effects, and be easy to administer. Each of these aspects is important to achieve good compliance. Table 4.6 highlights the most important characteristics of commonly used medication.

**Table 4.6: Pharmacological substances used for stone prevention - characteristics, specifics and dosage**

Agent	Rationale	Dose	Specifics and side effects	Stone type	Ref
Alkaline citrates	Alkalinisation  Hypocitraturia  Inhibition of calcium oxalate crystallisation	5-12 g/d (14-36 mmol/d)  Children: 0.1-0.15 g/kg/d	Daily dose for alkalinisation depends on urine pH	Calcium oxalate Uric acid Cystine	[47, 422, 444-450]
Allopurinol	Hyperuricosuria  Hyperuricaemia	100-300 mg/d  Children: 1-3 mg/kg/d	100 mg in isolated hyperuricosuria Renal insufficiency demands dose correction	Calcium oxalate Uric acid Ammonium urate 2,8-Dihydroxyadenine	[451-455]
Calcium	Enteric hyperoxaluria	1,000 mg/d	Intake 30 min before meals	Calcium oxalate	[435-437]
Captopril	Cystinuria Active decrease of urinary cystine levels	75-150 mg	Second-line option due to significant side effects	Cystine	[456, 457]
Febuxostat	Hyperuricosuria  Hyperuricaemia	80-120 mg/d	Acute gout contraindicated, pregnancy, xanthine stone formation	Calcium oxalate Uric acid	[458, 459]
L-Methionine	Acidification	600-1,500 mg/d	Hypercalciuria, bone demineralisation, systemic acidosis. No long-term therapy.	Infection stones Ammonium urate Calcium phosphate	[47, 460, 461]



Magnesium	Isolated hypomagnesiuria Enteric hyperoxaluria	200-400 mg/d  Children: 6 mg/kg/d	Renal insufficiency demands dose correction. Diarrhoea, chronic alkali losses, hypocitraturia.	Calcium oxalate	[462, 463]  low evidence
Sodium bicarbonate	Alkalinisation Hypocitraturia	4.5 g/d		Calcium oxalate Uric acid, Cystine	[464]
Pyridoxine	Primary hyperoxaluria	Initial dose 5 mg/kg/d  Max. 20 mg/kg/d	Polyneuropathia	Calcium oxalate	[465]
Thiazide (Hydrochlorothiazide)	Hypercalciuria	25-50 mg/d  Children: 0.5-1 mg/kg/d	Risk for agent-induced hypotonic blood pressure, diabetes, hyperuricaemia, hypokalaemia, followed by intracellular acidosis and hypocitraturia.	Calcium oxalate Calcium phosphate	[47, 462, 466-474]
Tiopronin	Cystinuria Active decrease of urinary cystine levels	Initial dose 250 mg/d  Max. 2,000 mg/d	Risk for tachyphylaxis and proteinuria.	Cystine	[475-478]

#### 4.4 Calcium oxalate stones

The criteria for identification of calcium oxalate stone formers with high recurrence risk are listed in Section 3.1.2.

##### 4.4.1 *Diagnosis*

Blood analysis requires measurement of creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), uric acid, and parathyroid hormone (PTH) (and vitamin D) in the case of increased calcium levels.

Urinalysis requires measurement of urine volume, urine pH profile, specific weight, calcium, oxalate, uric acid, citrate, sodium and magnesium.

##### 4.4.2 *Interpretation of results and aetiology*


The diagnostic and therapeutic algorithm for calcium oxalate stones is shown in Figure 4.2 [47, 422, 445-447, 451-453, 458, 462-464, 466-473, 479-483].

The most common metabolic abnormalities associated with calcium stone formation are hypercalciuria, which affects 30-60% of adult stone formers, and hyperoxaluria (26-67%), followed by hyperuricosuria (15-46%), hypomagnesiuria (7-23%), and hypocitraturia (5-29%). However, ranges tend to differ based on ethnicity [479].

- Elevated levels of ionised calcium in serum (or total calcium and albumin) require assessment of intact PTH to confirm or exclude suspected hyperparathyroidism (HPT).
- "Acidic arrest" (urine pH constantly  $\leq 5.8$ ) may promote co-crystallisation of uric acid and calcium oxalate. Similarly, increased uric acid excretion ( $> 4$  mmol/day in adults or  $> 12$  mg/kg/day in children) can act as a promoter.
- Urine pH levels constantly  $> 5.8$  in the day profile indicate renal tubular acidosis (RTA), provided UTI has been excluded. An ammonium chloride loading test confirms RTA and identifies RTA subtype (Section 4.6.5).
- Hypercalciuria may be associated with normocalcemia (idiopathic hypercalciuria, or granulomatous diseases) or hypercalcaemia (hyperparathyroidism, granulomatous diseases, vitamin D excess, or malignancy).
- Hypocitraturia (male  $< 1.7$  mmol/d, female  $< 1.9$  mmol/d) may be idiopathic or secondary to metabolic acidosis or hypokalaemia.
- Oxalate excretion  $> 0.5$  mmol/day in adults ( $> 0.37$  mmol/1.73 m<sup>2</sup>/day in children) confirms hyperoxaluria.
  - o primary hyperoxaluria (oxalate excretion mostly  $\geq 1$  mmol/day), appears in three genetically determined forms;

- o secondary hyperoxaluria (oxalate excretion  $\geq 0.5$  mmol/day, usually  $< 1$  mmol/day), occurs due to intestinal hyperabsorption of oxalate or extreme dietary oxalate intake;
- o mild hyperoxaluria (oxalate excretion 0.45-0.85 mmol/day), commonly found in idiopathic calcium oxalate stone formers.
- Hypomagnesuria ( $< 3.0$  mmol/day) may be related to poor dietary intake or to reduced intestinal absorption (chronic diarrhoea).

**Figure 4.2: Diagnostic and therapeutic algorithm for calcium oxalate stones**



<sup>1</sup> Be aware of excess calcium excretion.

<sup>2</sup> tid = three times/day (24h).

<sup>3</sup> No magnesium therapy for patients with renal insufficiency.

<sup>4</sup> There is no evidence that combination therapy (thiazide + citrate) (thiazide + allopurinol) is superior to thiazide therapy alone [466, 473].

<sup>5</sup> Febuxostat 80 mg/d.

#### 4.4.3 Specific treatment

General preventive measures are recommended for fluid intake and diet. Hyperoxaluric stone formers should consume foods with low oxalate content, whereas hyperuricosuric stone formers benefit from daily dietary reduction of purine. Figure 4.2 summarises the diagnostic algorithm and the pharmacological treatment of calcium oxalate stones [47, 422, 445-447, 451-453, 458, 462-464, 466-473, 479-483]. There is only low level evidence on the efficacy of preventing stone recurrence through pre-treatment stone composition and biochemistry measures, or on-treatment biochemistry measures [422].

#### 4.4.4 Recommendations for pharmacological treatment of patients with specific abnormalities in urine composition

Urinary risk factor	Suggested treatment	LE	GR
Hypercalcaemia	Thiazide + potassium citrate	1a	A
Hyperoxaluria	Oxalate restriction	2b	A
Enteric hyperoxaluria	Potassium citrate	3-4	C
	Calcium supplement	2	B
	Diet reduced in fat and oxalate	3	B
Hypocitraturia	Potassium citrate	1b	A
Hypocitraturia	Sodium bicarbonate if intolerant to potassium citrate	1b	A
Hyperuricosuria	Allopurinol	1a	A
	Febuxostat	1b	A
High sodium excretion	Restricted intake of salt	1b	A

Small urine volume	Increased fluid intake	1b	A
Urea level indicating a high intake of animal protein	Avoid excessive intake of animal protein	1b	A
No abnormality identified	High fluid intake	2b	B

#### 4.5 Calcium phosphate stones

Some calcium phosphate stone formers are at high-risk of recurrence. Further information on identifying high-risk patients is given in Section 3.1.2.

Calcium phosphate mainly appears in two completely different minerals: carbonate apatite and brushite. Carbonate apatite crystallisation occurs at a pH  $\geq 6.8$  and may be associated with infection.

Brushite crystallises at an optimum pH of 6.5-6.8, at high urinary concentrations of calcium ( $> 8$  mmol/day) and phosphate ( $> 35$  mmol/day). Its occurrence is not related to UTI.

Possible causes of calcium phosphate stones include HPT, RTA and UTI; each of which requires different therapy.


##### 4.5.1 Diagnosis

Diagnosis requires blood analysis for: creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), and PTH (in the case of increased calcium levels). Urinalysis includes measurement of: volume, urine pH profile, specific weight, calcium, phosphate and citrate.

##### 4.5.2 Interpretation of results and aetiology

General preventive measures are recommended for fluid intake and diet. The diagnostic and therapeutic algorithm for calcium phosphate stones is shown in Figure 4.3.

Figure 4.3: Diagnostic and therapeutic algorithm for calcium phosphate stones



HPT = hyperparathyroidism; RTA = renal tubular acidosis; UTI = urinary tract infection.

#### 4.5.3 **Pharmacological therapy** [47, 422, 466, 467, 471, 483]

Hyperparathyroidism and RTA are common causes of calcium phosphate stone formation. Although most patients with primary HPT require surgery, RTA can be corrected pharmacologically. If primary HPT and RTA have been excluded, pharmacotherapy for calcium phosphate calculi depends on effective reduction of urinary calcium levels using thiazides. If urine pH remains constantly > 6.2, urinary acidification with L-methionine may be helpful, however it is not commonly used and needs monitoring for systemic acidosis development. For infection-associated calcium phosphate stones, it is important to consider the guidance given for infection stones.

#### 4.5.4 **Recommendations for the treatment of calcium phosphate stones**

Urinary risk factor and suggested treatment	LE	GR
Prescribe thiazide in case of hypercalciuria.	1a	A
Advise patients to acidify their urine in case of inadequate urine pH.	3-4	C
Prescribe antibiotics in case of a UTI.	3-4	C

UTI = urinary tract infection.

### 4.6 **Disorders and diseases related to calcium stones**

#### 4.6.1 **Hyperparathyroidism** [484-487]

Primary HPT is responsible for an estimated 5% of all calcium stone formation. Renal stones occur in approximately 20% of patients with primary HPT. Elevated levels of PTH significantly increase calcium turnover, leading to hypercalcaemia and hypercalciuria. Serum calcium may be mildly elevated and serum PTH may be within the upper normal limits, therefore, repeated measurements may be needed; preferably with the patient fasting. Stones of HPT patients may contain both calcium oxalate and calcium phosphate.

If HPT is suspected, neck exploration should be performed to confirm the diagnosis. Primary HPT can only be cured by surgery.

#### 4.6.2 **Granulomatous diseases** [487]

Granulomatous diseases, such as sarcoidosis, may be complicated by hypercalcaemia and hypercalciuria secondary to increased calcitriol production. The latter is independent of PTH control, leading to increased calcium absorption in the gastrointestinal tract and suppression of PTH. Treatment focusses on the activity of the granulomatous diseases and may require steroids, hydroxychloroquine or ketoconazole. Treatment should be reserved for the specialist.

#### 4.6.3 **Primary hyperoxaluria** [465]

Patients with primary hyperoxaluria (PH) should be referred to specialised centres, as successful management requires an experienced interdisciplinary team. The main therapeutic aim is to reduce endogenous oxalate production, which is increased in patients with PH. In approximately one-third of patients with PH type I, pyridoxine therapy normalises or significantly reduces urinary oxalate excretion. The goal of adequate urine dilution is achieved by adjusting fluid intake to 3.5-4.0 L/day in adults (children 1.5 L/m<sup>2</sup> body surface area) and following a circadian drinking regimen.

Therapeutic options for preventing calcium oxalate crystallisation include hyperdiuresis, alkaline citrates and magnesium. However, in end-stage renal failure, PH requires simultaneous liver-kidney transplantation.

Treatment regimens are:

- Pyridoxine in PH type I: 5-20 mg/kg/day according to urinary oxalate excretion and patient tolerance;
- Alkaline citrate: 9-12 g/day in adults, 0.1-0.15 meq/kg/day in children;
- Magnesium: 200-400 mg/day (no magnesium in the case of renal insufficiency).

Urinary risk factor and suggested management of primary hyperoxaluria	LE	GR
Refer patients diagnosed with primary hyperoxaluria to a specialised centre where multidisciplinary care can be provided.		
Prescribe pyridoxine for primary hyperoxaluria.	3	B

#### 4.6.4 **Enteric hyperoxaluria** [437, 488]

Enteric hyperoxaluria is a particularly problematic condition in patients with intestinal malabsorption of fat. This abnormality is associated with a high risk of stone formation, and is seen after intestinal resection and

malabsorptive bariatric surgery and in Crohn's disease and pancreas insufficiency. In addition to hyperoxaluria, these patients usually present with hypocitraturia due to loss of alkali. Urine pH is usually low, as are urinary calcium and urine volume. All these abnormalities contribute to high levels of supersaturation with calcium oxalate, crystalluria, and stone formation.

Specific preventive measures are:


- Restricted intake of oxalate-rich foods;
- Restricted fat intake;
- Calcium supplementation at meal times to enable calcium oxalate complex formation in the intestine [437, 488];
- Sufficient fluid intake to balance intestinal loss of water caused by diarrhoea;
- Alkaline citrates to raise urinary pH and citrate.

Urinary risk factors and suggested management of enteric hyperoxaluria	LE	GR
Prescribe potassium citrate.	4	C
Advice patients to take a calcium supplement.	2	B
Advise patients to follow a diet reduced in fat and oxalate.	3	B

#### 4.6.5 Renal tubular acidosis [489, 490]

Renal tubular acidosis is caused by severe impairment of proton or bicarbonate handling along the nephron. Kidney stone formation most probably occurs in patients with distal RTA type I. Figure 4.4 outlines the diagnosis of RTA. Table 4.7 shows acquired and inherited causes of RTA.

**Figure 4.4: Diagnosis of renal tubular acidosis**



\*\* An alternative Ammonium Chloride loading test using  $\text{NH}_4\text{Cl}$  load with 0.05 g/kg body weight over 3 days might provide similar results and may be better tolerated by the patient. A second alternative in these cases could be the furosemide acidification test.

Renal tubular acidosis can be acquired or inherited. Reasons for acquired RTA can be obstructive uropathy, recurrent pyelonephritis, acute tubular necrosis, renal transplantation, analgesic nephropathy, sarcoidosis, idiopathic hypercalciuria, primary parathyroidism, and drug-induced (e.g. zonisamide). Table 4.7 shows the inherited causes of RTA.

**Table 4.7: Inherited causes of renal tubular acidosis**

Type - inheritance	Gene/gene product/function	Phenotype
Autosomal dominant	SLC4A1/AE1/Cl-bicarbonate exchanger	Hypercalciuria, hypokalaemia, osteomalacia
Autosomal recessive with hearing loss	ATP6V1B1/B1 subunit of vacuolar H-ATPase/proton secretion	Hypercalciuria, hypokalaemia, rickets
Autosomal recessive	ATP6V0A4/A4 subunit of vacuolar H-ATPase/proton secretion	Hypercalciuria, hypokalaemia, rickets

The main therapeutic aim is restoring a normal acid-base equilibrium. Despite the alkaline pH of urine in RTA, alkalinisation using alkaline citrates or sodium bicarbonate is key to normalising the metabolic changes (intracellular acidosis) responsible for stone formation (Table 4.8). The alkali load reduces tubular reabsorption of citrate, which in turn normalises citrate excretion and simultaneously reduces calcium turnover. Therapeutic success can be monitored by venous blood gas analysis (base excess:  $\pm 2.0$  mmol/L) in complete RTA. If excessive calcium excretion ( $> 8$  mmol/day) persists after re-establishing acid-base equilibrium, thiazides may lower urinary calcium excretion.

**Table 4.8: Pharmacological treatment of renal tubular acidosis**

Biochemical risk factor	Rationale for pharmacological therapy	Medication
Hypercalciuria	Calcium excretion $> 8$ mmol/day	Hydrochlorothiazide, - in adults: 25 mg/day initially, up to 50 mg/day - in children: 0.5-1 mg/kg/day Alternatives in adults: Chlorthalidone 25 mg/d Indapamide 2.5 mg/d
Inadequate urine pH	Intracellular acidosis in nephron	Alkaline citrate, 9-12 g/day divided in 3 doses OR Sodium bicarbonate, 1.5 g, 3 times daily

Urinary risk factor and suggested management of renal tubular acidosis	LE	GR
Prescribe potassium citrate for distal RTA.	2b	B
Prescribe thiazide + potassium citrate for hypercalciuria.	1a	A

RTA = renal tubular acidosis.

#### 4.6.6 **Nephrocalcinosis** [419]

Nephrocalcinosis (NC) refers to increased crystal deposition within the renal cortex or medulla, and occurs alone or in combination with renal stones. There are various metabolic causes. The main risk factors are: HPT, PH, RTA, vitamin D metabolic disorders, idiopathic hypercalciuria and hypocitraturia, and genetic disorders, including Dent's disease, Bartter's syndrome and Medullary sponge kidney. The many causes of NC means there is no single standard therapy. Therapeutic attention must focus on the underlying metabolic or genetic disease, while minimising the biochemical risk factors.

##### 4.6.6.1 *Diagnosis*

Diagnosis requires the following blood analysis: PTH (in the case of increased calcium levels), vitamin D and metabolites, vitamin A, sodium, potassium, magnesium, chloride, and blood gas analysis. Urinalysis should investigate: urine pH profile (minimum 4 times daily), daily urine volume, specific weight of urine, and levels of

calcium, oxalate, phosphate, uric acid, magnesium and citrate.

#### **4.7 Uric acid and ammonium urate stones**

All uric acid and ammonium urate stone formers are considered to be at high risk of recurrence [17]. Uric acid nephrolithiasis is responsible for approximately 10% of renal stones [491]. They are associated with hyperuricosuria or low urinary pH. Hyperuricosuria may be a result of dietary excess, endogenous overproduction (enzyme defects), myeloproliferative disorders, tumour lysis syndrome, drugs, gout or catabolism [492]. Low urinary pH may be caused by decreased urinary ammonium excretion (insulin resistance or gout), increased endogenous acid production (insulin resistance, metabolic syndrome, or exercise-induced lactic acidosis), increased acid intake (high animal protein intake), or increased base loss (diarrhoea) [492].

Ammonium urate stones are extremely rare, comprising < 1% of all types of urinary stones. They are associated with UTI, malabsorption (inflammatory bowel disease and ileostomy diversion or laxative abuse), potassium deficiency, hypokalemia and malnutrition.

Suggestions on uric acid and ammonium urate nephrolithiasis are based on level 3 and 4 evidence.

##### **4.7.1 Diagnosis**

Figure 4.5 shows the diagnostic and therapeutic algorithm for uric acid and ammonium urate stones. Blood analysis requires measurement of creatinine, potassium and uric acid levels. Urinalysis requires measurement of urine volume, urine pH profile, specific weight of urine, and uric acid level. Urine culture is needed in the case of ammonium urate stones.

##### **4.7.2 Interpretation of results**

Uric acid and ammonium urate stones form under completely different biochemical conditions. Acidic arrest (urine pH constantly  $\leq 5.8$ ) promotes uric acid crystallisation.


Hyperuricosuria is defined as uric acid excretion  $\geq 4$  mmol/day in adults or  $> 0.12$  mmol/kg/day in children. Hyperuricaemia may be present, but there is only weak evidence for its association with stone formation.

Hyperuricosuric calcium oxalate stone formation can be distinguished from uric acid stone formation by: urinary pH, which is usually  $> 5.5$  in calcium oxalate stone formation and  $< 5.5$  in uric acid stone formation and occasional absence of hyperuricosuria in patients with pure uric acid stones [493, 494]. Ammonium urate crystals form in urine at pH  $> 6.5$ , at high uric acid concentration when ammonium is present to serve as a cation [495-497].

##### **4.7.3 Specific treatment**

General preventive measures are recommended for fluid intake and diet. Hyperuricosuric stone formers benefit from purine reduction in their daily diet. Figure 4.5 describes pharmacological treatment [17, 411, 491-503]. For uric acid stones, allopurinol may change the stone composition distribution in patients with gout to a pattern similar to that in stone formers without gout [504].

Figure 4.5: Diagnostic and therapeutic algorithm for uric acid- and ammonium urate stones



<sup>1</sup> d: day.

<sup>2</sup> tid: three times a day.

<sup>3</sup> A higher pH may lead to calcium phosphate stone formation.

<sup>4</sup> In patients with high uric acid excretion, allopurinol may be helpful.

## 4.8 Struvite and infection stones

All infection-stone formers are deemed at high risk of recurrence.

Struvite stones represent 2-15% of the stones sent for analysis. Stones that contain struvite may originate de novo or grow on pre-existing stones, which are infected with urea-splitting bacteria [505]. There are several factors predisposing patients to struvite stone formation (Table 4.9) [506].

### 4.8.1 Diagnosis

Blood analysis requires measurement of creatinine, and urinalysis requires repeat urine pH measurements and urine culture.

#### Interpretation

Infection stones contain the following minerals: struvite and/or carbonate apatite and/or ammonium urate. Urine culture typically provides evidence for urease-producing bacteria, which increase ammonia ions and develop alkaline urine (Table 4.10). Carbonate apatite starts to crystallise at a urine pH level of 6.8. Struvite only precipitates at pH > 7.2 [507, 508]. *Proteus mirabilis* accounts for more than half of all urease-positive UTIs [509, 510].



#### 4.8.2 **Specific treatment**

General preventive measures are recommended for fluid intake and diet. Specific measures include complete surgical stone removal [506] short- or long-term antibiotic treatment [511], urinary acidification using methionine [460] or ammonium chloride [512], and advise to restrict intake of urease [513, 514]. For severe infections, acetohydroxamic acid may be an option [513, 514] (Figure 4.6), however, it is not licensed/available in all European countries.

#### 4.8.3 **Recommendations for therapeutic measures of infection stones**

<b>Recommendations for therapeutic measures</b>	<b>LE</b>	<b>GR</b>
Surgically remove the stone material as completely as possible.	3-4	A*
Prescribe a short-term antibiotic course.	3	B
Prescribe a long-term antibiotic course in case of recurrent infections.	3	B
Prescribe ammonium chloride, 1 g, 2 or 3 times daily to ensure urinary acidification.	3	B
Prescribe methionine, 200-500 mg, 1-3 times daily, as an alternative, to ensure urinary acidification.	3	B
Consider prescription of urease inhibitors in case of severe infection (if licensed).	1b	A

\*Upgraded following panel consensus.


**Table 4.9: Factors predisposing to struvite stone formation**

Neurogenic bladder
Spinal cord injury/paralysis
Continent urinary diversion
Ileal conduit
Foreign body
Stone disease
Indwelling urinary catheter
Urethral stricture
Benign prostatic hyperplasia
Bladder diverticulum
Cystocele
Caliceal diverticulum
Ureteropelvic junction obstruction

**Table 4.10: Most important species of urease-producing bacteria**

<b>Obligate urease-producing bacteria (&gt; 98%)</b>
<ul style="list-style-type: none"> <li>• <i>Proteus spp.</i></li> <li>• <i>Providencia rettgeri</i></li> <li>• <i>Morganella morganii</i></li> <li>• <i>Corynebacterium urealyticum</i></li> <li>• <i>Ureaplasma urealyticum</i></li> </ul>
<b>Facultative urease-producing bacteria</b>
<ul style="list-style-type: none"> <li>• <i>Enterobacter gergoviae</i></li> <li>• <i>Klebsiella spp.</i></li> <li>• <i>Providencia stuartii</i></li> <li>• <i>Serratia marcescens</i></li> <li>• <i>Staphylococcus spp.</i></li> </ul>
<b>CAUTION:</b> 0-5% of <i>Escherichia coli</i> , <i>Enterococcus spp.</i> and <i>Pseudomonas aeruginosa</i> strains may produce urease.

**Figure 4.6: Diagnostic and therapeutic algorithm for infection stones**



<sup>1</sup> Discussed with uric acid stones,

<sup>2</sup> Acetohydroxamic acid

\* When nationally available.

bid = twice a day; tid = three times a day.

## 4.9 Cystine stones

Cystine stones account for 1-2% of all urinary stones in adults and 6-8% of the stones reported in paediatric studies [26, 515]. All cystine stone formers are deemed at high risk of recurrence.

### 4.9.1 Diagnosis

Blood analysis includes measurement of creatinine, and urinalysis includes measurement of urine volume, pH profile, specific weight, and cystine.

#### Interpretation

- Cystine is poorly soluble in urine and crystallises spontaneously within the physiological urinary pH range.
- Cystine solubility depends strongly on urine pH: at pH 6.0, the limit of solubility is 1.33 mmol/L.
- Routine analysis of cystine is not suitable for therapeutic monitoring.
- Regardless of phenotype or genotype of the cystinuric patient, the clinical manifestations are the same [516].
- There is no role for genotyping patients in the routine management of cystinuria [517, 518].
- Reductive therapy targets the disulphide binding in the cysteine molecule. For therapy monitoring, it is essential to differentiate between cystine, cysteine and drug-cysteine complexes. Only high-performance liquid chromatography (HPLC)-based analysis differentiates between the different complexes formed by therapy.

- Diagnosis is established by stone analysis. The typical hexagonal crystals are detectable in only 20-25% of urine specimens from patients with cystinuria [519].
- The cyanide nitroprusside colorimetric qualitative test detects the presence of cystine at a threshold concentration of 75 mg/L, with a sensitivity of 72% and specificity of 95%. False-positive results in patients with Fanconi's syndrome, homocystinuria, or those taking various drugs, including Infection stones
- Quantitative 24-h urinary cystine excretion confirms the diagnosis in the absence of stone analysis.
- Levels above 30 mg/day are considered abnormal [520, 521].

#### 4.9.2 **Specific treatment**

General preventative measures for fluid intake and diet are recommended. A diet low in methionine may theoretically reduce urinary excretion of cystine; however, patients are unlikely to comply sufficiently with such a diet. A restricted intake of sodium is more easily achieved and is more effective in reducing urinary cystine. Patients are usually advised to avoid sodium consumption > 2 g/day [522].

A high level of diuresis is of fundamental importance, aiming for a 24-h urine volume of  $\geq 3$  L [523]. A considerable fluid intake evenly distributed throughout the day is necessary.

##### 4.9.2.1 *Pharmacological treatment of cystine stones*


The main therapeutic option for avoiding cystine crystallisation is to maintain urine pH > 7.5, to improve cystine solubility and ensure appropriate hydration with a minimum of 3.5 L/day in adults, or 1.5 L/m<sup>2</sup> body surface area in children.

Free cystine concentration can be decreased by reductive substances, which act by splitting the disulphide binding of cysteine.

Tiopronin is currently the best choice for cystine reduction. However, side effects often lead to treatment termination, for example, when nephrotic syndrome develops, or poor compliance, especially with long-term use.

After carefully considering the risk of early tachyphylaxis, putting into place a dose-escape phenomenon for long-term use, and recurrence risk, tiopronin is recommended at cystine levels > 3.0 mmol/day or in the case of recurring stone formation, notwithstanding other preventive measures.

Figure 4.7: Metabolic management of cystine stones



#### 4.9.3 Recommendations for the treatment of cystine stones

Therapeutic measures	LE	GR
<b>Urine dilution</b> Advise patients to increase their fluid intake so that 24-h urine volume exceeds 3 L. Intake should be $\geq 150$ mL/h.	3	B
<b>Alkalinisation</b> For patients with cystine excretion $< 3$ mmol/day, prescribe potassium citrate 3-10 mmol 2 or 3 times daily, to achieve pH $> 7.5$ .	3	B
<b>Complex formation with cystine</b> For patients with cystine excretion, $> 3$ mmol/day, or when other measures are insufficient: prescribe in addition to other measures tiopronin, 250-2,000 mg/day.	3	B

#### 4.10 2,8-Dihydroxyadenine stones and xanthine stones [17]

All 2,8-Dihydroxyadenine and xanthine stone formers are considered to be at high-risk of recurrence. Both stone types are rare. Diagnosis and specific prevention are similar to those for uric acid stones.

##### 4.10.1 2,8-Dihydroxyadenine stones

A genetically determined defect of adenine phosphoribosyl transferase causes high urinary excretion of poorly soluble 2,8-Dihydroxyadenine. High-dose allopurinol or febuxostat are important options, but should be given with regular monitoring.

#### 4.10.2 **Xanthine stones**

Patients who form xanthine stones usually show decreased levels of serum uric acid. There is no available pharmacological intervention.

#### 4.10.3 **Fluid intake and diet**

Recommendations for general preventive measures apply. Pharmacological intervention is difficult, therefore, high fluid intake ensures optimal specific weight levels of urine < 1.010. A purine-reduced diet decreases the risk of spontaneous crystallisation in urine.

#### 4.11 **Drug stones [47]**

Drug stones are induced by pharmacological treatment [524] (Table 4.11). Two types exist:

- stones formed by crystallised compounds of the drug;
- stones formed due to unfavourable changes in urine composition under drug therapy.

**Table 4.11: Compounds that cause drug stones**

<p><b>Active compounds crystallising in urine</b></p> <ul style="list-style-type: none"><li>• Allopurinol/oxypurinol</li><li>• Amoxicillin/ampicillin</li><li>• Ceftriaxone</li><li>• Quinolones</li><li>• Ephedrine</li><li>• Indinavir</li><li>• Magnesium trisilicate</li><li>• Sulphonamides</li><li>• Triamterene</li><li>• Zonisamide</li></ul> <p><b>Substances impairing urine composition</b></p> <ul style="list-style-type: none"><li>• Acetazolamide</li><li>• Allopurinol</li><li>• Aluminium magnesium hydroxide</li><li>• Ascorbic acid</li><li>• Calcium</li><li>• Furosemide</li><li>• Laxatives</li><li>• Methoxyflurane</li><li>• Vitamin D</li><li>• Topiramate</li></ul>
---

#### 4.12 **Matrix Stones**

Pure matrix stones are extremely rare with less than 70 cases described in the literature. They are more prevalent in females. The main risk factors are recurrent UTIs, especially due to *Proteus mirabilis* or *Escherichia coli*, previous surgery for stone disease, chronic renal failure and haemodialysis.

Complete endourological removal, frequently via the percutaneous approach, is critical. Given the rarity of matrix calculi a specific prophylactic regimen to minimise recurrence cannot be recommended. Eliminating infections and prophylactic use of antibiotics are most commonly proposed [223].

#### 4.13 **Unknown stone composition [16]**

An accurate medical history is the first step towards identifying risk factors (Table 4.12).

Diagnostic imaging begins with US examination of both kidneys to establish whether the patient is stone free. Stone detection by US should be followed by KUB and unenhanced multislice CT in adults to differentiate between calcium-containing and non-calcium stones.

Blood analysis demonstrates severe metabolic and organic disorders, such as renal insufficiency, HPT or other hypercalcaemic states and hyperuricaemia. In children, hyperoxalaemia is additionally screened for.

Urinalysis is performed routinely with a dipstick test as described above. Urine culture is required if there are signs of infection.

Constant urine pH < 5.8 in the daily profile indicates acidic arrest, which may promote uric acid crystallisation. Persistent urine pH > 5.8 in the daily profile indicates RTA, if UTI is excluded.

Microscopy of urinary sediment can help to discover rare stone types, because crystals of 2,8-dihydroxyadenine, cystine and xanthine are pathognomonic for the corresponding disease. In cases in which the presence of cystine is doubtful, a cyanide nitroprusside colorimetric qualitative test can be used to detect the presence of cystine in urine, with a sensitivity of 72% and specificity of 95%. False-positive results are possible in patients with Fanconi's syndrome or homocystinuria, or in those taking various drugs, including ampicillin or sulfa-containing medication [525, 526].

Following this programme, the most probable stone type can be assumed and specific patient evaluation can follow. However, if any expelled stone material is available, it should be analysed by diagnostic confirmation or correction.

**Table 4.12: Recommendations for the assessment of patients with stones of unknown composition**

Investigation	Rationale for investigation
Take a medical history	<ul style="list-style-type: none"> <li>• Stone history (former stone events, family history)</li> <li>• Dietary habits</li> <li>• Medication chart</li> </ul>
Perform diagnostic imaging	<ul style="list-style-type: none"> <li>• Ultrasound in the case of a suspected stone</li> <li>• Unenhanced helical CT</li> <li>• (Determination of Hounsfield units provides information about the possible stone composition)</li> </ul>
Perform a blood analysis	<ul style="list-style-type: none"> <li>• Creatinine</li> <li>• Calcium (ionised calcium or total calcium + albumin)</li> <li>• Uric acid</li> </ul>
Perform a urinalysis	<ul style="list-style-type: none"> <li>• Urine pH profile (measurement after each voiding, minimum 4 times daily)</li> <li>• Dipstick test: leukocytes, erythrocytes, nitrite, protein, urine pH, specific weight</li> <li>• Urine cultures</li> <li>• Microscopy of urinary sediment (morning urine)</li> <li>• Cyanide nitroprusside test (cystine exclusion)</li> </ul>

Further examinations depend on the results of the investigations listed above.

## 5. REFERENCES

1. Skolarikos, A., *et al.* Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. *Eur Urol*, 2015. 67: 750.  
<http://www.ncbi.nlm.nih.gov/pubmed/25454613>
2. Turk, C., *et al.* EAU Guidelines on Interventional Treatment for Urolithiasis. *Eur Urol*, 2015.  
<http://www.ncbi.nlm.nih.gov/pubmed/26344917>
3. Turk, C., *et al.* EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *Eur Urol*, 2015.  
<http://www.ncbi.nlm.nih.gov/pubmed/26318710>
4. Tiselius, H.G., *et al.* Guidelines on urolithiasis. *Eur Urol*, 2001. 40: 362.  
<http://www.ncbi.nlm.nih.gov/pubmed/11713390>
5. Preminger, G.M., *et al.* 2007 Guideline for the management of ureteral calculi. *Eur Urol*, 2007. 52: 1610.  
<http://www.ncbi.nlm.nih.gov/pubmed/18074433>
6. Preminger, G.M., *et al.* 2007 guideline for the management of ureteral calculi. *J Urol*, 2007. 178: 2418.  
<http://www.ncbi.nlm.nih.gov/pubmed/17993340>

7. MacLennan S., *et al.* What are the comparative benefits and harms of the different percutaneous nephrolithotomy (PCNL) tract sizes? PROSPERO International prospective register of systematic reviews, 2015.  
[http://www.crd.york.ac.uk/PROSPERO/display\\_record.asp?ID=CRD42015023766](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015023766)
8. Phillips, B., *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.  
<http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
9. Trinchieri., *et al.*, Epidemiology, in Stone Disease, K.S. C.P. Segura JW, Pak CY, Preminger GM, Tolley D., Eds. Health Publications: Paris. 2003.
10. Stamatelou, K.K., *et al.* Time trends in reported prevalence of kidney stones in the United States: 1976-1994. *Kidney Int*, 2003. 63: 1817.  
<http://www.ncbi.nlm.nih.gov/pubmed/12675858>
11. Hesse, A., *et al.* Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. *Eur Urol*, 2003. 44: 709.  
<http://www.ncbi.nlm.nih.gov/pubmed/14644124>
12. Sanchez-Martin, F.M., *et al.* [Incidence and prevalence of published studies about urolithiasis in Spain. A review]. *Actas Urol Esp*, 2007. 31: 511.  
<http://www.ncbi.nlm.nih.gov/pubmed/17711170>
13. Yasui, T., *et al.* Association of the loci 5q35.3, 7q14.3, and 13.q14.1 with urolithiasis: A case-control study in the Japanese population, involving genome-wide association study. *J Urol*, 2013. 189: e854.  
[https://www.auanet.org/university/abstract\\_detail.cfm?id=2082&meetingID=13SAN](https://www.auanet.org/university/abstract_detail.cfm?id=2082&meetingID=13SAN)
14. Strohmaier, W.L. Course of calcium stone disease without treatment. What can we expect? *Eur Urol*, 2000. 37: 339.  
<http://www.ncbi.nlm.nih.gov/pubmed/10720863>
15. Keoghane, S., *et al.* The natural history of untreated renal tract calculi. *BJU Int*, 2010. 105: 1627.  
<http://www.ncbi.nlm.nih.gov/pubmed/20438563>
16. Straub, M., *et al.* Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. *World J Urol*, 2005. 23: 309.  
<http://www.ncbi.nlm.nih.gov/pubmed/16315051>
17. Hesse, A.T., *et al.* (Eds.), *Urinary Stones, Diagnosis, Treatment and Prevention of Recurrence*. 3rd edition. 2009, Basel.
18. Basiri, A., *et al.* Familial relations and recurrence pattern in nephrolithiasis: new words about old subjects. *Urol J*, 2010. 7: 81.  
<http://www.ncbi.nlm.nih.gov/pubmed/20535692>
19. Goldfarb, D.S., *et al.* A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. *Kidney Int*, 2005. 67: 1053.  
<http://www.ncbi.nlm.nih.gov/pubmed/15698445>
20. Asplin, J.R., *et al.* Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. *J Urol*, 2007. 177: 565.  
<http://www.ncbi.nlm.nih.gov/pubmed/17222634>
21. Gonzalez, R.D., *et al.* Kidney stone risk following modern bariatric surgery. *Curr Urol Rep*, 2014. 15: 401.  
<http://www.ncbi.nlm.nih.gov/pubmed/24658828>
22. Rendina, D., *et al.* Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. *J Nephrol*, 2014. 27: 371.  
<http://www.ncbi.nlm.nih.gov/pubmed/24696310>
23. Dell'Orto, V.G., *et al.* Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. *Br J Clin Pharmacol*, 2014. 77: 958.  
<http://www.ncbi.nlm.nih.gov/pubmed/24219102>
24. Mufti, U.B., *et al.* Nephrolithiasis in autosomal dominant polycystic kidney disease. *J Endourol*, 2010. 24: 1557.  
<http://www.ncbi.nlm.nih.gov/pubmed/20818989>
25. Chen, Y., *et al.* Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. *Spinal Cord*, 2000. 38: 346.  
<http://www.ncbi.nlm.nih.gov/pubmed/10889563>
26. Leusmann, D.B., *et al.* Results of 5,035 stone analyses: a contribution to epidemiology of urinary stone disease. *Scand J Urol Nephrol*, 1990. 24: 205.  
<http://www.ncbi.nlm.nih.gov/pubmed/2237297>

27. Leusmann, D.B. Whewellite, weddellite and company: where do all the strange names originate? *BJU Int*, 2000. 86: 411.  
<http://www.ncbi.nlm.nih.gov/pubmed/10971263>
28. Kim, S.C., *et al.* Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. *Urol Res*, 2007. 35: 319.  
<http://www.ncbi.nlm.nih.gov/pubmed/17965956>
29. Wimpissinger, F., *et al.* The silence of the stones: asymptomatic ureteral calculi. *J Urol*, 2007. 178: 1341.  
<http://www.ncbi.nlm.nih.gov/pubmed/17706721>
30. Ray, A.A., *et al.* Limitations to ultrasound in the detection and measurement of urinary tract calculi. *Urology*, 2010. 76: 295.  
<http://www.ncbi.nlm.nih.gov/pubmed/20206970>
31. Smith-Bindman, R., *et al.* Ultrasonography versus computed tomography for suspected nephrolithiasis. *N Engl J Med*, 2014. 371: 1100.  
<http://www.ncbi.nlm.nih.gov/pubmed/25229916>
32. Heidenreich, A., *et al.* Modern approach of diagnosis and management of acute flank pain: review of all imaging modalities. *Eur Urol*, 2002. 41: 351.  
<http://www.ncbi.nlm.nih.gov/pubmed/12074804>
33. Kennish, S.J., *et al.* Is the KUB radiograph redundant for investigating acute ureteric colic in the non-contrast enhanced computed tomography era? *Clin Radiol*, 2008. 63: 1131.  
<http://www.ncbi.nlm.nih.gov/pubmed/18774360>
34. Worster, A., *et al.* The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. *Ann Emerg Med*, 2002. 40: 280.  
<http://www.ncbi.nlm.nih.gov/pubmed/12192351>
35. Wu, D.S., *et al.* Indinavir urolithiasis. *Curr Opin Urol*, 2000. 10: 557.  
<http://www.ncbi.nlm.nih.gov/pubmed/11148725>
36. El-Nahas, A.R., *et al.* A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shock wave lithotripsy: the value of high-resolution noncontrast computed tomography. *Eur Urol*, 2007. 51: 1688.  
<http://www.ncbi.nlm.nih.gov/pubmed/17161522>
37. Patel, T., *et al.* Skin to stone distance is an independent predictor of stone-free status following shockwave lithotripsy. *J Endourol*, 2009. 23: 1383.  
<http://www.ncbi.nlm.nih.gov/pubmed/19694526>
38. Zarse, C.A., *et al.* CT visible internal stone structure, but not Hounsfield unit value, of calcium oxalate monohydrate (COM) calculi predicts lithotripsy fragility in vitro. *Urol Res*, 2007. 35: 201.  
<http://www.ncbi.nlm.nih.gov/pubmed/17565491>
39. Jellison, F.C., *et al.* Effect of low dose radiation computerized tomography protocols on distal ureteral calculus detection. *J Urol*, 2009. 182: 2762.  
<http://www.ncbi.nlm.nih.gov/pubmed/19837431>
40. Poletti, P.A., *et al.* Low-dose versus standard-dose CT protocol in patients with clinically suspected renal colic. *AJR Am J Roentgenol*, 2007. 188: 927.  
<http://www.ncbi.nlm.nih.gov/pubmed/17377025>
41. Niemann, T., *et al.* Diagnostic performance of low-dose CT for the detection of urolithiasis: a meta-analysis. *AJR Am J Roentgenol*, 2008. 191: 396.  
<http://www.ncbi.nlm.nih.gov/pubmed/18647908>
42. Kluner, C., *et al.* Does ultra-low-dose CT with a radiation dose equivalent to that of KUB suffice to detect renal and ureteral calculi? *J Comput Assist Tomogr*, 2006. 30: 44.  
<http://www.ncbi.nlm.nih.gov/pubmed/16365571>
43. Caoili, E.M., *et al.* Urinary tract abnormalities: initial experience with multi-detector row CT urography. *Radiology*, 2002. 222: 353.  
<http://www.ncbi.nlm.nih.gov/pubmed/11818599>
44. Van Der Molen, A.J., *et al.* CT urography: definition, indications and techniques. A guideline for clinical practice. *Eur Radiol*, 2008. 18: 4.  
<http://www.ncbi.nlm.nih.gov/pubmed/17973110>
45. Thomson, J.M., *et al.* Computed tomography versus intravenous urography in diagnosis of acute flank pain from urolithiasis: a randomized study comparing imaging costs and radiation dose. *Australas Radiol*, 2001. 45: 291.  
<http://www.ncbi.nlm.nih.gov/pubmed/11531751>



46. (2010) S-3 Guideline AWMF-Register-Nr. 043/044 Urinary Tract Infections. Epidemiology, diagnostics, therapy and management of uncomplicated bacterial community acquired urinary tract infections in adults.  
<http://www.awmf.org/leitlinien/detail/II/043-044.html>
47. Pearle M.S., A.J.R., Coe F.L., *et al.* , Medical management of urolithiasis. 2nd International consultation on Stone Disease, ed. K.S. Denstedt J. 2008.
48. Mandel, N., *et al.* Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. *J Urol*, 2003. 169: 2026.  
<http://www.ncbi.nlm.nih.gov/pubmed/12771710>
49. Hesse, A., *et al.* Quality control in urinary stone analysis: results of 44 ring trials (1980-2001). *Clin Chem Lab Med*, 2005. 43: 298.  
<http://www.ncbi.nlm.nih.gov/pubmed/15843235>
50. Sutor, D.J., *et al.* Identification standards for human urinary calculus components, using crystallographic methods. *Br J Urol*, 1968. 40: 22.  
<http://www.ncbi.nlm.nih.gov/pubmed/5642759>
51. Abdel-Halim, R.E., *et al.* A review of urinary stone analysis techniques. *Saudi Med J*, 2006. 27: 1462.  
<http://www.ncbi.nlm.nih.gov/pubmed/17013464>
52. Swartz, M.A., *et al.* Admission for nephrolithiasis in pregnancy and risk of adverse birth outcomes. *Obstet Gynecol*, 2007. 109: 1099.  
<http://www.ncbi.nlm.nih.gov/pubmed/17470589>
53. Patel, S.J., *et al.* Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. *Radiographics*, 2007. 27: 1705.  
<http://www.ncbi.nlm.nih.gov/pubmed/18025513>
54. Asrat, T., *et al.* Ultrasonographic detection of ureteral jets in normal pregnancy. *Am J Obstet Gynecol*, 1998. 178: 1194.  
<http://www.ncbi.nlm.nih.gov/pubmed/9662301>
55. Roy, C., *et al.* Assessment of painful ureterohydronephrosis during pregnancy by MR urography. *Eur Radiol*, 1996. 6: 334.  
<http://www.ncbi.nlm.nih.gov/pubmed/8798002>
56. Juan, Y.S., *et al.* Management of symptomatic urolithiasis during pregnancy. *Kaohsiung J Med Sci*, 2007. 23: 241.  
<http://www.ncbi.nlm.nih.gov/pubmed/17525006>
57. Cody, D.D., *et al.* Strategies for formulating appropriate MDCT techniques when imaging the chest, abdomen, and pelvis in pediatric patients. *AJR Am J Roentgenol*, 2004. 182: 849.  
<http://www.ncbi.nlm.nih.gov/pubmed/15039151>
58. Masselli, G., *et al.* Stone disease in pregnancy: imaging-guided therapy. *Insights Imaging*, 2014. 5: 691.  
<http://www.ncbi.nlm.nih.gov/pubmed/25249333>
59. Sternberg, K., *et al.* Pediatric stone disease: an evolving experience. *J Urol*, 2005. 174: 1711.  
<http://www.ncbi.nlm.nih.gov/pubmed/16148688>
60. Palmer, L.S. Pediatric urologic imaging. *Urol Clin North Am*, 2006. 33: 409.  
<http://www.ncbi.nlm.nih.gov/pubmed/16829274>
61. Passerotti, C., *et al.* Ultrasound versus computerized tomography for evaluating urolithiasis. *J Urol*, 2009. 182: 1829.  
<http://www.ncbi.nlm.nih.gov/pubmed/19692054>
62. Tasian, G.E., *et al.* Evaluation and medical management of kidney stones in children. *J Urol*, 2014. 192: 1329.  
<http://www.ncbi.nlm.nih.gov/pubmed/24960469>
63. Riccabona, M., *et al.* Imaging recommendations in paediatric urology. Minutes of the ESPR urology task force session on childhood obstructive uropathy, high-grade fetal hydronephrosis, childhood haematuria, and urolithiasis in childhood. ESPR Annual Congress, Edinburgh, UK, June 2008. *Pediatr Radiol*, 2009. 39: 891.  
<http://www.ncbi.nlm.nih.gov/pubmed/19565235>
64. Darge, K., *et al.* [Modern ultrasound technologies and their application in pediatric urinary tract imaging]. *Radiologe*, 2005. 45: 1101.  
<http://www.ncbi.nlm.nih.gov/pubmed/16086170>
65. Pepe, P., *et al.* Functional evaluation of the urinary tract by color-Doppler ultrasonography (CDU) in 100 patients with renal colic. *Eur J Radiol*, 2005. 53: 131.  
<http://www.ncbi.nlm.nih.gov/pubmed/15607864>

66. Oner, S., *et al.* Comparison of spiral CT and US in the evaluation of pediatric urolithiasis. *Jbr-btr*, 2004. 87: 219.  
<http://www.ncbi.nlm.nih.gov/pubmed/15587558>
67. Palmer, J.S., *et al.* Diagnosis of pediatric urolithiasis: role of ultrasound and computerized tomography. *J Urol*, 2005. 174: 1413.  
<http://www.ncbi.nlm.nih.gov/pubmed/16145452>
68. Riccabona, M., *et al.* Conventional imaging in paediatric urology. *Eur J Radiol*, 2002. 43: 100.  
<http://www.ncbi.nlm.nih.gov/pubmed/12127207>
69. Chateil, J.F., *et al.* [Practical measurement of radiation dose in pediatric radiology: use of the dose surface product in digital fluoroscopy and for neonatal chest radiographs]. *J Radiol*, 2004. 85: 619.  
<http://www.ncbi.nlm.nih.gov/pubmed/15205653>
70. Stratton, K.L., *et al.* Implications of ionizing radiation in the pediatric urology patient. *J Urol*, 2010. 183: 2137.  
<http://www.ncbi.nlm.nih.gov/pubmed/20399463>
71. Tamm, E.P., *et al.* Evaluation of the patient with flank pain and possible ureteral calculus. *Radiology*, 2003. 228: 319.  
<http://www.ncbi.nlm.nih.gov/pubmed/12819343>
72. Leppert, A., *et al.* Impact of magnetic resonance urography on preoperative diagnostic workup in children affected by hydronephrosis: should IVU be replaced? *J Pediatr Surg*, 2002. 37: 1441.  
<http://www.ncbi.nlm.nih.gov/pubmed/12378450>
73. Phillips, E., *et al.* Emergency room management of ureteral calculi: current practices. *J Endourol*, 2009. 23: 1021.  
<http://www.ncbi.nlm.nih.gov/pubmed/19445640>
74. Micali, S., *et al.* Medical therapy of urolithiasis. *J Endourol*, 2006. 20: 841.  
<http://www.ncbi.nlm.nih.gov/pubmed/17144848>
75. Engeler, D.S., *et al.* The ideal analgesic treatment for acute renal colic--theory and practice. *Scand J Urol Nephrol*, 2008. 42: 137.  
<http://www.ncbi.nlm.nih.gov/pubmed/17899475>
76. Shokeir, A.A., *et al.* Resistive index in renal colic: the effect of nonsteroidal anti-inflammatory drugs. *BJU Int*, 1999. 84: 249.  
<http://www.ncbi.nlm.nih.gov/pubmed/10468715>
77. Krum, H., *et al.* Blood pressure and cardiovascular outcomes in patients taking nonsteroidal anti-inflammatory drugs. *Cardiovasc Ther*, 2012. 30: 342.  
<http://www.ncbi.nlm.nih.gov/pubmed/21884017>
78. Bhala, N., *et al.* Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*, 2013. 382: 769.  
<http://www.ncbi.nlm.nih.gov/pubmed/23726390>
79. Holdgate, A., *et al.* Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. *Cochrane Database Syst Rev*, 2005: CD004137.  
<http://www.ncbi.nlm.nih.gov/pubmed/15846699>
80. Ebell, M.H. NSAIDs vs. opiates for pain in acute renal colic. *Am Fam Physician*, 2004. 70: 1682.  
<http://www.ncbi.nlm.nih.gov/pubmed/15554485>
81. Holdgate, A., *et al.* Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. *BMJ*, 2004. 328: 1401.  
<http://www.ncbi.nlm.nih.gov/pubmed/15178585>
82. Seitz, C., *et al.* Medical therapy to facilitate the passage of stones: what is the evidence? *Eur Urol*, 2009. 56: 455.  
<http://www.ncbi.nlm.nih.gov/pubmed/19560860>
83. Li, W.M., *et al.* Clinical predictors of stone fragmentation using slow-rate shock wave lithotripsy. *Urol Int*, 2007. 79: 124.  
<http://www.ncbi.nlm.nih.gov/pubmed/17851280>
84. Ramsey, S., *et al.* Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. *J Endourol*, 2010. 24: 185.  
<http://www.ncbi.nlm.nih.gov/pubmed/20063999>
85. Lynch, M.F., *et al.* Percutaneous nephrostomy and ureteric stent insertion for acute renal deobstruction: Consensus based guidance. *British Journal of Medical & Surgical Urology*, 2008. 1: 120.  
[http://www.bjmsu.com/article/S1875-9742\(08\)00095-5/abstract](http://www.bjmsu.com/article/S1875-9742(08)00095-5/abstract)

86. Pearle, M.S., *et al.* Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. *J Urol*, 1998. 160: 1260.  
<http://www.ncbi.nlm.nih.gov/pubmed/9751331>
87. ElSheemy, M.S., *et al.* Ureteric stents vs percutaneous nephrostomy for initial urinary drainage in children with obstructive anuria and acute renal failure due to ureteric calculi: a prospective, randomised study. *BJU Int*, 2015. 115: 473.  
<http://www.ncbi.nlm.nih.gov/pubmed/24698195>
88. Lo, C.W., *et al.* Effectiveness of Prophylactic Antibiotics against Post-Ureteroscopic Lithotripsy Infections: Systematic Review and Meta-Analysis. *Surg Infect (Larchmt)*, 2015. 16: 415.  
<http://www.ncbi.nlm.nih.gov/pubmed/26207401>
89. Grabe, M. Antimicrobial agents in transurethral prostatic resection. *J Urol*, 1987. 138: 245.  
<http://www.ncbi.nlm.nih.gov/pubmed/3298693>
90. Gravas, S., *et al.* Postoperative infection rates in low risk patients undergoing percutaneous nephrolithotomy with and without antibiotic prophylaxis: a matched case control study. *J Urol*, 2012. 188: 843.  
<http://www.ncbi.nlm.nih.gov/pubmed/22819398>
91. Hsieh, C.H., *et al.* Are prophylactic antibiotics necessary in patients with preoperative sterile urine undergoing ureterorenoscopic lithotripsy? *BJU Int*, 2014. 113: 275.  
<http://www.ncbi.nlm.nih.gov/pubmed/24127851>
92. Klingler, H.C., *et al.* Stone treatment and coagulopathy. *Eur Urol*, 2003. 43: 75.  
<http://www.ncbi.nlm.nih.gov/pubmed/12507547>
93. Kefer, J.C., *et al.* Safety and efficacy of percutaneous nephrostolithotomy in patients on anticoagulant therapy. *J Urol*, 2009. 181: 144.  
<http://www.ncbi.nlm.nih.gov/pubmed/19012931>
94. Baron, T.H., *et al.* Management of antithrombotic therapy in patients undergoing invasive procedures. *N Engl J Med*, 2013. 368: 2113.  
<http://www.ncbi.nlm.nih.gov/pubmed/23718166>
95. Naspro, R., *et al.* Antiplatelet therapy in patients with coronary stent undergoing urologic surgery: is it still no man's land? *Eur Urol*, 2013. 64: 101.  
<http://www.ncbi.nlm.nih.gov/pubmed/23428067>
96. Eberli, D., *et al.* Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. *J Urol*, 2010. 183: 2128.  
<http://www.ncbi.nlm.nih.gov/pubmed/20399452>
97. Razvi, H., *et al.* Risk factors for perinephric hematoma formation after shockwave lithotripsy: a matched case-control analysis. *J Endourol*, 2012. 26: 1478.  
<http://www.ncbi.nlm.nih.gov/pubmed/22712655>
98. Rassweiler, J.J., *et al.* Treatment of renal stones by extracorporeal shockwave lithotripsy: an update. *Eur Urol*, 2001. 39: 187.  
<http://www.ncbi.nlm.nih.gov/pubmed/11223679>
99. Fischer, C., *et al.* [Extracorporeal shock-wave lithotripsy induced ultrastructural changes to the renal parenchyma under aspirin use. Electron microscopic findings in the rat kidney]. *Urologe A*, 2007. 46: 150.  
<http://www.ncbi.nlm.nih.gov/pubmed/17221245>
100. Becopoulos, T., *et al.* Extracorporeal lithotripsy in patients with hemophilia. *Eur Urol*, 1988. 14: 343.  
<http://www.ncbi.nlm.nih.gov/pubmed/3169076>
101. Ishikawa, J., *et al.* Extracorporeal shock wave lithotripsy in von Willebrand's disease. *Int J Urol*, 1996. 3: 58.  
<http://www.ncbi.nlm.nih.gov/pubmed/8646601>
102. Zanetti, G., *et al.* Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. *J Endourol*, 2001. 15: 237.  
<http://www.ncbi.nlm.nih.gov/pubmed/11339387>
103. Schnabel, M.J., *et al.* Incidence and risk factors of renal hematoma: a prospective study of 1,300 SWL treatments. *Urolithiasis*, 2014. 42: 247.  
<http://www.ncbi.nlm.nih.gov/pubmed/24419328>
104. Schnabel, M.J., *et al.* Antiplatelet and anticoagulative medication during shockwave lithotripsy. *J Endourol*, 2014. 28: 1034.  
<http://www.ncbi.nlm.nih.gov/pubmed/24851726>
105. Turna, B., *et al.* Safety and efficacy of flexible ureterorenoscopy and holmium:YAG lithotripsy for intrarenal stones in anticoagulated cases. *J Urol*, 2008. 179: 1415.  
<http://www.ncbi.nlm.nih.gov/pubmed/18289567>

106. Toepfer, N.J., *et al.* The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. *Urology*, 2013. 82: 773.  
<http://www.ncbi.nlm.nih.gov/pubmed/23876586>
107. Aboumarzouk, O.M., *et al.* Flexible ureteroscopy and holmium:YAG laser lithotripsy for stone disease in patients with bleeding diathesis: a systematic review of the literature. *Int Braz J Urol*, 2012. 38: 298.  
<http://www.ncbi.nlm.nih.gov/pubmed/22765861>
108. Watterson, J.D., *et al.* Safety and efficacy of holmium: YAG laser lithotripsy in patients with bleeding diatheses. *J Urol*, 2002. 168: 442.  
<http://www.ncbi.nlm.nih.gov/pubmed/12131284>
109. Elkoushy, M.A., *et al.* Ureteroscopy in patients with coagulopathies is associated with lower stone-free rate and increased risk of clinically significant hematuria. *Int Braz J Urol*, 2012. 38: 195.  
<http://www.ncbi.nlm.nih.gov/pubmed/22555043>
110. Kuo, R.L., *et al.* Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. *Urology*, 1998. 52: 609.  
<http://www.ncbi.nlm.nih.gov/pubmed/9763079>
111. Gupta, A.D., *et al.* Coronary stent management in elective genitourinary surgery. *BJU Int*, 2012. 110: 480.  
<http://www.ncbi.nlm.nih.gov/pubmed/22192977>
112. Coptcoat, M.J., *et al.* The steinstrasse: a legacy of extracorporeal lithotripsy? *Eur Urol*, 1988. 14: 93.  
<http://www.ncbi.nlm.nih.gov/pubmed/3360043>
113. Ather, M.H., *et al.* Does ureteral stenting prior to shock wave lithotripsy influence the need for intervention in steinstrasse and related complications? *Urol Int*, 2009. 83: 222.  
<http://www.ncbi.nlm.nih.gov/pubmed/19752621>
114. Lucio, J., 2nd, *et al.* Steinstrasse predictive factors and outcomes after extracorporeal shockwave lithotripsy. *Int Braz J Urol*, 2011. 37: 477.  
<http://www.ncbi.nlm.nih.gov/pubmed/21888699>
115. Al-Awadi, K.A., *et al.* Steinstrasse: a comparison of incidence with and without J stenting and the effect of J stenting on subsequent management. *BJU Int*, 1999. 84: 618.  
<http://www.ncbi.nlm.nih.gov/pubmed/10510104>
116. Madbouly, K., *et al.* Risk factors for the formation of a steinstrasse after extracorporeal shock wave lithotripsy: a statistical model. *J Urol*, 2002. 167: 1239.  
<http://www.ncbi.nlm.nih.gov/pubmed/11832705>
117. Hardy, M.R., *et al.* Silent renal obstruction with severe functional loss after extracorporeal shock wave lithotripsy: a report of 2 cases. *J Urol*, 1987. 137: 91.  
<http://www.ncbi.nlm.nih.gov/pubmed/3795373>
118. Moursy, E., *et al.* Tamsulosin as an expulsive therapy for steinstrasse after extracorporeal shock wave lithotripsy: a randomized controlled study. *Scand J Urol Nephrol*, 2010. 44: 315.  
<http://www.ncbi.nlm.nih.gov/pubmed/20560802>
119. Resim, S., *et al.* Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. *Urology*, 2005. 66: 945.  
<http://www.ncbi.nlm.nih.gov/pubmed/16286100>
120. Goyal, R., *et al.* Does the type of steinstrasse predict the outcome of expectant therapy? *Indian Journal of Urology*, 2006. 22: 135.  
<http://www.indianjurol.com/text.asp?2006/22/2/135/26569>
121. Rabbani, S.M. Treatment of steinstrasse by transureteral lithotripsy. *Urol J*, 2008. 5: 89.  
<http://www.ncbi.nlm.nih.gov/pubmed/18592460>
122. Bernardo, N.O., *et al.* Chemolysis of urinary calculi. *Urol Clin North Am*, 2000. 27: 355.  
<http://www.ncbi.nlm.nih.gov/pubmed/10778477>
123. Chughtai, M.N., *et al.* Management of uric acid stone. *J Pak Med Assoc*, 1992. 42: 153.  
<http://www.ncbi.nlm.nih.gov/pubmed/1404830>
124. Tiselius, H.G., *et al.* Minimally invasive treatment of infection staghorn stones with shock wave lithotripsy and chemolysis. *Scand J Urol Nephrol*, 1999. 33: 286.  
<http://www.ncbi.nlm.nih.gov/pubmed/10572989>
125. Becker, G. Uric acid stones. *Nephrology*, 2007. 12: S21.  
<http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1797.2007.00774.x/abstract>
126. El-Gamal, O., *et al.* Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. *Urol Res*, 2012. 40: 219.  
<http://www.ncbi.nlm.nih.gov/pubmed/21858663>

127. Ohmori, K., *et al.* Effects of shock waves on the mouse fetus. *J Urol*, 1994. 151: 255.  
<http://www.ncbi.nlm.nih.gov/pubmed/8254823>
128. Stroom, S.B., *et al.* Extracorporeal shock wave lithotripsy in patients with bleeding diatheses. *J Urol*, 1990. 144: 1347.  
<http://www.ncbi.nlm.nih.gov/pubmed/2231922>
129. Carey, S.W., *et al.* Extracorporeal shock wave lithotripsy for patients with calcified ipsilateral renal arterial or abdominal aortic aneurysms. *J Urol*, 1992. 148: 18.  
<http://www.ncbi.nlm.nih.gov/pubmed/1613866>
130. Musa, A.A. Use of double-J stents prior to extracorporeal shock wave lithotripsy is not beneficial: results of a prospective randomized study. *Int Urol Nephrol*, 2008. 40: 19.  
<http://www.ncbi.nlm.nih.gov/pubmed/17394095>
131. Mohayuddin, N., *et al.* The outcome of extracorporeal shockwave lithotripsy for renal pelvic stone with and without JJ stent--a comparative study. *J Pak Med Assoc*, 2009. 59: 143.  
<http://www.ncbi.nlm.nih.gov/pubmed/19288938>
132. Platonov, M.A., *et al.* Pacemakers, implantable cardioverter/defibrillators, and extracorporeal shockwave lithotripsy: evidence-based guidelines for the modern era. *J Endourol*, 2008. 22: 243.  
<http://www.ncbi.nlm.nih.gov/pubmed/18294028>
133. Yilmaz, E., *et al.* Optimal frequency in extracorporeal shock wave lithotripsy: prospective randomized study. *Urology*, 2005. 66: 1160.  
<http://www.ncbi.nlm.nih.gov/pubmed/16360432>
134. Pace, K.T., *et al.* Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double-blind trial. *J Urol*, 2005. 174: 595.  
<http://www.ncbi.nlm.nih.gov/pubmed/16006908>
135. Madbouly, K., *et al.* Slow versus fast shock wave lithotripsy rate for urolithiasis: a prospective randomized study. *J Urol*, 2005. 173: 127.  
<http://www.ncbi.nlm.nih.gov/pubmed/15592053>
136. Semins, M.J., *et al.* The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. *J Urol*, 2008. 179: 194.  
<http://www.ncbi.nlm.nih.gov/pubmed/18001796>
137. Li, K., *et al.* Optimal frequency of shock wave lithotripsy in urolithiasis treatment: a systematic review and meta-analysis of randomized controlled trials. *J Urol*, 2013. 190: 1260.  
<http://www.ncbi.nlm.nih.gov/pubmed/23538240>
138. Nguyen, D.P., *et al.* Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial. *J Urol*, 2015. 194: 418.  
<http://www.ncbi.nlm.nih.gov/pubmed/25661296>
139. Pishchalnikov, Y.A., *et al.* Why stones break better at slow shockwave rates than at fast rates: in vitro study with a research electrohydraulic lithotripter. *J Endourol*, 2006. 20: 537.  
<http://www.ncbi.nlm.nih.gov/pubmed/16903810>
140. Connors, B.A., *et al.* Extracorporeal shock wave lithotripsy at 60 shock waves/min reduces renal injury in a porcine model. *BJU Int*, 2009. 104: 1004.  
<http://www.ncbi.nlm.nih.gov/pubmed/19338532>
141. Moon, K.B., *et al.* Optimal shock wave rate for shock wave lithotripsy in urolithiasis treatment: a prospective randomized study. *Korean J Urol*, 2012. 53: 790.  
<http://www.ncbi.nlm.nih.gov/pubmed/23185672>
142. Ng, C.F., *et al.* A prospective, randomized study of the clinical effects of shock wave delivery for unilateral kidney stones: 60 versus 120 shocks per minute. *J Urol*, 2012. 188: 837.  
<http://www.ncbi.nlm.nih.gov/pubmed/22819406>
143. Connors, B.A., *et al.* Effect of initial shock wave voltage on shock wave lithotripsy-induced lesion size during step-wise voltage ramping. *BJU Int*, 2009. 103: 104.  
<http://www.ncbi.nlm.nih.gov/pubmed/18680494>
144. Handa, R.K., *et al.* Optimising an escalating shockwave amplitude treatment strategy to protect the kidney from injury during shockwave lithotripsy. *BJU Int*, 2012. 110: E1041.  
<http://www.ncbi.nlm.nih.gov/pubmed/22612388>
145. Maloney, M.E., *et al.* Progressive increase of lithotripter output produces better in-vivo stone comminution. *J Endourol*, 2006. 20: 603.  
<http://www.ncbi.nlm.nih.gov/pubmed/16999607>
146. Demirci, D., *et al.* Comparison of conventional and step-wise shockwave lithotripsy in management of urinary calculi. *J Endourol*, 2007. 21: 1407.  
<http://www.ncbi.nlm.nih.gov/pubmed/18044996>

147. Honey, R.J., *et al.* Shock wave lithotripsy: a randomized, double-blind trial to compare immediate versus delayed voltage escalation. *Urology*, 2010. 75: 38.  
<http://www.ncbi.nlm.nih.gov/pubmed/19896176>
148. Pishchalnikov, Y.A., *et al.* Air pockets trapped during routine coupling in dry head lithotripsy can significantly decrease the delivery of shock wave energy. *J Urol*, 2006. 176: 2706.  
<http://www.ncbi.nlm.nih.gov/pubmed/17085200>
149. Jain, A., *et al.* Effect of air bubbles in the coupling medium on efficacy of extracorporeal shock wave lithotripsy. *Eur Urol*, 2007. 51: 1680.  
<http://www.ncbi.nlm.nih.gov/pubmed/17112655>
150. Logarakis, N.F., *et al.* Variation in clinical outcome following shock wave lithotripsy. *J Urol*, 2000. 163: 721.  
<http://www.ncbi.nlm.nih.gov/pubmed/10687964>
151. Eichel, L., *et al.* Operator experience and adequate anesthesia improve treatment outcome with third-generation lithotripters. *J Endourol*, 2001. 15: 671.  
<http://www.ncbi.nlm.nih.gov/pubmed/11697394>
152. Sorensen, C., *et al.* Comparison of intravenous sedation versus general anesthesia on the efficacy of the Doli 50 lithotripter. *J Urol*, 2002. 168: 35.  
<http://www.ncbi.nlm.nih.gov/pubmed/12050487>
153. Cleveland, R.O., *et al.* Effect of stone motion on in vitro comminution efficiency of Storz Modulith SLX. *J Endourol*, 2004. 18: 629.  
<http://www.ncbi.nlm.nih.gov/pubmed/15597649>
154. Honey, R.J., *et al.* A prospective study examining the incidence of bacteriuria and urinary tract infection after shock wave lithotripsy with targeted antibiotic prophylaxis. *J Urol*, 2013. 189: 2112.  
<http://www.ncbi.nlm.nih.gov/pubmed/23276509>
155. Lu, Y., *et al.* Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: a systematic review and meta-analysis. *J Urol*, 2012. 188: 441.  
<http://www.ncbi.nlm.nih.gov/pubmed/22704118>
156. Grabe M., *et al.* EAU Guidelines on Urological Infections, in EAU Guidelines, Edn. published as the 30th EAU Annual Meeting, Madrid, E.A.o.U.G. Office, Editor. 2015, European Association of Urology Guidelines Office: Arnhem, The Netherlands.  
<http://www.uroweb.org/guidelines/online-guidelines/>
157. Gravina, G.L., *et al.* Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. *Urology*, 2005. 66: 24.  
<http://www.ncbi.nlm.nih.gov/pubmed/15992885>
158. Naja, V., *et al.* Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. *Urology*, 2008. 72: 1006.  
<http://www.ncbi.nlm.nih.gov/pubmed/18799202>
159. Bhagat, S.K., *et al.* Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi? *J Urol*, 2007. 177: 2185.  
<http://www.ncbi.nlm.nih.gov/pubmed/17509314>
160. Wang, H., *et al.* Effect of alpha1-adrenergic antagonists on lower ureteral stones with extracorporeal shock wave lithotripsy. *Asian J Surg*, 2010. 33: 37.  
<http://www.ncbi.nlm.nih.gov/pubmed/20497881>
161. Zhu, Y., *et al.* alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. *BJU Int*, 2010. 106: 256.  
<http://www.ncbi.nlm.nih.gov/pubmed/19889063>
162. Hussein, M.M. Does tamsulosin increase stone clearance after shockwave lithotripsy of renal stones? A prospective, randomized controlled study. *Scand J Urol Nephrol*, 2010. 44: 27.  
<http://www.ncbi.nlm.nih.gov/pubmed/19947900>
163. Singh, S.K., *et al.* Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. *Urol J*, 2011. 8: 14.  
<http://www.ncbi.nlm.nih.gov/pubmed/21404197>
164. Zheng, S., *et al.* Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis. *Scand J Urol Nephrol*, 2010. 44: 425.  
<http://www.ncbi.nlm.nih.gov/pubmed/21080841>
165. Falahatkar, S., *et al.* Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi? *J Endourol*, 2011. 25: 495.  
<http://www.ncbi.nlm.nih.gov/pubmed/21166579>

166. Schuler, T.D., *et al.* Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. *J Endourol*, 2009. 23: 387.  
<http://www.ncbi.nlm.nih.gov/pubmed/19245302>
167. Pearle, M.S., *et al.* Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or less. *J Urol*, 2005. 173: 2005.  
<http://www.ncbi.nlm.nih.gov/pubmed/15879805>
168. Lingeman, J.E., *et al.* Comparison of results and morbidity of percutaneous nephrostolithotomy and extracorporeal shock wave lithotripsy. *J Urol*, 1987. 138: 485.  
<http://www.ncbi.nlm.nih.gov/pubmed/3625845>
169. Sayed, M.A., *et al.* Steinstrasse after extracorporeal shockwave lithotripsy: aetiology, prevention and management. *BJU Int*, 2001. 88: 675.  
<http://www.ncbi.nlm.nih.gov/pubmed/11890235>
170. Skolarikos, A., *et al.* Extracorporeal shock wave lithotripsy 25 years later: complications and their prevention. *Eur Urol*, 2006. 50: 981.  
<http://www.ncbi.nlm.nih.gov/pubmed/16481097>
171. Osman, M.M., *et al.* 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. *Eur Urol*, 2005. 47: 860.  
<http://www.ncbi.nlm.nih.gov/pubmed/15925084>
172. Tan, Y.M., *et al.* Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital. *Scand J Urol Nephrol*, 2002. 36: 363.  
<http://www.ncbi.nlm.nih.gov/pubmed/12487741>
173. Muller-Mattheis, V.G., *et al.* Bacteremia during extracorporeal shock wave lithotripsy of renal calculi. *J Urol*, 1991. 146: 733.  
<http://www.ncbi.nlm.nih.gov/pubmed/1875482>
174. Dhar, N.B., *et al.* A multivariate analysis of risk factors associated with subcapsular hematoma formation following electromagnetic shock wave lithotripsy. *J Urol*, 2004. 172: 2271.  
<http://www.ncbi.nlm.nih.gov/pubmed/15538247>
175. Zanetti, G., *et al.* Cardiac dysrhythmias induced by extracorporeal shockwave lithotripsy. *J Endourol*, 1999. 13: 409.  
<http://www.ncbi.nlm.nih.gov/pubmed/10479005>
176. Rodrigues Netto, N., Jr., *et al.* Small-bowel perforation after shockwave lithotripsy. *J Endourol*, 2003. 17: 719.  
<http://www.ncbi.nlm.nih.gov/pubmed/14642028>
177. Holmberg, G., *et al.* Perforation of the bowel during SWL in prone position. *J Endourol*, 1997. 11: 313.  
<http://www.ncbi.nlm.nih.gov/pubmed/9355944>
178. Maker, V., *et al.* Gastrointestinal injury secondary to extracorporeal shock wave lithotripsy: a review of the literature since its inception. *J Am Coll Surg*, 2004. 198: 128.  
<http://www.ncbi.nlm.nih.gov/pubmed/14698320>
179. Kim, T.B., *et al.* Life-threatening complication after extracorporeal shock wave lithotripsy for a renal stone: a hepatic subcapsular hematoma. *Korean J Urol*, 2010. 51: 212.  
<http://www.ncbi.nlm.nih.gov/pubmed/20414400>
180. Ng, C.F., *et al.* Hepatic haematoma after shockwave lithotripsy for renal stones. *Urol Res*, 2012. 40: 785.  
<http://www.ncbi.nlm.nih.gov/pubmed/22782117>
181. Chen, C.S., *et al.* Subcapsular hematoma of spleen--a complication following extracorporeal shock wave lithotripsy for ureteral calculus. *Changgeng Yi Xue Za Zhi*, 1992. 15: 215.  
<http://www.ncbi.nlm.nih.gov/pubmed/1295657>
182. Lingeman, J.E., *et al.* Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. *JAMA*, 1990. 263: 1789.  
<http://www.ncbi.nlm.nih.gov/pubmed/2313851>
183. Krambeck, A.E., *et al.* Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol*, 2006. 175: 1742.  
<http://www.ncbi.nlm.nih.gov/pubmed/16600747>
184. Eassa, W.A., *et al.* Prospective study of the long-term effects of shock wave lithotripsy on renal function and blood pressure. *J Urol*, 2008. 179: 964.  
<http://www.ncbi.nlm.nih.gov/pubmed/18207167>

185. Yu, C., *et al.* A systematic review and meta-analysis of new onset hypertension after extracorporeal shock wave lithotripsy. *Int Urol Nephrol*, 2014. 46: 719.  
<http://www.ncbi.nlm.nih.gov/pubmed/22903789>
186. Fankhauser, C.D., *et al.* Long-term Adverse Effects of Extracorporeal Shock-wave Lithotripsy for Nephrolithiasis and Ureterolithiasis: A Systematic Review. *Urology*, 2015. 85: 991.  
<http://www.ncbi.nlm.nih.gov/pubmed/25917723>
187. Lu, Y., *et al.* Randomized prospective trial of tubeless versus conventional minimally invasive percutaneous nephrolithotomy. *World J Urol*, 2013. 31: 1303.  
<http://www.ncbi.nlm.nih.gov/pubmed/22903789>
188. Mishra, S., *et al.* Prospective comparative study of miniperc and standard PNL for treatment of 1 to 2 cm size renal stone. *BJU Int*, 2011. 108: 896.  
<http://www.ncbi.nlm.nih.gov/pubmed/21477212>
189. Knoll, T., *et al.* Do patients benefit from miniaturized tubeless percutaneous nephrolithotomy? A comparative prospective study. *J Endourol*, 2010. 24: 1075.  
<http://www.ncbi.nlm.nih.gov/pubmed/20575685>
190. Sabnis, R.B., *et al.* Micropercutaneous nephrolithotomy (microperc) vs retrograde intrarenal surgery for the management of small renal calculi: a randomized controlled trial. *BJU Int*, 2013. 112: 355.  
<http://www.ncbi.nlm.nih.gov/pubmed/23826843>
191. Yamaguchi, A., *et al.* Operating times and bleeding complications in percutaneous nephrolithotomy: a comparison of tract dilation methods in 5,537 patients in the Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study. *J Endourol*, 2011. 25: 933.  
<http://www.ncbi.nlm.nih.gov/pubmed/21568697>
192. Tepeler, A., *et al.* Comparison of intrarenal pelvic pressure during micro-percutaneous nephrolithotomy and conventional percutaneous nephrolithotomy. *Urolithiasis*, 2014. 42: 275.  
<http://www.ncbi.nlm.nih.gov/pubmed/24522489>
193. Ganesamoni, R., *et al.* Prospective randomized controlled trial comparing laser lithotripsy with pneumatic lithotripsy in miniperc for renal calculi. *J Endourol*, 2013. 27: 1444.  
<http://www.ncbi.nlm.nih.gov/pubmed/24251428>
194. Gupta, P.K. Is the holmium:YAG laser the best intracorporeal lithotripter for the ureter? A 3-year retrospective study. *J Endourol*, 2007. 21: 305.  
<http://www.ncbi.nlm.nih.gov/pubmed/17444776>
195. Hofbauer, J., *et al.* Electrohydraulic versus pneumatic disintegration in the treatment of ureteral stones: a randomized, prospective trial. *J Urol*, 1995. 153: 623.  
<http://www.ncbi.nlm.nih.gov/pubmed/7861499>
196. Andonian, S., *et al.* Does imaging modality used for percutaneous renal access make a difference? A matched case analysis. *J Endourol*, 2013. 27: 24.  
<http://www.ncbi.nlm.nih.gov/pubmed/22834999>
197. Astroza, G., *et al.* Effect of supine vs prone position on outcomes of percutaneous nephrolithotomy in staghorn calculi: results from the Clinical Research Office of the Endourology Society Study. *Urology*, 2013. 82: 1240.  
<http://www.ncbi.nlm.nih.gov/pubmed/24063939>
198. Wang, Y., *et al.* Prone versus modified supine position in percutaneous nephrolithotomy: a prospective randomized study. *Int J Med Sci*, 2013. 10: 1518.  
<http://www.ncbi.nlm.nih.gov/pubmed/24046526>
199. Zhang, X., *et al.* Is the supine position superior to the prone position for percutaneous nephrolithotomy (PCNL)? *Urolithiasis*, 2014. 42: 87.  
<http://www.ncbi.nlm.nih.gov/pubmed/24141694>
200. Osman, M., *et al.* Percutaneous nephrolithotomy with ultrasonography-guided renal access: experience from over 300 cases. *BJU Int*, 2005. 96: 875.  
<http://www.ncbi.nlm.nih.gov/pubmed/16153221>
201. Jessen, J.P., *et al.* Percutaneous nephrolithotomy under combined sonographic/radiologic guided puncture: results of a learning curve using the modified Clavien grading system. *World J Urol*, 2013. 31: 1599.  
<http://www.ncbi.nlm.nih.gov/pubmed/23283412>
202. Desai, M.R., *et al.* A prospective randomized comparison of type of nephrostomy drainage following percutaneous nephrostolithotomy: large bore versus small bore versus tubeless. *J Urol*, 2004. 172: 565.  
<http://www.ncbi.nlm.nih.gov/pubmed/15247731>



203. Cormio, L., *et al.* Exit strategies following percutaneous nephrolithotomy (PCNL): a comparison of surgical outcomes in the Clinical Research Office of the Endourological Society (CROES) PCNL Global Study. *World J Urol*, 2013. 31: 1239.  
<http://www.ncbi.nlm.nih.gov/pubmed/22752586>
204. Istanbuluoglu, M.O., *et al.* Effectiveness of totally tubeless percutaneous nephrolithotomy in selected patients: a prospective randomized study. *Int Urol Nephrol*, 2009. 41: 541.  
<http://www.ncbi.nlm.nih.gov/pubmed/19165617>
205. Gonen, M., *et al.* Tubeless and stentless percutaneous nephrolithotomy in patients requiring supracostal access. *Urol Int*, 2009. 82: 440.  
<http://www.ncbi.nlm.nih.gov/pubmed/19506412>
206. Garofalo, M., *et al.* Tubeless procedure reduces hospitalization and pain after percutaneous nephrolithotomy: results of a multivariable analysis. *Urolithiasis*, 2013. 41: 347.  
<http://www.ncbi.nlm.nih.gov/pubmed/23632910>
207. Seitz, C., *et al.* Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. *Eur Urol*, 2012. 61: 146.  
<http://www.ncbi.nlm.nih.gov/pubmed/21978422>
208. Zanetti, G., *et al.* Infections and urolithiasis: current clinical evidence in prophylaxis and antibiotic therapy. *Arch Ital Urol Androl*, 2008. 80: 5.  
<http://www.ncbi.nlm.nih.gov/pubmed/18533618>
209. Gonen, M., *et al.* Factors affecting fever following percutaneous nephrolithotomy: a prospective clinical study. *J Endourol*, 2008. 22: 2135.  
<http://www.ncbi.nlm.nih.gov/pubmed/1881156>
210. Wendt-Nordahl, G., *et al.* Do new generation flexible ureterorenoscopes offer a higher treatment success than their predecessors? *Urol Res*, 2011. 39: 185.  
<http://www.ncbi.nlm.nih.gov/pubmed/21052986>
211. Binbay, M., *et al.* Is there a difference in outcomes between digital and fiberoptic flexible ureterorenoscopy procedures? *J Endourol*, 2010. 24: 1929.  
<http://www.ncbi.nlm.nih.gov/pubmed/21043835>
212. Humphreys, M.R., *et al.* A new world revealed: early experience with digital ureteroscopy. *J Urol*, 2008. 179: 970.  
<http://www.ncbi.nlm.nih.gov/pubmed/18207196>
213. Mitchell, S., *et al.* First digital flexible ureterorenoscope: initial experience. *J Endourol*, 2008. 22: 47.  
<http://www.ncbi.nlm.nih.gov/pubmed/18315473>
214. Auge, B.K., *et al.* Ureteroscopic management of lower-pole renal calculi: technique of calculus displacement. *J Endourol*, 2001. 15: 835.  
<http://www.ncbi.nlm.nih.gov/pubmed/11724125>
215. Assimos, D.G., *et al.* The role of open stone surgery since extracorporeal shock wave lithotripsy. *J Urol*, 1989. 142: 263.  
<http://www.ncbi.nlm.nih.gov/pubmed/2746742>
216. Segura, J.W. Current surgical approaches to nephrolithiasis. *Endocrinol Metab Clin North Am*, 1990. 19: 919.  
<http://www.ncbi.nlm.nih.gov/pubmed/2081519>
217. Honeck, P., *et al.* Does open stone surgery still play a role in the treatment of urolithiasis? Data of a primary urolithiasis center. *J Endourol*, 2009. 23: 1209.  
<http://www.ncbi.nlm.nih.gov/pubmed/19538063>
218. Bichler, K.H., *et al.* Indications for open stone removal of urinary calculi. *Urol Int*, 1997. 59: 102.  
<http://www.ncbi.nlm.nih.gov/pubmed/9392057>
219. Paik, M.L., *et al.* Is there a role for open stone surgery? *Urol Clin North Am*, 2000. 27: 323.  
<http://www.ncbi.nlm.nih.gov/pubmed/10778474>
220. Ansari, M.S., *et al.* Impact of socioeconomic status in etiology and management of urinary stone disease. *Urol Int*, 2003. 70: 255.  
<http://www.ncbi.nlm.nih.gov/pubmed/12776701>
221. Alivizatos, G., *et al.* Is there still a role for open surgery in the management of renal stones? *Curr Opin Urol*, 2006. 16: 106.  
<http://www.ncbi.nlm.nih.gov/pubmed/16479213>
222. Basiri, A., *et al.* Comparison of safety and efficacy of laparoscopic pyelolithotomy versus percutaneous nephrolithotomy in patients with renal pelvic stones: a randomized clinical trial. *Urol J*, 2014. 11: 1932.  
<http://www.ncbi.nlm.nih.gov/pubmed/25433470>

223. Beltrami, P., *et al.* The endourological treatment of renal matrix stones. *Urol Int*, 2014. 93: 394.  
<http://www.ncbi.nlm.nih.gov/pubmed/24969358>
224. Prakash, J., *et al.* Retroperitoneoscopic versus open mini-incision ureterolithotomy for upper- and mid-ureteric stones: a prospective randomized study. *Urolithiasis*, 2014. 42: 133.  
<http://www.ncbi.nlm.nih.gov/pubmed/24272062>
225. Singh, V., *et al.* Prospective randomized comparison of retroperitoneoscopic pyelolithotomy versus percutaneous nephrolithotomy for solitary large pelvic kidney stones. *Urol Int*, 2014. 92: 392.  
<http://www.ncbi.nlm.nih.gov/pubmed/24135482>
226. Al-Hunayan, A., *et al.* Management of solitary renal pelvic stone: laparoscopic retroperitoneal pyelolithotomy versus percutaneous nephrolithotomy. *J Endourol*, 2011. 25: 975.  
<http://www.ncbi.nlm.nih.gov/pubmed/21612433>
227. Skolarikos, A., *et al.* Laparoscopic urinary stone surgery: an updated evidence-based review. *Urol Res*, 2010. 38: 337.  
<http://www.ncbi.nlm.nih.gov/pubmed/20396871>
228. Giedelman, C., *et al.* Laparoscopic anatomic nephrolithotomy: developments of the technique in the era of minimally invasive surgery. *J Endourol*, 2012. 26: 444.  
<http://www.ncbi.nlm.nih.gov/pubmed/22142215>
229. Wang, X., *et al.* Laparoscopic pyelolithotomy compared to percutaneous nephrolithotomy as surgical management for large renal pelvic calculi: a meta-analysis. *J Urol*, 2013. 190: 888.  
<http://www.ncbi.nlm.nih.gov/pubmed/23454154>
230. Brandt, B., *et al.* Painful caliceal calculi. The treatment of small nonobstructing caliceal calculi in patients with symptoms. *Scand J Urol Nephrol*, 1993. 27: 75.  
<http://www.ncbi.nlm.nih.gov/pubmed/8493473>
231. Glowacki, L.S., *et al.* The natural history of asymptomatic urolithiasis. *J Urol*, 1992. 147: 319.  
<http://www.ncbi.nlm.nih.gov/pubmed/1732583>
232. Burgher, A., *et al.* Progression of nephrolithiasis: long-term outcomes with observation of asymptomatic calculi. *J Endourol*, 2004. 18: 534.  
<http://www.ncbi.nlm.nih.gov/pubmed/15333216>
233. Hubner, W., *et al.* Treatment of caliceal calculi. *Br J Urol*, 1990. 66: 9.  
<http://www.ncbi.nlm.nih.gov/pubmed/2393803>
234. Inci, K., *et al.* Prospective long-term followup of patients with asymptomatic lower pole caliceal stones. *J Urol*, 2007. 177: 2189.  
<http://www.ncbi.nlm.nih.gov/pubmed/17509315>
235. Keeley, F.X., Jr., *et al.* Preliminary results of a randomized controlled trial of prophylactic shock wave lithotripsy for small asymptomatic renal calyceal stones. *BJU Int*, 2001. 87: 1.  
<http://www.ncbi.nlm.nih.gov/pubmed/11121982>
236. Collins, J.W., *et al.* Is there a role for prophylactic shock wave lithotripsy for asymptomatic calyceal stones? *Curr Opin Urol*, 2002. 12: 281.  
<http://www.ncbi.nlm.nih.gov/pubmed/12072647>
237. Rebuck, D.A., *et al.* The natural history of renal stone fragments following ureteroscopy. *Urology*, 2011. 77: 564.  
<http://www.ncbi.nlm.nih.gov/pubmed/21109293>
238. Andersson, L., *et al.* Small renal caliceal calculi as a cause of pain. *J Urol*, 1983. 130: 752.  
<http://www.ncbi.nlm.nih.gov/pubmed/6887409>
239. Mee, S.L., *et al.* Small caliceal stones: is extracorporeal shock wave lithotripsy justified? *J Urol*, 1988. 139: 908.  
<http://www.ncbi.nlm.nih.gov/pubmed/3361660>
240. Argyropoulos, A.N., *et al.* Evaluation of outcome following lithotripsy. *Curr Opin Urol*, 2010. 20: 154.  
<http://www.ncbi.nlm.nih.gov/pubmed/19898239>
241. Srisubat, A., *et al.* Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. *Cochrane Database Syst Rev*, 2014. 11: CD007044.  
<http://www.ncbi.nlm.nih.gov/pubmed/19821393>
242. Sahinkanat, T., *et al.* Evaluation of the effects of relationships between main spatial lower pole calyceal anatomic factors on the success of shock-wave lithotripsy in patients with lower pole kidney stones. *Urology*, 2008. 71: 801.  
<http://www.ncbi.nlm.nih.gov/pubmed/18279941>
243. Danuser, H., *et al.* Extracorporeal shock wave lithotripsy of lower calyx calculi: how much is treatment outcome influenced by the anatomy of the collecting system? *Eur Urol*, 2007. 52: 539.  
<http://www.ncbi.nlm.nih.gov/pubmed/17400366>

244. Preminger, G.M. Management of lower pole renal calculi: shock wave lithotripsy versus percutaneous nephrolithotomy versus flexible ureteroscopy. *Urol Res*, 2006. 34: 108.  
<http://www.ncbi.nlm.nih.gov/pubmed/16463145>
245. Zheng, C., *et al.* Retrograde intrarenal surgery versus percutaneous nephrolithotomy for treatment of renal stones >2 cm: a meta-analysis. *Urol Int*, 2014. 93: 417.  
<http://www.ncbi.nlm.nih.gov/pubmed/25170589>
246. Karakoyunlu, N., *et al.* A comparison of standard PCNL and staged retrograde FURS in pelvis stones over 2 cm in diameter: a prospective randomized study. *Urolithiasis*, 2015. 43: 283.  
<http://www.ncbi.nlm.nih.gov/pubmed/25838180>
247. Donaldson, J.F., *et al.* Systematic review and meta-analysis of the clinical effectiveness of shock wave lithotripsy, retrograde intrarenal surgery, and percutaneous nephrolithotomy for lower-pole renal stones. *Eur Urol*, 2015. 67: 612.  
<http://www.ncbi.nlm.nih.gov/pubmed/25449204>
248. Kumar, A., *et al.* A prospective, randomized comparison of shock wave lithotripsy, retrograde intrarenal surgery and miniperc for treatment of 1 to 2 cm radiolucent lower calyceal renal calculi: a single center experience. *J Urol*, 2015. 193: 160.  
<http://www.ncbi.nlm.nih.gov/pubmed/25066869>
249. Sener, N.C., *et al.* Prospective randomized trial comparing shock wave lithotripsy and flexible ureterorenoscopy for lower pole stones smaller than 1 cm. *Urolithiasis*, 2014. 42: 127.  
<http://www.ncbi.nlm.nih.gov/pubmed/24220692>
250. Manikandan, R., *et al.* Do anatomic factors pose a significant risk in the formation of lower pole stones? *Urology*, 2007. 69: 620.  
<http://www.ncbi.nlm.nih.gov/pubmed/17445636>
251. Sumino, Y., *et al.* Predictors of lower pole renal stone clearance after extracorporeal shock wave lithotripsy. *J Urol*, 2002. 168: 1344.  
<http://www.ncbi.nlm.nih.gov/pubmed/12352389>
252. De, S., *et al.* Percutaneous nephrolithotomy versus retrograde intrarenal surgery: a systematic review and meta-analysis. *Eur Urol*, 2015. 67: 125.  
<http://www.ncbi.nlm.nih.gov/pubmed/25064687>
253. Gokce G., *et al.* The evaluation of extracorporeal shockwave lithotripsy (ESWL), retrograde intrarenal surgery (RIRS) and micro percutaneous nephrolithotomy (mPCNL) treatments in kidney stones smaller than two centimeters. *J Endourol*, 2014. 28: A267.
254. Sener, N.C., *et al.* Asymptomatic lower pole small renal stones: shock wave lithotripsy, flexible ureteroscopy, or observation? A prospective randomized trial. *Urology*, 2015. 85: 33.  
<http://www.ncbi.nlm.nih.gov/pubmed/25440816>
255. Madbouly, K., *et al.* Impact of lower pole renal anatomy on stone clearance after shock wave lithotripsy: fact or fiction? *J Urol*, 2001. 165: 1415.  
<http://www.ncbi.nlm.nih.gov/pubmed/11342888>
256. Hyams, E.S., *et al.* Flexible ureterorenoscopy and holmium laser lithotripsy for the management of renal stone burdens that measure 2 to 3 cm: a multi-institutional experience. *J Endourol*, 2010. 24: 1583.  
<http://www.ncbi.nlm.nih.gov/pubmed/20629566>
257. Riley, J.M., *et al.* Retrograde ureteroscopy for renal stones larger than 2.5 cm. *J Endourol*, 2009. 23: 1395.  
<http://www.ncbi.nlm.nih.gov/pubmed/19694527>
258. Aboumarzouk, O.M., *et al.* Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. *Cochrane Database Syst Rev*, 2012. 5: CD006029.  
<http://www.ncbi.nlm.nih.gov/pubmed/22592707>
259. Skolarikos, A., *et al.* The role for active monitoring in urinary stones: a systematic review. *J Endourol*, 2010. 24: 923.  
<http://www.ncbi.nlm.nih.gov/pubmed/20482232>
260. Reference withdrawn
261. Campschroer, T., *et al.* Alpha-blockers as medical expulsive therapy for ureteral stones. *Cochrane Database Syst Rev*, 2014. 4: CD008509.  
<http://www.ncbi.nlm.nih.gov/pubmed/24691989>
262. Pickard, R., *et al.* Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. *Lancet*, 2015. 386: 341.  
<http://www.ncbi.nlm.nih.gov/pubmed/25998582>

263. Liatsikos, E.N., *et al.* Doxazosin for the management of distal-ureteral stones. *J Endourol*, 2007. 21: 538.  
<http://www.ncbi.nlm.nih.gov/pubmed/17523910>
264. Hollingsworth, J.M., *et al.* Medical therapy to facilitate urinary stone passage: a meta-analysis. *Lancet*, 2006. 368: 1171.  
<http://www.ncbi.nlm.nih.gov/pubmed/17011944>
265. Borghi, L., *et al.* Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. *J Urol*, 1994. 152: 1095.  
<http://www.ncbi.nlm.nih.gov/pubmed/8072071>
266. Porpiglia, F., *et al.* Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. *Urology*, 2000. 56: 579.  
<http://www.ncbi.nlm.nih.gov/pubmed/11018608>
267. Dellabella, M., *et al.* Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. *J Urol*, 2005. 174: 167.  
<http://www.ncbi.nlm.nih.gov/pubmed/15947613>
268. Porpiglia, F., *et al.* Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? *Eur Urol*, 2006. 50: 339.  
<http://www.ncbi.nlm.nih.gov/pubmed/11018608>
269. Dellabella, M., *et al.* Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. *Urology*, 2005. 66: 712.  
<http://www.ncbi.nlm.nih.gov/pubmed/15947613>
270. Yilmaz, E., *et al.* The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. *J Urol*, 2005. 173: 2010.  
<http://www.ncbi.nlm.nih.gov/pubmed/15879806>
271. John, T.T., *et al.* Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. *Urology*, 2010. 75: 1040.  
<http://www.ncbi.nlm.nih.gov/pubmed/19819530>
272. Ghoneim, I.A., *et al.* Extracorporeal shock wave lithotripsy in impacted upper ureteral stones: a prospective randomized comparison between stented and non-stented techniques. *Urology*, 2010. 75: 45.  
<http://www.ncbi.nlm.nih.gov/pubmed/19811806>
273. Cybulski, P.A., *et al.* Ureteroscopy: anesthetic considerations. *Urol Clin North Am*, 2004. 31: 43.  
<http://www.ncbi.nlm.nih.gov/pubmed/15040400>
274. Sun, X., *et al.* Treatment of large impacted proximal ureteral stones: randomized comparison of percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. *J Endourol*, 2008. 22: 913.  
<http://www.ncbi.nlm.nih.gov/pubmed/18429682>
275. Dickstein, R.J., *et al.* Is a safety wire necessary during routine flexible ureteroscopy? *J Endourol*, 2010. 24: 1589.  
<http://www.ncbi.nlm.nih.gov/pubmed/20836719>
276. Eandi, J.A., *et al.* Evaluation of the impact and need for use of a safety guidewire during ureteroscopy. *J Endourol*, 2008. 22: 1653.  
<http://www.ncbi.nlm.nih.gov/pubmed/18721045>
277. Stern, J.M., *et al.* Safety and efficacy of ureteral access sheaths. *J Endourol*, 2007. 21: 119.  
<http://www.ncbi.nlm.nih.gov/pubmed/17338606>
278. L'Esperance J, O., *et al.* Effect of ureteral access sheath on stone-free rates in patients undergoing ureteroscopic management of renal calculi. *Urology*, 2005. 66: 252.  
<http://www.ncbi.nlm.nih.gov/pubmed/16040093>
279. Traxer, O., *et al.* Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. *J Urol*, 2013. 189: 580.  
<http://www.ncbi.nlm.nih.gov/pubmed/22982421>
280. Aboumarzouk, O.M., *et al.* Flexible ureteroscopy and laser lithotripsy for stones >2 cm: a systematic review and meta-analysis. *J Endourol*, 2012. 26: 1257.  
<http://www.ncbi.nlm.nih.gov/pubmed/22642568>
281. Bach, T., *et al.* Working tools in flexible ureterorenoscopy--influence on flow and deflection: what does matter? *J Endourol*, 2008. 22: 1639.  
<http://www.ncbi.nlm.nih.gov/pubmed/18620506>

282. Leijte, J.A., *et al.* Holmium laser lithotripsy for ureteral calculi: predictive factors for complications and success. *J Endourol*, 2008. 22: 257.  
<http://www.ncbi.nlm.nih.gov/pubmed/18294030>
283. Pierre, S., *et al.* Holmium laser for stone management. *World J Urol*, 2007. 25: 235.  
<http://www.ncbi.nlm.nih.gov/pubmed/17340157>
284. Garg, S., *et al.* Ureteroscopic laser lithotripsy versus ballistic lithotripsy for treatment of ureteric stones: a prospective comparative study. *Urol Int*, 2009. 82: 341.  
<http://www.ncbi.nlm.nih.gov/pubmed/19440025>
285. Binbay, M., *et al.* Evaluation of pneumatic versus holmium:YAG laser lithotripsy for impacted ureteral stones. *Int Urol Nephrol*, 2011. 43: 989.  
<http://www.ncbi.nlm.nih.gov/pubmed/21479563>
286. Ahmed, M., *et al.* Systematic evaluation of ureteral occlusion devices: insertion, deployment, stone migration, and extraction. *Urology*, 2009. 73: 976.  
<http://www.ncbi.nlm.nih.gov/pubmed/19394493>
287. Rubenstein, R.A., *et al.* Prestenting improves ureteroscopic stone-free rates. *J Endourol*, 2007. 21: 1277.  
<http://www.ncbi.nlm.nih.gov/pubmed/18042014>
288. Song, T., *et al.* Meta-analysis of postoperatively stenting or not in patients underwent ureteroscopic lithotripsy. *Urol Res*, 2012. 40: 67.  
<http://www.ncbi.nlm.nih.gov/pubmed/21573923>
289. Haleblan, G., *et al.* Ureteral stenting and urinary stone management: a systematic review. *J Urol*, 2008. 179: 424.  
<http://www.ncbi.nlm.nih.gov/pubmed/18076928>
290. Nabi, G., *et al.* Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. *BMJ*, 2007. 334: 572.  
<http://www.ncbi.nlm.nih.gov/pubmed/17311851>
291. Moon, T.D. Ureteral stenting--an obsolete procedure? *J Urol*, 2002. 167: 1984.  
<http://www.ncbi.nlm.nih.gov/pubmed/11956423>
292. Wang, C.J., *et al.* Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. *Urol Res*, 2009. 37: 147.  
<http://www.ncbi.nlm.nih.gov/pubmed/19277623>
293. Lee, Y.J., *et al.* Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. *Urolithiasis*, 2013. 41: 247.  
<http://www.ncbi.nlm.nih.gov/pubmed/23515684>
294. Lamb, A.D., *et al.* Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. *BJU Int*, 2011. 108: 1894.  
<http://www.ncbi.nlm.nih.gov/pubmed/21453351>
295. Geavlete, P., *et al.* Complications of 2735 retrograde semirigid ureteroscopy procedures: a single-center experience. *J Endourol*, 2006. 20: 179.  
<http://www.ncbi.nlm.nih.gov/pubmed/16548724>
296. Perez Castro, E., *et al.* Differences in ureteroscopic stone treatment and outcomes for distal, mid-, proximal, or multiple ureteral locations: the Clinical Research Office of the Endourological Society ureteroscopy global study. *Eur Urol*, 2014. 66: 102.  
<http://www.ncbi.nlm.nih.gov/pubmed/24507782>
297. Kumar, V., *et al.* Percutaneous ureterolitholapaxy: the best bet to clear large bulk impacted upper ureteral calculi. *Arch Esp Urol*, 1996. 49: 86.  
<http://www.ncbi.nlm.nih.gov/pubmed/8678608>
298. el-Nahas, A.R., *et al.* Percutaneous treatment of large upper tract stones after urinary diversion. *Urology*, 2006. 68: 500.  
<http://www.ncbi.nlm.nih.gov/pubmed/16979745>
299. El-Assmy, A., *et al.* Extracorporeal shock wave lithotripsy of upper urinary tract calculi in patients with cystectomy and urinary diversion. *Urology*, 2005. 66: 510.  
<http://www.ncbi.nlm.nih.gov/pubmed/16140067>
300. Moufid, K., *et al.* Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. *Urol Ann*, 2013. 5: 140.  
<http://www.ncbi.nlm.nih.gov/pubmed/24049373>
301. Topaloglu, H., *et al.* A comparison of antegrade percutaneous and laparoscopic approaches in the treatment of proximal ureteral stones. *Biomed Res Int*, 2014. 2014: 691946.  
<http://www.ncbi.nlm.nih.gov/pubmed/25295266>

302. Skolarikos, A., *et al.* Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi. *Arch Ital Urol Androl*, 2010. 82: 56.  
<http://www.ncbi.nlm.nih.gov/pubmed/20593724>
303. Hong, Y.K., *et al.* Ureteroscopic lithotripsy using Swiss Lithoclast for treatment of ureteral calculi: 12-years experience. *J Korean Med Sci*, 2009. 24: 690.  
<http://www.ncbi.nlm.nih.gov/pubmed/19654954>
304. Cui, X., *et al.* Comparison between extracorporeal shock wave lithotripsy and ureteroscopic lithotripsy for treating large proximal ureteral stones: a meta-analysis. *Urology*, 2015. 85: 748.  
<http://www.ncbi.nlm.nih.gov/pubmed/25681251>
305. MacLennan S., *et al.* What are the benefits and harms of ureteroscopy (URS) compared with shock wave lithotripsy (SWL) in the treatment of upper ureteral stones in children and adults? PROSPERO International prospective register of systematic reviews, 2015.  
[http://www.crd.york.ac.uk/PROSPERO/display\\_record.asp?ID=CRD42015023769](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015023769)
306. El-Nahas, A.R., *et al.* Predictors of clinical significance of residual fragments after extracorporeal shockwave lithotripsy for renal stones. *J Endourol*, 2006. 20: 870.  
<http://www.ncbi.nlm.nih.gov/pubmed/17144853>
307. Buchholz, N.P., *et al.* Minor residual fragments after extracorporeal shockwave lithotripsy: spontaneous clearance or risk factor for recurrent stone formation? *J Endourol*, 1997. 11: 227.  
<http://www.ncbi.nlm.nih.gov/pubmed/9376838>
308. Beck, E.M., *et al.* The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. *J Urol*, 1991. 145: 6.  
<http://www.ncbi.nlm.nih.gov/pubmed/1984100>
309. Candau, C., *et al.* Natural history of residual renal stone fragments after ESWL. *Eur Urol*, 2000. 37: 18.  
<http://www.ncbi.nlm.nih.gov/pubmed/10671779>
310. Krings, F., *et al.* Extracorporeal shock wave lithotripsy retreatment (“stir-up”) promotes discharge of persistent caliceal stone fragments after primary extracorporeal shock wave lithotripsy. *J Urol*, 1992. 148: 1040.  
<http://www.ncbi.nlm.nih.gov/pubmed/1507326>
311. Fine, J.K., *et al.* Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. *J Urol*, 1995. 153: 27.  
<http://www.ncbi.nlm.nih.gov/pubmed/7966783>
312. Siener, R., *et al.* Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. *Eur Urol*, 2003. 44: 467.  
<http://www.ncbi.nlm.nih.gov/pubmed/14499683>
313. Cicerello, E., *et al.* Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. *J Urol*, 1994. 151: 5.  
<http://www.ncbi.nlm.nih.gov/pubmed/8254832>
314. Chiong, E., *et al.* Randomized controlled study of mechanical percussion, diuresis, and inversion therapy to assist passage of lower pole renal calculi after shock wave lithotripsy. *Urology*, 2005. 65: 1070.  
<http://www.ncbi.nlm.nih.gov/pubmed/15922429>
315. Tsai, Y.L., *et al.* Comparative study of conservative and surgical management for symptomatic moderate and severe hydronephrosis in pregnancy: a prospective randomized study. *Acta Obstet Gynecol Scand*, 2007. 86: 1047.  
<http://www.ncbi.nlm.nih.gov/pubmed/17712643>
316. Mokhmalji, H., *et al.* Percutaneous nephrostomy versus ureteral stents for diversion of hydronephrosis caused by stones: a prospective, randomized clinical trial. *J Urol*, 2001. 165: 1088.  
<http://www.ncbi.nlm.nih.gov/pubmed/11257644>
317. vanSonnenberg, E., *et al.* Symptomatic renal obstruction or urosepsis during pregnancy: treatment by sonographically guided percutaneous nephrostomy. *AJR Am J Roentgenol*, 1992. 158: 91.  
<http://www.ncbi.nlm.nih.gov/pubmed/1727366>
318. Semins, M.J., *et al.* The safety of ureteroscopy during pregnancy: a systematic review and meta-analysis. *J Urol*, 2009. 181: 139.  
<http://www.ncbi.nlm.nih.gov/pubmed/19012926>
319. Ishii, H., *et al.* Current status of ureteroscopy for stone disease in pregnancy. *Urolithiasis*, 2014. 42: 1.  
<http://www.ncbi.nlm.nih.gov/pubmed/24374899>

320. Teleb, M., *et al.* Definitive ureteroscopy and intracorporeal lithotripsy in treatment of ureteral calculi during pregnancy. *Arab J Urol*, 2014. 12: 299.  
<http://www.ncbi.nlm.nih.gov/pubmed/26019966>
321. Toth, C., *et al.* Percutaneous nephrolithotomy in early pregnancy. *Int Urol Nephrol*, 2005. 37: 1.  
<http://www.ncbi.nlm.nih.gov/pubmed/16132747>
322. Kato, H., *et al.* Continent urinary reservoir formation with transverse colon for patients with pelvic irradiation. *Int J Urol*, 2002. 9: 200.  
<http://www.ncbi.nlm.nih.gov/pubmed/12010313>
323. Holmes, D.G., *et al.* Long-term complications related to the modified Indiana pouch. *Urology*, 2002. 60: 603.  
<http://www.ncbi.nlm.nih.gov/pubmed/12385916>
324. Yang, W.J., *et al.* Long-term effects of ileal conduit urinary diversion on upper urinary tract in bladder cancer. *Urology*, 2006. 68: 324.  
<http://www.ncbi.nlm.nih.gov/pubmed/16904445>
325. Assimos, D.G. Nephrolithiasis in patients with urinary diversion. *J Urol*, 1996. 155: 69.  
<http://www.ncbi.nlm.nih.gov/pubmed/7490901>
326. Cohen, T.D., *et al.* Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. *J Urol*, 1996. 155: 62.  
<http://www.ncbi.nlm.nih.gov/pubmed/7490899>
327. Deliveliotis, C., *et al.* Shockwave lithotripsy for urinary stones in patients with urinary diversion after radical cystectomy. *J Endourol*, 2002. 16: 717.  
<http://www.ncbi.nlm.nih.gov/pubmed/12542873>
328. Stein, J.P., *et al.* Complications of the afferent antireflux valve mechanism in the Kock ileal reservoir. *J Urol*, 1996. 155: 1579.  
<http://www.ncbi.nlm.nih.gov/pubmed/8627827>
329. Matlaga, B.R., *et al.* Computerized tomography guided access for percutaneous nephrostolithotomy. *J Urol*, 2003. 170: 45.  
<http://www.ncbi.nlm.nih.gov/pubmed/12796641>
330. Hensle, T.W., *et al.* Preventing reservoir calculi after augmentation cystoplasty and continent urinary diversion: the influence of an irrigation protocol. *BJU Int*, 2004. 93: 585.  
<http://www.ncbi.nlm.nih.gov/pubmed/15008735>
331. Raj, G.V., *et al.* The incidence of nephrolithiasis in patients with spinal neural tube defects. *J Urol*, 1999. 162: 1238.  
<http://www.ncbi.nlm.nih.gov/pubmed/10458475>
332. Gros, D.A., *et al.* Urolithiasis in spina bifida. *Eur J Pediatr Surg*, 1998. 8 Suppl 1: 68.  
<http://www.ncbi.nlm.nih.gov/pubmed/9926338>
333. Kondo, A., *et al.* [Urolithiasis in those patients with myelodysplasia]. *Nihon Hinyokika Gakkai Zasshi*, 2003. 94: 15.  
<http://www.ncbi.nlm.nih.gov/pubmed/12638200>
334. Rendeli, C., *et al.* Latex sensitisation and allergy in children with myelomeningocele. *Childs Nerv Syst*, 2006. 22: 28.  
<http://www.ncbi.nlm.nih.gov/pubmed/15703967>
335. Christman, M.S., *et al.* Morbidity and efficacy of ureteroscopic stone treatment in patients with neurogenic bladder. *J Urol*, 2013. 190: 1479.  
<http://www.ncbi.nlm.nih.gov/pubmed/23454151>
336. Harper, J.M., *et al.* Risk factors for calculus formation in patients with renal transplants. *Br J Urol*, 1994. 74: 147.  
<http://www.ncbi.nlm.nih.gov/pubmed/7921929>
337. Cho, D.K., *et al.* Urinary calculi in renal transplant recipients. *Transplantation*, 1988. 45: 899.  
<http://www.ncbi.nlm.nih.gov/pubmed/3285534>
338. Hayes, J.M., *et al.* Renal transplant calculi. A reevaluation of risks and management. *Transplantation*, 1989. 47: 949.  
<http://www.ncbi.nlm.nih.gov/pubmed/2660356>
339. Shoskes, D.A., *et al.* Urological complications in 1,000 consecutive renal transplant recipients. *J Urol*, 1995. 153: 18.  
<http://www.ncbi.nlm.nih.gov/pubmed/7966766>
340. Klingler, H.C., *et al.* Urolithiasis in allograft kidneys. *Urology*, 2002. 59: 344.  
<http://www.ncbi.nlm.nih.gov/pubmed/11880067>
341. Trivedi, A., *et al.* Management of calculi in a donor kidney. *Transplant Proc*, 2007. 39: 761.  
<http://www.ncbi.nlm.nih.gov/pubmed/17445593>

342. Yigit, B., *et al.* Stone disease in kidney transplantation. *Transplant Proc*, 2004. 36: 187.  
<http://www.ncbi.nlm.nih.gov/pubmed/15013342>
343. Gupta, M., *et al.* Treatment of stones associated with complex or anomalous renal anatomy. *Urol Clin North Am*, 2007. 34: 431.  
<http://www.ncbi.nlm.nih.gov/pubmed/17678992>
344. Challacombe, B., *et al.* Multimodal management of urolithiasis in renal transplantation. *BJU Int*, 2005. 96: 385.  
<http://www.ncbi.nlm.nih.gov/pubmed/16042735>
345. Rifaioğlu, M.M., *et al.* Percutaneous management of stones in transplanted kidneys. *Urology*, 2008. 72: 508.  
<http://www.ncbi.nlm.nih.gov/pubmed/18653217>
346. Minon Cifuentes, J., *et al.* Percutaneous nephrolithotomy in transplanted kidney. *Urology*, 1991. 38: 232.  
<http://www.ncbi.nlm.nih.gov/pubmed/1887537>
347. Wyatt, J., *et al.* Treatment outcomes for percutaneous nephrolithotomy in renal allografts. *J Endourol*, 2009. 23: 1821.  
<http://www.ncbi.nlm.nih.gov/pubmed/19814697>
348. Del Pizzo, J.J., *et al.* Ureteroscopic evaluation in renal transplant recipients. *J Endourol*, 1998. 12: 135.  
<http://www.ncbi.nlm.nih.gov/pubmed/9607439>
349. Basiri, A., *et al.* Ureteroscopic management of urological complications after renal transplantation. *Scand J Urol Nephrol*, 2006. 40: 53.  
<http://www.ncbi.nlm.nih.gov/pubmed/16452057>
350. Lu, H.F., *et al.* Donor-gifted allograft urolithiasis: early percutaneous management. *Urology*, 2002. 59: 25.  
<http://www.ncbi.nlm.nih.gov/pubmed/11796274>
351. Rhoderick, T.M., *et al.* Extracorporeal shock wave lithotripsy in the renal transplant patient: a case report and review of literature. *Clin Transplant*, 1992. 6: 375.  
<http://www.ncbi.nlm.nih.gov/pubmed/10147926>
352. Atala, A., *et al.* Extracorporeal shock-wave lithotripsy in transplanted kidney. *Urology*, 1993. 41: 60.  
<http://www.ncbi.nlm.nih.gov/pubmed/8420082>
353. Raboy, A., *et al.* Laparoscopic ureterolithotomy. *Urology*, 1992. 39: 223.  
<http://www.ncbi.nlm.nih.gov/pubmed/1532102>
354. Gaur, D.D. Retroperitoneal endoscopic ureterolithotomy: our experience in 12 patients. *J Endourol*, 1993. 7: 501.  
<http://www.ncbi.nlm.nih.gov/pubmed/8124346>
355. Gaur, D.D. Retroperitoneal laparoscopic ureterolithotomy. *World J Urol*, 1993. 11: 175.  
<http://www.ncbi.nlm.nih.gov/pubmed/8401638>
356. Gaur, D.D., *et al.* Retroperitoneal laparoscopic pyelolithotomy. *J Urol*, 1994. 151: 927.  
<http://www.ncbi.nlm.nih.gov/pubmed/8126827>
357. Escovar Diaz, P., *et al.* [Laparoscopic ureterolithotomy]. *Arch Esp Urol*, 1993. 46: 633.  
<http://www.ncbi.nlm.nih.gov/pubmed/8239742>
358. Locke, D.R., *et al.* Extracorporeal shock-wave lithotripsy in horseshoe kidneys. *Urology*, 1990. 35: 407.  
<http://www.ncbi.nlm.nih.gov/pubmed/2336770>
359. Somani, B.K., *et al.* E33 Outcome of ureteroscopy for stone disease in patients with horseshoe kidney (HSK): Results from a systematic review of literature. *European Urology Supplements*. 12: 41.  
<http://www.sciencedirect.com/science/article/pii/S1569905613617005>
360. Gelet, A., *et al.* Endopyelotomy with the Acucise cutting balloon device. Early clinical experience. *Eur Urol*, 1997. 31: 389.  
<http://www.ncbi.nlm.nih.gov/pubmed/9187895>
361. Faerber, G.J., *et al.* Retrograde treatment of ureteropelvic junction obstruction using the ureteral cutting balloon catheter. *J Urol*, 1997. 157: 454.  
<http://www.ncbi.nlm.nih.gov/pubmed/8996330>
362. Berkman, D.S., *et al.* Treatment outcomes after endopyelotomy performed with or without simultaneous nephrolithotomy: 10-year experience. *J Endourol*, 2009. 23: 1409.  
<http://www.ncbi.nlm.nih.gov/pubmed/19694529>



363. Nakada, S.Y., *et al.* Retrospective analysis of the effect of crossing vessels on successful retrograde endopyelotomy outcomes using spiral computerized tomography angiography. *J Urol*, 1998. 159: 62.  
<http://www.ncbi.nlm.nih.gov/pubmed/9400437>
364. Reis-Santos JM. Age of first stone episode. In: Urolithiasis. Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, eds. Cape Town: University of Cape Town, 2000. 375.
365. Robertson WG, Whitfield H, Unwin RJ, *et al.* In: Possible causes of the changing pattern of the age of onset of urinary stone disease in the UK. Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, eds. Urolithiasis. Cape Town: University of Cape Town, 2000. 366.
366. Djelloul, Z., *et al.* [Urinary stones in Western Algeria: study of the composition of 1,354 urinary stones in relation to their anatomical site and the age and gender of the patients]. *Prog Urol*, 2006. 16: 328.  
<http://www.ncbi.nlm.nih.gov/pubmed/16821346>
367. Sarica, K. Pediatric urolithiasis: etiology, specific pathogenesis and medical treatment. *Urol Res*, 2006. 34: 96.  
<http://www.ncbi.nlm.nih.gov/pubmed/16432692>
368. Sarica, K. Medical aspect and minimal invasive treatment of urinary stones in children. *Arch Ital Urol Androl*, 2008. 80: 43.  
<http://www.ncbi.nlm.nih.gov/pubmed/18683808>
369. Sayasone, S., *et al.* Bladder stones in childhood: a descriptive study in a rural setting in Saravan Province, Lao PDR. *Southeast Asian J Trop Med Public Health*, 2004. 35 Suppl 2: 50.  
<http://www.ncbi.nlm.nih.gov/pubmed/15906634>
370. Aldaqadossi, H.A., *et al.* Efficacy and safety of tamsulosin as a medical expulsive therapy for stones in children. *Arab J Urol*, 2015. 13: 107.  
<http://www.ncbi.nlm.nih.gov/pubmed/26413330>
371. Aydogdu, O., *et al.* Effectiveness of doxazosin in treatment of distal ureteral stones in children. *J Urol*, 2009. 182: 2880.  
<http://www.ncbi.nlm.nih.gov/pubmed/19846149>
372. Mokhless, I., *et al.* Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study. *J Pediatr Urol*, 2012. 8: 544.  
<http://www.ncbi.nlm.nih.gov/pubmed/22099477>
373. Lahme, S. Shockwave lithotripsy and endourological stone treatment in children. *Urol Res*, 2006. 34: 112.  
<http://www.ncbi.nlm.nih.gov/pubmed/16446980>
374. Smaldone, M.C., *et al.* Contemporary surgical management of pediatric urolithiasis. *Urol Clin North Am*, 2010. 37: 253.  
<http://www.ncbi.nlm.nih.gov/pubmed/20569803>
375. Landau, E.H., *et al.* Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotripter. *J Urol*, 2009. 182: 1835.  
<http://www.ncbi.nlm.nih.gov/pubmed/19692011>
376. Frick, J., *et al.* Long-term follow-up after extracorporeal shock wave lithotripsy in children. *Eur Urol*, 1991. 19: 225.  
<http://www.ncbi.nlm.nih.gov/pubmed/1855529>
377. D'Addessi, A., *et al.* Is extracorporeal shock wave lithotripsy in pediatrics a safe procedure? *J Pediatr Surg*, 2008. 43: 591.  
<http://www.ncbi.nlm.nih.gov/pubmed/18405701>
378. Lu, P., *et al.* The clinical efficacy of extracorporeal shock wave lithotripsy in pediatric urolithiasis: a systematic review and meta-analysis. *Urolithiasis*, 2015. 43: 199.  
<http://www.ncbi.nlm.nih.gov/pubmed/25721456>
379. Salem, H.K., *et al.* Slow vs rapid delivery rate shock wave lithotripsy for pediatric renal urolithiasis: a prospective randomized study. *J Urol*, 2014. 191: 1370.  
<http://www.ncbi.nlm.nih.gov/pubmed/24262496>
380. Aldridge, R.D., *et al.* Anesthesia for pediatric lithotripsy. *Paediatr Anaesth*, 2006. 16: 236.  
<http://www.ncbi.nlm.nih.gov/pubmed/16490086>
381. Sarica, K., *et al.* Long-term follow-up of renal morphology and function in children after lithotripsy. *Urol Int*, 1995. 54: 95.  
<http://www.ncbi.nlm.nih.gov/pubmed/7747366>
382. Griffin, S.J., *et al.* Safety of shock wave lithotripsy for treatment of pediatric urolithiasis: 20-year experience. *J Urol*, 2010. 183: 2332.  
<http://www.ncbi.nlm.nih.gov/pubmed/20400129>

383. Reisiger, K., *et al.* Pediatric nephrolithiasis: does treatment affect renal growth? *Urology*, 2007. 69: 1190.  
<http://www.ncbi.nlm.nih.gov/pubmed/17572213>
384. Kurien, A., *et al.* Extracorporeal shock wave lithotripsy in children: equivalent clearance rates to adults is achieved with fewer and lower energy shock waves. *BJU Int*, 2009. 103: 81.  
<http://www.ncbi.nlm.nih.gov/pubmed/18727616>
385. Desai, M. Endoscopic management of stones in children. *Curr Opin Urol*, 2005. 15: 107.  
<http://www.ncbi.nlm.nih.gov/pubmed/15725934>
386. Straub, M., *et al.* Pediatric urolithiasis: the current surgical management. *Pediatr Nephrol*, 2010. 25: 1239.  
<http://www.ncbi.nlm.nih.gov/pubmed/20130924>
387. Smaldone, M.C., *et al.* Endourological management of pediatric stone disease: present status. *J Urol*, 2009. 181: 17.  
<http://www.ncbi.nlm.nih.gov/pubmed/19012920>
388. Kapoor, R., *et al.* Safety and efficacy of percutaneous nephrolithotomy in the pediatric population. *J Endourol*, 2008. 22: 637.  
<http://www.ncbi.nlm.nih.gov/pubmed/18338958>
389. Hosseini, S.R., *et al.* One shot tract dilation for percutaneous nephrolithotomy: is it safe and effective in preschool children? *Urol Int*, 2014. 92: 440.  
<http://www.ncbi.nlm.nih.gov/pubmed/24603110>
390. Song, G., *et al.* Advantages of tubeless mini-percutaneous nephrolithotomy in the treatment of preschool children under 3 years old. *J Pediatr Surg*, 2015. 50: 655.  
<http://www.ncbi.nlm.nih.gov/pubmed/25840082>
391. Samad, L., *et al.* Tubed vs tubeless PCNL in children. *J Pak Med Assoc*, 2012. 62: 892.  
<http://www.ncbi.nlm.nih.gov/pubmed/23139970>
392. Smaldone, M.C., *et al.* Is ureteroscopy first line treatment for pediatric stone disease? *J Urol*, 2007. 178: 2128.  
<http://www.ncbi.nlm.nih.gov/pubmed/17870124>
393. Erturhan, S., *et al.* Ureteroscopic management of ureteral calculi in children. *J Endourol*, 2007. 21: 397.  
<http://www.ncbi.nlm.nih.gov/pubmed/17451329>
394. Basiri, A., *et al.* A multicenter, randomized, controlled trial of transureteral and shock wave lithotripsy--which is the best minimally invasive modality to treat distal ureteral calculi in children? *J Urol*, 2010. 184: 1106.  
<http://www.ncbi.nlm.nih.gov/pubmed/20650490>
395. Basiri, A., *et al.* Ureteral calculi in children: what is best as a minimally invasive modality? *Urol J*, 2008. 5: 67.  
<http://www.ncbi.nlm.nih.gov/pubmed/18592456>
396. Ishii, H., *et al.* Ureteroscopy for stone disease in the paediatric population: a systematic review. *BJU Int*, 2015. 115: 867.  
<http://www.ncbi.nlm.nih.gov/pubmed/25203925>
397. Safwat, A.S., *et al.* Experience with ureteroscopic holmium laser lithotripsy in children. *Pediatr Surg Int*, 2008. 24: 579.  
<http://www.ncbi.nlm.nih.gov/pubmed/18365216>
398. Kim, S.S., *et al.* Pediatric flexible ureteroscopic lithotripsy: the children's hospital of Philadelphia experience. *J Urol*, 2008. 180: 2616.  
<http://www.ncbi.nlm.nih.gov/pubmed/18950810>
399. Ishii, H., *et al.* Flexible ureteroscopy and laserripsy (FURSL) for paediatric renal calculi: results from a systematic review. *J Pediatr Urol*, 2014. 10: 1020.  
<http://www.ncbi.nlm.nih.gov/pubmed/25241397>
400. Cannon, G.M., *et al.* Ureteroscopic management of lower-pole stones in a pediatric population. *J Endourol*, 2007. 21: 1179.  
<http://www.ncbi.nlm.nih.gov/pubmed/17949321>
401. Mokhless, I.A., *et al.* Retrograde intrarenal surgery monotherapy versus shock wave lithotripsy for stones 10 to 20 mm in preschool children: a prospective, randomized study. *J Urol*, 2014. 191: 1496.  
<http://www.ncbi.nlm.nih.gov/pubmed/24679882>
402. Muslumanoglu, A.Y., *et al.* Extracorporeal shock wave lithotripsy as first line treatment alternative for urinary tract stones in children: a large scale retrospective analysis. *J Urol*, 2003. 170: 2405.  
<http://www.ncbi.nlm.nih.gov/pubmed/14634438>

403. Casale, P., *et al.* Transperitoneal laparoscopic pyelolithotomy after failed percutaneous access in the pediatric patient. *J Urol*, 2004. 172: 680.  
<http://www.ncbi.nlm.nih.gov/pubmed/15247760>
404. Fragoso, A.C., *et al.* Minimal access surgery in the management of pediatric urolithiasis. *J Pediatr Urol*, 2009. 5: 42.  
<http://www.ncbi.nlm.nih.gov/pubmed/18805739>
405. Elderwy, A.A., *et al.* Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study. *J Urol*, 2014. 191: 1491.  
<http://www.ncbi.nlm.nih.gov/pubmed/24679880>
406. Sarica, K., *et al.* Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. *J Endourol*, 2006. 20: 875.  
<http://www.ncbi.nlm.nih.gov/pubmed/17144854>
407. Parks, J.H., *et al.* A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. *J Urol*, 2002. 167: 1607.  
<http://www.ncbi.nlm.nih.gov/pubmed/11912373>
408. Nayan, M., *et al.* Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. *Can Urol Assoc J*, 2012. 6: 30.  
<http://www.ncbi.nlm.nih.gov/pubmed/22396364>
409. Ferraz, R.R., *et al.* Preservation of urine samples for metabolic evaluation of stone-forming patients. *Urol Res*, 2006. 34: 329.  
<http://www.ncbi.nlm.nih.gov/pubmed/16896690>
410. Yilmaz, G., *et al.* Are preservatives necessary in 24-hour urine measurements? *Clin Biochem*, 2008. 41: 899.  
<http://www.ncbi.nlm.nih.gov/pubmed/18371307>
411. Coe, F.L., *et al.* Kidney stone disease. *J Clin Invest*, 2005. 115: 2598.  
<http://www.ncbi.nlm.nih.gov/pubmed/16200192>
412. Norman, R.W., *et al.* When should patients with symptomatic urinary stone disease be evaluated metabolically? *J Urol*, 1984. 132: 1137.  
<http://www.ncbi.nlm.nih.gov/pubmed/6502804>
413. Assimos D. Urine evaluation (in: Evaluation of the stone former), in 2ND International Consultation on Stone Disease, H.M. Assimos D. Chew B, Hautmann R, Holmes R, Williams J, Wolf JS, Editor. 2007, Health Publications.
414. Hesse A, T.H., Jahnen A., *Urinary Stones: Diagnosis, Treatment and Prevention of Recurrence.*, in *Uric acid stones*. 2002, S Karger AG, Basel.
415. Tiselius, H.G. Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. *Eur Urol*, 1989. 16: 48.  
<http://www.ncbi.nlm.nih.gov/pubmed/2714318>
416. Ackermann, D., *et al.* Use of the computer program EQUIL to estimate pH in model solutions and human urine. *Urol Res*, 1989. 17: 157.  
<http://www.ncbi.nlm.nih.gov/pubmed/2749945>
417. Kavanagh, J.P., *et al.* Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls? *J Urol*, 2006. 175: 766.  
<http://www.ncbi.nlm.nih.gov/pubmed/16407047>
418. Rodgers AL, *et al.* JESS: What can it teach us?, in *Proceedings of Renal Stone Disease 1st Annual International Urolithiasis Research Symposium*, Nov 2006., AP Evan, J.E. Lingeman and J.C. Williams, Jr. (Eds), 2007, American Institute of Physics: Melville, New York
419. Hoppe, B., *et al.* Diagnostic examination of the child with urolithiasis or nephrocalcinosis. *Pediatr Nephrol*, 2010. 25: 403.  
<http://www.ncbi.nlm.nih.gov/pubmed/19104842>
420. Borghi, L., *et al.* Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. *J Urol*, 1996. 155: 839.  
<http://www.ncbi.nlm.nih.gov/pubmed/8583588>
421. Sarica, K., *et al.* The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. *Urol Res*, 2006. 34: 184.  
<http://www.ncbi.nlm.nih.gov/pubmed/16463053>
422. Fink, H.A., *et al.* Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. *Ann Intern Med*, 2013. 158: 535.  
<http://www.ncbi.nlm.nih.gov/pubmed/23546565>

423. Siener, R., *et al.* Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. *Kidney Int*, 2003. 63: 1037.  
<http://www.ncbi.nlm.nih.gov/pubmed/12631085>
424. Wabner, C.L., *et al.* Effect of orange juice consumption on urinary stone risk factors. *J Urol*, 1993. 149: 1405.  
<http://www.ncbi.nlm.nih.gov/pubmed/8501777>
425. Gettman, M.T., *et al.* Effect of cranberry juice consumption on urinary stone risk factors. *J Urol*, 2005. 174: 590.  
<http://www.ncbi.nlm.nih.gov/pubmed/16006907>
426. Shuster, J., *et al.* Soft drink consumption and urinary stone recurrence: a randomized prevention trial. *J Clin Epidemiol*, 1992. 45: 911.  
<http://www.ncbi.nlm.nih.gov/pubmed/1624973>
427. Kocvara, R., *et al.* A prospective study of nonmedical prophylaxis after a first kidney stone. *BJU Int*, 1999. 84: 393.  
<http://www.ncbi.nlm.nih.gov/pubmed/10468751>
428. Hess, B., *et al.* Effects of a 'common sense diet' on urinary composition and supersaturation in patients with idiopathic calcium urolithiasis. *Eur Urol*, 1999. 36: 136.  
<http://www.ncbi.nlm.nih.gov/pubmed/10420035>
429. Ebisuno, S., *et al.* Results of long-term rice bran treatment on stone recurrence in hypercalciuric patients. *Br J Urol*, 1991. 67: 237.  
<http://www.ncbi.nlm.nih.gov/pubmed/1902388>
430. Hiatt, R.A., *et al.* Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. *Am J Epidemiol*, 1996. 144: 25.  
<http://www.ncbi.nlm.nih.gov/pubmed/8659482>
431. Dussol, B., *et al.* A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. *Nephron Clin Pract*, 2008. 110: c185.  
<http://www.ncbi.nlm.nih.gov/pubmed/18957869>
432. Turney, B.W., *et al.* Diet and risk of kidney stones in the Oxford cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). *Eur J Epidemiol*, 2014. 29: 363.  
<http://www.ncbi.nlm.nih.gov/pubmed/24752465>
433. Auer, B.L., *et al.* The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. *Clin Chem Lab Med*, 1998. 36: 143.  
<http://www.ncbi.nlm.nih.gov/pubmed/9589801>
434. Borghi, L., *et al.* Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med*, 2002. 346: 77.  
<http://www.ncbi.nlm.nih.gov/pubmed/11784873>
435. Fink, H.A., *et al.* Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. *Eur Urol*, 2009. 56: 72.  
<http://www.ncbi.nlm.nih.gov/pubmed/19321253>
436. Curhan, G.C., *et al.* Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med*, 1997. 126: 497.  
<http://www.ncbi.nlm.nih.gov/pubmed/9092314>
437. von Unruh, G.E., *et al.* Dependence of oxalate absorption on the daily calcium intake. *J Am Soc Nephrol*, 2004. 15: 1567.  
<http://www.ncbi.nlm.nih.gov/pubmed/15153567>
438. Curhan, G.C., *et al.* A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*, 1993. 328: 833.  
<http://www.ncbi.nlm.nih.gov/pubmed/8441427>
439. Coe, F.L. Hyperuricosuric calcium oxalate nephrolithiasis. *Adv Exp Med Biol*, 1980. 128: 439.  
<http://www.ncbi.nlm.nih.gov/pubmed/7424690>
440. Ettinger B. Hyperuricosuric calcium stone disease. In: *Kidney Stones: Medical and Surgical Management*. Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds. Lippincott-Raven: Philadelphia, 1996. 851.
441. Siener, R., *et al.* The role of overweight and obesity in calcium oxalate stone formation. *Obes Res*, 2004. 12: 106.  
<http://www.ncbi.nlm.nih.gov/pubmed/14742848>
442. Madore, F., *et al.* Nephrolithiasis and risk of hypertension. *Am J Hypertens*, 1998. 11: 46.  
<http://www.ncbi.nlm.nih.gov/pubmed/9504449>
443. Madore, F., *et al.* Nephrolithiasis and risk of hypertension in women. *Am J Kidney Dis*, 1998. 32: 802.  
<http://www.ncbi.nlm.nih.gov/pubmed/9820450>

444. Tiselius, H.G., *et al.* Effects of citrate on the different phases of calcium oxalate crystallization. *Scanning Microsc*, 1993. 7: 381.  
<http://www.ncbi.nlm.nih.gov/pubmed/8316807>
445. Barcelo, P., *et al.* Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. *J Urol*, 1993. 150: 1761.  
<http://www.ncbi.nlm.nih.gov/pubmed/8230497>
446. Hofbauer, J., *et al.* Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. *Br J Urol*, 1994. 73: 362.  
<http://www.ncbi.nlm.nih.gov/pubmed/8199822>
447. Ettinger, B., *et al.* Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. *J Urol*, 1997. 158: 2069.  
<http://www.ncbi.nlm.nih.gov/pubmed/9366314>
448. Soygur, T., *et al.* Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. *J Endourol*, 2002. 16: 149.  
<http://www.ncbi.nlm.nih.gov/pubmed/12028622>
449. Premgamone, A., *et al.* A long-term study on the efficacy of a herbal plant, *Orthosiphon grandiflorus*, and sodium potassium citrate in renal calculi treatment. *Southeast Asian J Trop Med Public Health*, 2001. 32: 654.  
<http://www.ncbi.nlm.nih.gov/pubmed/11944733>
450. Lojanapiwat, B., *et al.* Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. *Int Braz J Urol*, 2011. 37: 611.  
<http://www.ncbi.nlm.nih.gov/pubmed/22099273>
451. Favus, M.J., *et al.* The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. *Scand J Urol Nephrol Suppl*, 1980. 53: 265.  
<http://www.ncbi.nlm.nih.gov/pubmed/6938003>
452. Miano L, Petta S, Galatioto GP, *et al.* In: A placebo controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis. Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. *Urolithiasis and Related Clinical Research*. New York: Plenum Press, 1985. 521.
453. Ettinger, B., *et al.* Randomized trial of allopurinol in the prevention of calcium oxalate calculi. *N Engl J Med*, 1986. 315: 1386.  
<http://www.ncbi.nlm.nih.gov/pubmed/3534570>
454. Robertson, W.G., *et al.*, A Multicentre Trial to Evaluate Three Treatments for Recurrent Idiopathic Calcium Stone Disease — A Preliminary Report, in *Urolithiasis and Related Clinical Research*, P. Schwille, L. Smith, W. Robertson & W. Vahlensieck, Editors. 1985, Springer US.
455. Smith, M.J. Placebo versus allopurinol for renal calculi. *J Urol*, 1977. 117: 690.  
<http://www.ncbi.nlm.nih.gov/pubmed/875139>
456. Cohen, T.D., *et al.* Clinical effect of captopril on the formation and growth of cystine calculi. *J Urol*, 1995. 154: 164.  
<http://www.ncbi.nlm.nih.gov/pubmed/7776415>
457. Coulthard, M.G., *et al.* The treatment of cystinuria with captopril. *Am J Kidney Dis*, 1995. 25: 661.  
<http://www.ncbi.nlm.nih.gov/pubmed/7702068>
458. Goldfarb, D.S., *et al.* Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. *Clin J Am Soc Nephrol*, 2013. 8: 1960.  
<http://www.ncbi.nlm.nih.gov/pubmed/23929928>
459. Nouvenne, A., *et al.* New pharmacologic approach to patients with idiopathic calcium nephrolithiasis and high uricosuria: Febuxostat vs allopurinol. A pilot study. *European Journal of Internal Medicine*. 24: e64.  
<http://www.ejinme.com/action/showMultipleAbstracts>
460. Jarrar, K., *et al.* Struvite stones: long term follow up under metaphylaxis. *Ann Urol (Paris)*, 1996. 30: 112.  
<http://www.ncbi.nlm.nih.gov/pubmed/8766146>
461. Hesse, A., *et al.* Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. *World J Urol*, 1999. 17: 308.  
<http://www.ncbi.nlm.nih.gov/pubmed/10552150>
462. Ettinger, B., *et al.* Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. *J Urol*, 1988. 139: 679.  
<http://www.ncbi.nlm.nih.gov/pubmed/3280829>

463. Prien, E.L., Sr., *et al.* Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. *J Urol*, 1974. 112: 509.  
<http://www.ncbi.nlm.nih.gov/pubmed/4414543>
464. Pinheiro, V.B., *et al.* The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. *Urology*, 2013. 82: 33.  
<http://www.ncbi.nlm.nih.gov/pubmed/23602798>
465. Hoppe, B., *et al.* The primary hyperoxalurias. *Kidney Int*, 2009. 75: 1264.  
<http://www.ncbi.nlm.nih.gov/pubmed/19225556>
466. Borghi, L., *et al.* Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. *J Cardiovasc Pharmacol*, 1993. 22 Suppl 6: S78.  
<http://www.ncbi.nlm.nih.gov/pubmed/7508066>
467. Brocks, P., *et al.* Do thiazides prevent recurrent idiopathic renal calcium stones? *Lancet*, 1981. 2: 124.  
<http://www.ncbi.nlm.nih.gov/pubmed/6113485>
468. Mortensen, J.T., *et al.* Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. *Int Urol Nephrol*, 1986. 18: 265.  
<http://www.ncbi.nlm.nih.gov/pubmed/3533825>
469. Laerum, E., *et al.* Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. *Acta Med Scand*, 1984. 215: 383.  
<http://www.ncbi.nlm.nih.gov/pubmed/6375276>
470. Ohkawa, M., *et al.* Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. *Br J Urol*, 1992. 69: 571.  
<http://www.ncbi.nlm.nih.gov/pubmed/1638340>
471. Scholz, D., *et al.* Double-blind study with thiazide in recurrent calcium lithiasis. *J Urol*, 1982. 128: 903.  
<http://www.ncbi.nlm.nih.gov/pubmed/7176047>
472. Nicar, M.J., *et al.* Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. *J Urol*, 1984. 131: 430.  
<http://www.ncbi.nlm.nih.gov/pubmed/6699979>
473. Fernandez-Rodriguez, A., *et al.* [The role of thiazides in the prophylaxis of recurrent calcium lithiasis]. *Actas Urol Esp*, 2006. 30: 305.  
<http://www.ncbi.nlm.nih.gov/pubmed/16749588>
474. Ahlstrand, C., Sandvall, K., Tiselius H.G., Prophylactic treatment of calcium-stone-formers with hydrochlorothiazide and magnesium., in *Renal Stones—Aspects on Their Formation, Removal and Prevention*, H.G. Tiselius, Ed. 1996, Akademityck AB: Edsbruk, Sweden.
475. Dolin, D.J., *et al.* Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. *J Endourol*, 2005. 19: 429.  
<http://www.ncbi.nlm.nih.gov/pubmed/15865542>
476. Chow, G.K., *et al.* Medical treatment of cystinuria: results of contemporary clinical practice. *J Urol*, 1996. 156: 1576.  
<http://www.ncbi.nlm.nih.gov/pubmed/8863541>
477. Pak, C.Y., *et al.* Management of cystine nephrolithiasis with alpha-mercaptopyronylglycine. *J Urol*, 1986. 136: 1003.  
<http://www.ncbi.nlm.nih.gov/pubmed/3534301>
478. Tekin, A., *et al.* Cystine calculi in children: the results of a metabolic evaluation and response to medical therapy. *J Urol*, 2001. 165: 2328.  
<http://www.ncbi.nlm.nih.gov/pubmed/11371943>
479. Worcester, E.M., *et al.* New insights into the pathogenesis of idiopathic hypercalciuria. *Semin Nephrol*, 2008. 28: 120.  
<http://www.ncbi.nlm.nih.gov/pubmed/18359393>
480. Wolf, H., *et al.* Do thiazides prevent recurrent idiopathic renal calcium oxalate stones? *Proc Eur Dial Transplant Assoc*, 1983. 20: 477.  
<http://www.ncbi.nlm.nih.gov/pubmed/6361755>
481. Johansson, G., *et al.* Effects of magnesium hydroxide in renal stone disease. *J Am Coll Nutr*, 1982. 1: 179.  
<http://www.ncbi.nlm.nih.gov/pubmed/6764473>
482. Khan, S.R., *et al.* Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. *J Urol*, 1993. 149: 412.  
<http://www.ncbi.nlm.nih.gov/pubmed/8426432>

483. Pearle, M.S., *et al.* Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. *J Endourol*, 1999. 13: 679.  
<http://www.ncbi.nlm.nih.gov/pubmed/10608521>
484. Silverberg, S.J., *et al.* A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. *N Engl J Med*, 1999. 341: 1249.  
<http://www.ncbi.nlm.nih.gov/pubmed/10528034>
485. Mollerup, C.L., *et al.* Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. *Bmj*, 2002. 325: 807.  
<http://www.ncbi.nlm.nih.gov/pubmed/12376441>
486. Evan, A.E., *et al.* Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. *Kidney Int*, 2008. 74: 223.  
<http://www.ncbi.nlm.nih.gov/pubmed/18449170>
487. Rizzato, G., *et al.* Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. *Sarcoidosis Vasc Diffuse Lung Dis*, 1996. 13: 167.  
<http://www.ncbi.nlm.nih.gov/pubmed/8893387>
488. Takei, K., *et al.* Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. *Urol Int*, 1998. 61: 192.  
<http://www.ncbi.nlm.nih.gov/pubmed/9933846>
489. Domrongkitchaiporn, S., *et al.* Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. *Am J Kidney Dis*, 2002. 39: 383.  
<http://www.ncbi.nlm.nih.gov/pubmed/11840381>
490. Maxwell AP. Genetic renal abnormalities. *Medicine*, 2007. 35: 386.
491. Mandel, N.S., *et al.* Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. *J Urol*, 1989. 142: 1516.  
<http://www.ncbi.nlm.nih.gov/pubmed/2585627>
492. Cameron, M.A., *et al.* Uric acid nephrolithiasis. *Urol Clin North Am*, 2007. 34: 335.  
<http://www.ncbi.nlm.nih.gov/pubmed/17678984>
493. Millman, S., *et al.* Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. *Kidney Int*, 1982. 22: 366.  
<http://www.ncbi.nlm.nih.gov/pubmed/7176335>
494. Pak, C.Y., *et al.* Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. *Urology*, 2002. 60: 789.  
<http://www.ncbi.nlm.nih.gov/pubmed/12429297>
495. Chou, Y.H., *et al.* Clinical study of ammonium acid urate urolithiasis. *Kaohsiung J Med Sci*, 2012. 28: 259.  
<http://www.ncbi.nlm.nih.gov/pubmed/22531304>
496. Wagner, C.A., *et al.* Urinary pH and stone formation. *J Nephrol*, 2010. 23 Suppl 16: S165.  
<http://www.ncbi.nlm.nih.gov/pubmed/21170875>
497. Miano, R., *et al.* Stones and urinary tract infections. *Urol Int*, 2007. 79 Suppl 1: 32.  
<http://www.ncbi.nlm.nih.gov/pubmed/17726350>
498. Rodman JS, *et al.* Diagnosis and treatment of uric acid calculi., in *Kidney Stones. Medical and Surgical Management*, F.M. Coe FL, Pak CYC, Parks JH, Preminger GM., Editor. 1996, Lippincott-Raven: Philadelphia.
499. Low, R.K., *et al.* Uric acid-related nephrolithiasis. *Urol Clin North Am*, 1997. 24: 135.  
<http://www.ncbi.nlm.nih.gov/pubmed/9048857>
500. Shekarriz, B., *et al.* Uric acid nephrolithiasis: current concepts and controversies. *J Urol*, 2002. 168: 1307.  
<http://www.ncbi.nlm.nih.gov/pubmed/12352383>
501. Pak, C.Y., *et al.* Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. *J Clin Invest*, 1977. 59: 426.  
<http://www.ncbi.nlm.nih.gov/pubmed/14173>
502. Wilcox, W.R., *et al.* Solubility of uric acid and monosodium urate. *Med Biol Eng*, 1972. 10: 522.  
<http://www.ncbi.nlm.nih.gov/pubmed/5074854>
503. Mattle, D., *et al.* Preventive treatment of nephrolithiasis with alkali citrate--a critical review. *Urol Res*, 2005. 33: 73.  
<http://www.ncbi.nlm.nih.gov/pubmed/15875173>
504. Marchini, G.S., *et al.* Gout, stone composition and urinary stone risk: a matched case comparative study. *J Urol*, 2013. 189: 1334.  
<http://www.ncbi.nlm.nih.gov/pubmed/23022002>

505. Kramer, G., *et al.* Role of bacteria in the development of kidney stones. *Curr Opin Urol*, 2000. 10: 35.  
<http://www.ncbi.nlm.nih.gov/pubmed/10650513>
506. Gettman, M.T., *et al.* Struvite stones: diagnosis and current treatment concepts. *J Endourol*, 1999. 13: 653.  
<http://www.ncbi.nlm.nih.gov/pubmed/10608517>
507. Bichler, K.H., *et al.* Urinary infection stones. *Int J Antimicrob Agents*, 2002. 19: 488.  
<http://www.ncbi.nlm.nih.gov/pubmed/12135839>
508. Carpentier, X., *et al.* Relationships between carbonation rate of carbapatite and morphologic characteristics of calcium phosphate stones and etiology. *Urology*, 2009. 73: 968.  
<http://www.ncbi.nlm.nih.gov/pubmed/19394492>
509. Thompson, R.B., *et al.* Bacteriology of infected stones. *Urology*, 1973. 2: 627.  
<http://www.ncbi.nlm.nih.gov/pubmed/4587909>
510. McLean, R.J., *et al.* The ecology and pathogenicity of urease-producing bacteria in the urinary tract. *Crit Rev Microbiol*, 1988. 16: 37.  
<http://www.ncbi.nlm.nih.gov/pubmed/3053050>
511. Wong HY, *et al.* Medical management and prevention of struvite stones, in *Kidney Stones: Medical and Surgical Management*, Coe & F.M. FL, Pak CYC, Parks JH, Preminger GM., Eds. 1996, Lippincott-Raven: Philadelphia.
512. Wall, I., *et al.* Long-term acidification of urine in patients treated for infected renal stones. *Urol Int*, 1990. 45: 336.  
<http://www.ncbi.nlm.nih.gov/pubmed/2288050>
513. Griffith, D.P., *et al.* Randomized, double-blind trial of Lithostat (acetoxyhydroxamic acid) in the palliative treatment of infection-induced urinary calculi. *Eur Urol*, 1991. 20: 243.  
<http://www.ncbi.nlm.nih.gov/pubmed/1726639>
514. Williams, J.J., *et al.* A randomized double-blind study of acetoxyhydroxamic acid in struvite nephrolithiasis. *N Engl J Med*, 1984. 311: 760.  
<http://www.ncbi.nlm.nih.gov/pubmed/6472365>
515. Milliner, D.S., *et al.* Urolithiasis in pediatric patients. *Mayo Clin Proc*, 1993. 68: 241.  
<http://www.ncbi.nlm.nih.gov/pubmed/8474265>
516. Rogers, A., *et al.* Management of cystinuria. *Urol Clin North Am*, 2007. 34: 347.  
<http://www.ncbi.nlm.nih.gov/pubmed/17678985>
517. Dello Strologo, L., *et al.* Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. *J Am Soc Nephrol*, 2002. 13: 2547.  
<http://www.ncbi.nlm.nih.gov/pubmed/12239244>
518. Lee, W.S., *et al.* Cloning and chromosomal localization of a human kidney cDNA involved in cystine, dibasic, and neutral amino acid transport. *J Clin Invest*, 1993. 91: 1959.  
<http://www.ncbi.nlm.nih.gov/pubmed/8486766>
519. Knoll, T., *et al.* Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. *Pediatr Nephrol*, 2005. 20: 19.  
<http://www.ncbi.nlm.nih.gov/pubmed/15602663>
520. Nakagawa, Y., *et al.* Clinical use of cystine supersaturation measurements. *J Urol*, 2000. 164: 1481.  
<http://www.ncbi.nlm.nih.gov/pubmed/11025687>
521. Fjellstedt, E., *et al.* Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. *Urol Res*, 2001. 29: 303.  
<http://www.ncbi.nlm.nih.gov/pubmed/11762791>
522. Ng, C.S., *et al.* Contemporary management of cystinuria. *J Endourol*, 1999. 13: 647.  
<http://www.ncbi.nlm.nih.gov/pubmed/10608516>
523. Biyani, C.S., Cartledge, J. J. Cystinuria—diagnosis and management. *EAU-EBU Update Series* 2006. 4: 175.  
[http://eu-acme.org/europeanurology/upload\\_articles/Cystinuria.pdf](http://eu-acme.org/europeanurology/upload_articles/Cystinuria.pdf)
524. Matlaga, B.R., *et al.* Drug-induced urinary calculi. *Rev Urol*, 2003. 5: 227.  
<http://www.ncbi.nlm.nih.gov/pubmed/16985842>
525. Finocchiaro, R., *et al.* Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. *Urol Res*, 1998. 26: 401.  
<http://www.ncbi.nlm.nih.gov/pubmed/9879820>
526. Nakagawa, Y., *et al.* A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. *Clin Chim Acta*, 1999. 289: 57.  
<http://www.ncbi.nlm.nih.gov/pubmed/10556653>



## 6. CONFLICT OF INTEREST

All members of the Urolithiasis Guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the European Association of Urology website:

<http://www.uroweb.org/guidelines/online-guidelines/>. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

